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Characterisation of guanylin and uroguanylin in the digestive system 
Florent Dyé 
Guanylin and uroguanylin are closely related peptides originating from the intestinal mucosa 
with established roles in salt and water homeostasis and the regulation of gut physiology. 
These hormones are secreted as the propeptides, ProGuanylin and ProUroguanylin, and post-
translationally processed into active peptides in the intestinal lumen. Those active peptides 
activate the guanylyl cyclase C (GC-C) receptor from the lumen and catalyse the production of 
the intracellular secondary messenger cGMP. Subsequently cGMP stimulates both cGMP-
dependent protein kinase II (PKGII) and protein kinase A (PKA). Both PKGII and PKA 
phosphorylate the cystic fibrosis transmembrane conductance regulator (CFTR), leading to an 
efflux of chloride in the lumen, resulting in fluid secretion into the intestine. The importance 
of this hormone-receptor system in human gastrointestinal physiology is epitomised by GC-C 
being the receptor for diarrheagenic bacterial enterotoxins. Observed human mutations in the 
receptor cause its hyperactivation or inactivation, leading to familial syndromes of diarrhoea 
and meconium ileus, respectively. The function of guanylin and uroguanylin is not restricted 
to intestinal physiology, as several other studies demonstrated their role on water and salt 
homeostasis in the kidney as well as a potential hypothalamic satiety effect. Therefore, the 
control of the guanylin peptides’ secretion may serve to regulate food intake through 
endocrine regulation. 
Understanding the role of guanylin peptides in healthy & disease states, the regulation of their 
secretion and their localisation in the digestive system has been limited by the lack of specific 
antibodies against the active human peptides and their prohormone precursors. The aim of 
this project was to address these deficiencies. 
In this thesis, specific antibodies were generated and utilised in immunoassays, which 
provided the ability to quantify accurately the circulating levels of proforms in human samples. 
Furthermore, liquid chromatography–mass spectrometry (LC-MS) analysis on human and 
mouse biological samples challenged the current knowledge of the bioactive peptides. The 
newly developed immunoassays provided opportunities to investigate pharmacological 
mediators that modulate guanylin and uroguanylin secretion from intestinal epithelium into 
the gut lumen and bloodstream. Finally, using newly generated transgenic mice expressing a 
fluorescent protein under the control of the guanylin promoter, the localisation of guanylin-
expressing cells was examined in the gastrointestinal tract. 
Whilst several models used in this study did not draw a consensus on the specific stimuli 
resulting in proforms’ secretion, the tools developed advanced the knowledge on the 
localisation of guanylin-expressing cells. Understanding the mechanisms of expression will 
provide novel insights into the physiological roles of these peptides and their possible 
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Chapter 1: Introduction 
1.1 The digestive system 
The digestive system is composed of the gastrointestinal tract as well as accessory organs of 
digestion such as liver, gall bladder and pancreas. The gastrointestinal tract is composed of all 
structures between mouth and anus, encompassing the oesophagus, stomach, small and large 
intestine. The digestive system has three important roles: breakdown food extracts, absorb 
the nutrients and, finally, expel metabolic waste products.  
In brief, the stomach stores food temporarily and initialises digestion mechanically by 
movement of the stomach, and chemically through secretion of pepsins and hydrochloric acid. 
The digestion process continues in the small intestine, the primary site of nutrient absorption 
(Boron and Boulpaep, 2016). The large intestine reabsorbs electrolytes and fluids and stores 
undigested material before expulsion from the body. Accessory glands and organs help the 
digestive process: the pancreas secretes digestive enzymes into the duodenum as well as 
bicarbonate (HCO3-) to neutralise acids from stomach. Bile is secreted by the liver and stored 
in the gallbladder before being secreted in the duodenum where it plays an important role in 
the digestion of fat (Boron and Boulpaep, 2016).  
1.1.1 Structure of the small and large intestine 
The intestine includes the small intestine encompassing the duodenum, jejunum and ileum 
and the large intestine or colon subdivided into ascending, transverse, descending, sigmoid 
colon and rectum. While the basic anatomical organisation of the gastrointestinal tract can 
vary along its length, a similar organisation can be found in the tissue structure from surface 
to lumen: a serosa, muscle layers (muscularis externa), a submucosa, and a mucosa (figure 
1.1). The serosa is a layer of connective tissue covered with squamous epithelial cells that 
envelops the muscularis externa. This muscle layer is composed of 2 layers of smooth muscle 
with the outer layer being longitudinal and the inner layer being circular muscle (Lowe and 
Anderson, 2015). The submucosal layer contains loose connective tissue with collagen and 
elastin fibrils, large blood vessels and glands that secrete intestinal fluid into the lumen. The 
mucosa is the inner layer of the gastrointestinal tract in contact with the lumen. It entails a 
muscularis mucosae, which is the last layer of smooth muscle, and contains the lamina propria 
and the epithelium (Lowe and Anderson, 2015; Boron and Boulpaep, 2016). The lamina 
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propria is a layer of loose connective tissue containing blood capillaries, enteric neurons 
(Furness, 2000), and immune cells such as lymphocytes and mast cells (Mowat and Agace, 
2014). The intestinal epithelium is a single layer of cells in close contact with the lumen of the 
gastrointestinal tract within which the nature of cells varies along the GI tract. In the small 
intestine the epithelial surface area is amplified by a monolayer of cells that evaginate into 
structures called villi and other structures called crypts (figure 1.1). In contrast, the colon only 
presents crypts or invagination, and has a surface epithelium. Therefore, crypts and villi allow 
for an enormous extension of the surface area in contact with the lumen, believed to be 
greater than 200m2 in humans (Vereecke, Beyaert and van Loo, 2011). 
 
Figure 1.1: Schematic illustration of the mammalian small intestinal. Figure adapted from Husvéth, 2011. 
 
1.1.2 Epithelial cells of the small and large intestine 
Small and large intestine epithelium regenerates rapidly with a complete cell renewal of 4-5 
days (Heath, 1996) and is composed of diverse cell populations. Enterocytes are the 
predominant cell type in the intestine and represent 80-95% of intestinal epithelial cells 
(Cheng and Leblond, 1974a; van der Flier and Clevers, 2009). Goblet cells represent 4-16% of 
the cellular population with their abundance increasing along the gastrointestinal tract (Hazel 
Cheng, 1974; Karam, 1999). Enteroendocrine and tuft cells represent 1% and 0.4% of the cell 
population, respectively (Cheng and Leblond, 1974b; Gerbe et al., 2011). Paneth cells are 
located at the bottom of the crypt in the small intestine. While the colon does not possess 
Paneth cells at the bottom of the crypts, Paneth-like cells were discovered in response to 
mucosal inflammation (Cunliffe et al., 2001; Fahlgren et al., 2003). Finally, M-cells, were 
described in the 1970s but are still a poorly defined cell lineage within the intestinal epithelium 











antigens (pinocytosis) and deliver/present these to underlying lymphocyte (Miller et al., 2007; 
Ohno, 2016). 
All cells from the large and small intestine are derived from stem cells. Stem cells are located 
at the niche of the crypt with an approximate ratio of 15 cells per crypt (Bjerknes and Cheng, 
1999; Clevers and Bevins, 2013), and are discernible by their Lgr5+ biomarker (Barker et al., 
2007). These stem cells proliferate to generate a pool of undifferentiated cells forming the 
transit amplifying (TA) zone which can replenish the stem cell pool following damage to the 
epithelial cell layer(Potten, Booth and Pritchard, 1997; Yan et al., 2012) as well as differentiate 
into non-multipotent epithelial cells from the secretory (goblet, Paneth and enteroendocrine 
cells) or absorptive (enterocytes) lineages (Barker and Clevers, 2010) (figure 1.2). The 
proliferative activity of the stem cells is Wnt-dependent, with evidence suggesting Wnt 
secretion by neighbouring Paneth cells and/or subepithelial telocytes (Sato et al., 2011; 
Shoshkes-Carmel et al., 2018). 
 
Figure 1.2: Schematic illustration of the structure of the intestinal structures from the small intestine and 
colon. The small intestine presents both crypts and villi whereas the colon presents crypts that end at the 
surface epithelium. In the intestine, enterocytes are the major type of cells, with other cell types such as 
enteroendocrine cells, goblet cells and tuft cells are distributed among the enterocytes. Intestinal epithelial 
stem cells, are present at the bottom of the crypt interspaced by Paneth cells. TA zone represents the transit 
amplifying zone. Figure adapted from Mowat and Agace, 2014. 
 
The cell differentiation process is regulated by the Notch signalling pathway (figure 1.3).  
Briefly, Notch receptors and ligands play a key role in cell allocation. When any of the 5 Notch 
ligands bind any of the 4 Notch receptors, the Notch receptor is cleaved. The free Notch 
intracellular domain (NICD) is translocated into the nucleus, which in turn promotes the 
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transcription of the Hairy/Enhancer of Split (HES). HES can inhibit the transcription factor 
Math1 (van der Flier and Clevers, 2009; May and Kaestner, 2010), allowing the cell to become 
an enterocyte. When the Notch signalling pathway is not active, expression of Math1 leads 
cells to a secretory fate (Yang et al., 2001). An important aspect of the Notch signalling 
pathway is its lateral inhibition of neighbouring cells that will, as a consequence, adopt a 
different fate (Artavanis-Tsakonas, Rand and Lake, 1999). Other specialisations in the 
secretory lineage occur to differentiate cells between Paneth cells, goblet cells and 
enteroendocrine cells with the transcription factors Ngn3 being essential for differentiation 
into enteroendocrine cells (Mellitzer et al., 2010). The inhibitory effect of Gfi1 on Ngn3 was 
proven necessary for the differentiation of cells into either Paneth or goblet cells (Shroyer et 
al., 2005). Klf4 was confirmed as essential for the differentiation of goblet cells (Katz et al., 
2002) and Sox9 crucial for the differentiation of Paneth cells (Mori-Akiyama et al., 2007). While 
also expressed in Tuft cells, Sox9 was not indispensable to their differentiation (Gerbe et al., 
2016). It was demonstrated that the Wnt pathway also impacted the cell differentiation of 
cells from the secretory lineage (Pinto et al., 2003). 
Cells from the TA zone migrate to the villi (or toward the surface epithelium in the case of the 
colon) except for Paneth cells and rare enteroendocrine cells which migrate to the niche of 




Figure 1.3: Simplified overview of the epithelial cell lineage differentiation in the intestine. Wnt and Notch 
pathways are acting on both the proliferation of the intestinal stem cells as well as the differentiation into the 
different cell types present in the epithelium. Figure adapted from (van der Flier and Clevers, 2009). 
 
Enteroendocrine cells 
Pear-shaped enteroendocrine cells (EEC) are located in the epithelium of the GI tract and 
represent 1% of the total epithelial cells in the small and large intestines. The apical surface 
presents microvilli directly into the GI lumen, while the basolateral surface releases hormone-
containing vesicles (Pearse et al., 1970; Schonhoff, Giel-Moloney and Leiter, 2004; Crosnier, 
Stamataki and Lewis, 2006). More than 10 subclasses of EECs have been identified and 
classified according to the principal peptide hormone that is produced within each cell. For 
instance, D-cells secrete somatostatin (Van Op den bosch et al., 2009), G-cells secrete gastrin 
(Dockray, Dimaline and Varro, 2005), I-cells secrete cholecystokinin (CCK) (Liddle, 1997), K-
cells secrete glucose-dependent insulinotropic polypeptide (GIP) (Baggio and Drucker, 2007), 
L cells produce glucagon-like peptides GLP1 and GLP2 as well as peptide YY (PYY) and insulin-
like 5 peptide (Insl5) (Sjölund et al., 1983; Habib et al., 2012; Drucker and Yusta, 2014; Billing 
et al., 2018). Although it was first believed that each subcategory of EECs only secreted 
hormones from a single peptide precursor (except in the case of PYY and GLP-1), new evidence 
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highlights the co-expression of hormones from individual cells (Habib et al., 2012; Fothergill 
et al., 2017). 
While some hormones such as serotonin (5-HT) and somatostatin are secreted by EECs 
throughout the entire gastrointestinal tract, subclasses of EECs are distributed to varying 
degrees along the small and large intestines (figure 1.4). Enterochromaffin cells (EC), 
enterochromaffin-like cells (ECL), D-cells, G-cells and P/D1 cells are present within the 
stomach. In the duodenum, K-cells, I-cells and S-cells are the major cell types found. N-cells 
are present in duodenum as well as jejunum and ileum. Finally, L-cells are produced 
throughout the whole intestine with a different secretion gradient between GLP, PYY and Insl5 
(Gribble and Reimann, 2016). The EEC lifecycle is estimated to 3-10 days in the duodenum and 
jejunum, and 60 days in ileum and colon (Tsubouchi and Leblond, 1979). 
 
Figure 1.4: Schematic representation of enteroendocrine hormone distribution and cell-type along the small 
and large intestine. Enteroendocrine hormones are secreted from specialised cell-types, with varying 
densities along the intestine as indicated. Figure adapted by F. Reimann, based on an immunohistochemical 
study by Sjölund et al., 1983 and updated to include Insl5 using data from Grosse et al., 2014.  
 
The main role of the EECs is to respond to nutrients passing through the GI tract and to 
transform the received information into gut hormone signals (Engelstoft et al., 2008). These 
signals can act locally to regulate gut motility, absorption, secretion of digestive enzymes as 
well as acting outside the gastrointestinal tract to regulate satiety, energy expenditure, energy 
homeostasis, and glucose homeostasis (Murphy and Bloom, 2006; Engelstoft et al., 2008; 




Goblet cells were so-named due to their cup-like appearance. Goblet cells are highly polarised 
with the nucleus confined to the basolateral side and secretory granules at the apical side of 
the cell. Granules distend the cell’s theca resulting in the goblet cell shape (Guyton and Hall, 
2016). The apical side of the cell presents microvilli increasing the surface area of the cell for 
secretion. They are the most abundant cells from the secretory lineage within the intestinal 
epithelium with up to 10-15% of the small intestine epithelium composed of goblet cells, while 
the colon epithelium may contain up to 50% of goblet cells (Noah, Donahue and Shroyer, 
2011).  
Goblet cells secrete mucins, in particular MUC2 which is the main structural molecule of the 
intestinal mucous. The assembly of this large and complex molecule is a major task for the 
goblet cell (Karlsson et al., 1996). It is assumed that the mucus secreted by goblet cells is the 
first line of defence against physical and chemical injury and therefore the main role of goblet 
cells is to function in the  innate immune response and the protection from pathogens (Kim 
and Ho, 2010; Johansson and Hansson, 2014; Pelaseyed et al., 2014). As well as mucins, goblet 
cells secrete components of the mucus layer such as the Fc-γ-binding protein (Fcgbp) which 
stabilises the mucous layer (Johansson, Thomsson and Hansson, 2009), resistin-like molecule 
β (RELMβ) inhibiting intestinal worm infection (Herbert et al., 2009), and trefoil peptides 
promoting the epithelial growth and repair (Taupin and Podolsky, 2003; Rodríguez-Piñeiro et 
al., 2013).  
Enterocytes 
Enterocytes (or colonocytes in the large intestine) are the most abundant cell type from 
duodenum to colon and usually represent more than 80% of all intestinal epithelial cells 
(Cheng and Leblond, 1974a). Their main role is the absorption of nutrients from the luminal 
surface and transfer to the basolateral side of the cell. Enterocytes are highly polarised cells 
that present rigid and closely positioned microvilli on the apical side. These microvilli, 
described as a brush border, increase the cell surface area in the intestinal lumen (Mooseker, 
1985). The enterocytes on the apical surface form a continuous, filamentous and negatively 
charged glycocalyx formed by acidic mucopolysaccharides and glycoproteins (Maury et al., 
1995). This glycocalyx layer contains glycoproteins and dissacharidases that facilitate terminal 
digestion (Semenza, 1986). The glycocalyx presence is also considered to serve as a protective 
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barrier for the epithelium as it prevents macromolecular aggregates, bacteria, and viruses to 
come in contact with the epithelium (Frey et al., 1996). 
As mentioned previously, enterocytes principle function is to absorb nutrient macromolecules 
across the epithelium to the basolateral side. Nutrients such as sugars, amino acids and ions 
are absorbed via epithelial transporters. Enterocytes, which are unable to perform 
phagocytosis, absorb macromolecules via pinocytosis: clathrin-mediated endocytosis and 
caveolae-mediated endocytosis mechanisms (Snoeck, Goddeeris and Cox, 2005). Enterocytes 
undergo continuous maturation throughout their movement towards the tip of the villus. 
When reaching the tip of the villus, the mature enterocyte’s life terminates by the cell’s 
expulsion in the lumen concomitantly to its apoptosis. It is suggested that cells are shed away 
by concerted contraction from neighbouring cells and cytoplasmic elongation underneath the 
detaching cell to preserve the epithelial barrier function and integrity during enterocyte death 
(Rosenblatt, Raff and Cramer, 2001; Vereecke, Beyaert and van Loo, 2011). 
Paneth cells  
In comparison with other cell lineages, the Paneth cell lineage is quite different. Paneth cells 
reside at the basis of the crypt of Lieberkühn in the small intestine only. They are the few rare 
cells, that when differentiating, migrate towards the crypt niche (H Cheng, 1974) where their 
differentiation is completed and the most matured cells can be identified (Bjerknes and Cheng, 
1981). Each crypt contains around 10 mature Paneth cells that have a life span of 30 days 
(Bjerknes and Cheng, 1981; Garabedian et al., 1997; Clevers and Bevins, 2013).  
Paneth cells contain large secretory granules that are present on the apical surface. These 
granules contain proteins that are involved in the innate immune response including α-
defensins, lysozyme, secretory phospholipase A2, lipopolysaccharide (LPS)-binding protein, 
RegIII-g, and xanthine oxidase, matrix metalloproteinase 7 (MMP7), CD95 ligand, IgA, CD1d, 
cysteine-rich intestinal polypeptide (CRIP), CD15, and metallothionein, as well as 
proinflammatory mediators (interleukin17A, tumour necrosis factor-α (TNF-α), IL-1b, and 
lipokines) (Ouellette, no date; Takahashi et al., 2008; Stappenbeck, 2009). Antimicrobial 
peptides and proteins are discharged via exocytosis in the lumen playing a key role to defend 
the crypt from microbial invasion in the crypt. The antimicrobial peptides defence extends to 
the mucosal epithelium via their diffusion through the mucus layer (Meyer-Hoffert et al., 
2008). The defence provided by the antimicrobial peptides also contribute to the microbiota 
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composition (Forte, 1999; Peterson et al., 2007; Hapfelmeier et al., 2010; Salzman et al., 
2010). 
A final important role of the Paneth cells is their implication in the stem cell niche and on the 
stem cells. It was shown that the Paneth cells support the stem cells in “minigut” organoid 
cultures by secreting EGF, Wnt3 and Notch ligand Dll4 (Sato et al., 2011). Paneth cells could 
play as nutritional sensors and adjust the stem cell response to calorie restriction through the 
mTORC1 signalling pathway (Yilmaz et al., 2012). 
Tuft cells 
Tuft cells (or brush cells) are a rare type of epithelial cells that account for 0.4-1% of the total 
intestinal epithelial cell population (Gerbe, Legraverend and Jay, 2012; Howitt et al., 2016). 
Their characteristic shape consists of brush-like microvilli on the apical side with the presence 
of lateral microvilli (von Moltke, 2018). The role of the apical brush-like process has not been 
defined as their characterisation has been limited by the lack of cell-specific markers. 
However, more recently, doublecortin-like kinase 1 (DCLK1) has recently been identified as a 
putative specific marker for tuft cells (Gerbe et al., 2016; Howitt et al., 2016; von Moltke et 
al., 2016).  
It has been suggested that tuft cells may serve as taste chemosensory cells. Evidence showed 
that tuft cells express taste-related GPCRs such as the taste receptor type1 members 1 and 3 
(Bezencon, le Coutre and Damak, 2007; Hass, Schwarzenbacher and Breer, 2010) as well as 
taste-related proteins: transient receptor potential cation channel subfamily M member 5 
(Trpm5) and Phospholipase Cβ2 (PLCβ2) (Bezencon, le Coutre and Damak, 2007; Bezençon et 
al., 2008; Liu et al., 2011) which convert bitter, sweet and umami tastes into signals.  
M cells 
M cells (or Microfold cells) are a poorly characterised cell type found in the follicle-associated 
epithelium (FAE) of Peyer’s patches and lymphoid follicles and account for 5-10% of epithelial 
cells in those areas (Owen and Jones, 1974b). M cells display fold-like structures (that gave 
the name microfold cells) on the apical side instead of microvilli, and the basolateral side is 
invaginated. These invaginations accommodate dendritic cells, macrophages or lymphocytes, 
and facilitate the presentation of microbes to those antigen-presenting cells (Brandtzaeg et 
al., 2008). For instance, glycoprotein 2 (GP2) is an M cell specific marker working as a bacterial 
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receptor (Hase et al., 2009). Therefore, it is suggested that the role of M cells is to sample the 
lumen and transfer the detected pathogens to the immune system (Ohno, 2016). 
1.1.3 Microbiota and cross-talk with the gut epithelium 
In addition to containing food and nutrients, the intestinal lumen also comprises a diverse and 
dynamic microorganism population that inhabits or passes by the gastrointestinal tract, called 
gut microbiota. The number of microorganisms is estimated to be above 1014 with a combined 
genome containing at least 100 times as many genes as the human genome (Bäckhed et al., 
2005; Gill et al., 2006). The microbiota is not only comprised of bacteria, but also archaea, 
fungi, viruses and parasites can also be present and play a role in a mutually beneficial 
relationship with the host (Neish, 2009; Scarpellini et al., 2015). 
It is now assumed that the microbiota offers benefits to the host and acts in multiple 
physiological roles such as housekeeping the intestinal epithelium integrity (Natividad and 
Verdu, 2013), immunity (Gerritsen et al., 2011; Bäumler and Sperandio, 2016) and nutrition 
(den Besten et al., 2013). Digestive metabolic pathways of anaerobic microbiota leads to the 
release of vitamin K, folate or short-chain fatty acids (SCFAs). SCFAs, a fermentation end 
product of dietary fibre constitutes an important source of energy to the host and a key 
metabolic mediator (Tolhurst et al., 2012; Larraufie et al., 2018; Lu, Gribble and Reimann, 
2018). It was also suggested that SCFAs have an effect on host immunity (Biagi et al., 2013). 
As described previously, the intestinal epithelium offers a strong physical and chemical barrier 
to detrimental enteric microorganisms. It is suspected that the enterocyte closely packed villi 
structure, as well as the presence of glycoprotein enzymes, brush border glycocalyx and 
secretion of antibacterial mucins and defensins in the mucus, are all measures employed by 
the host to defend itself. The microbiota provides another important protective line of 
resistance against exogenous bacteria and prevents potential invasion. The microbiota can 
prevent pathogen attachment to the epithelial cells using antimicrobial activity 
(Klaenhammer, 1993; Ramare et al., 1993; Riley and Wertz, 2002; Servin, 2004) as well as 
competing for nutrient availability (Hooper et al., 1999; Nicholson and Wilson, 2003; Srikanth 
and McCormick, 2008).  
Even though microbiota and host work cooperatively to protect the integrity of the intestinal 
epithelial, exogenous microbiota-fashioned counter strategies can be used to take-over 
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signalling pathways and cellular mechanisms, with some pathogenic microbes targeting 
specific epithelial structures (Schauer, 1997). For instance, it was shown that human 
enterotoxigenic E. coli (ETEC) strains bind via their pili to epithelial cells before starting a 
colonisation process associated with acute diarrheal disease (Deneke et al., 1983). These ETEC 
can then deregulate fluid secretion and provoke secretory diarrhoea via their enterotoxin 
peptides such as the heat stable peptides variants (STa) acting via the endogenous guanylate 
cyclase C (GC-C) receptor present on enterocytes (Carey, 1978; Field et al., 1978; Hughes et 
al., 1978). 
1.2 Guanylin peptides 
1.2.1 The guanylate cyclase C receptor and its activation 
The guanylate cyclase C (GC-C) receptor is a type I transmembrane receptor that belongs to a 
large natriuretic peptide receptor family: the guanylate cyclase receptors. The guanylate 
cyclase family responds to a diverse range of signals that catalyse the conversion of guanosine 
triphosphate to cyclic guanosine-3′,5′ monophosphate (cGMP). (Schulz et al., 1990).  
The GC-C is a 1050 amino acid protein consisting of an extracellular receptor domain and a 
transmembrane domain, as well as kinase and catalytic domains (Vaandrager, 2002). The 
receptor is mainly expressed in the intestine on the brush border membrane of epithelial cells 
(de Jonge, 1975) and is distributed throughout the small intestine along the crypt-villus axis. 
In the colon, the receptor is mainly restricted to the crypts (Basu and Visweswariah, 2010). 
Orthologue GC-C receptors were identified in birds and fish substantiating its evolutionary 
conservation and probable importance (Biswas et al., 2009). The GC-C was discovered in the 
1970s as the intestinal receptor for exogenous diarrhoeagenic bacterial heat-stable 
enterotoxins (STs) (Field et al., 1978; Hughes et al., 1978). When investigating the cause of 
bacterial diarrhoea, boiling diarrhoea-inducing substances was demonstrated insufficient to 
eliminate the diarrheal effect, thus concluding that heat-stable toxins were activating the 
receptor as well as heat-labile toxins (Forte, 2004b). GC-C was found to be the principal 
receptor for heat-stable enterotoxins (STa), a major causative factor in ETEC-induced 
secretory diarrhoea, causing the commonly experienced “traveller’s diarrhoea” as well as 
significantly contributing towards increased infant mortality in developing countries (Field et 
al., 1978; Hughes et al., 1978; Okoh and Osode, 2008). To date, only two endogenous ligands 
have been found in humans, namely guanylin and uroguanylin. 
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1.2.2 Discovery of the guanylin peptides 
Identification of STa as an exogenous ligand for the GC-C receptor in the small and large 
intestines did not initially prompt the search for potential endogenous ligands. Fifteen years 
after the discovery of the receptor, the endogenous counterparts to STa, guanylin and 
uroguanylin, were discovered in 1992 and 1993, respectively (Mark G Currie et al., 1992; 
Hamra et al., 1993). Guanylin was initially purified from rat jejunum and demonstrated to 
increase cGMP levels in T84 human colon carcinoma cells. The protein sequence was assessed 
using an automated Edman degradation chemistry which allowed the determination of 
protein sequence after extracting the peptides by boiling the tissue samples in acid (Mark G 
Currie et al., 1992).  
When extracts of rat kidney showed cGMP-stimulating activity in T84 cells such as STa or 
guanylin (M G Currie et al., 1992; Schulz, Chrisman and Garbers, 1992), a renal source of 
guanylin was investigated. Hamra et al., anticipating the isolation of guanylin from opossum’s 
urine, were surprised to isolate two peptides that activated the human intestinal T84 cell GC-
C. The first was guanylin while the second was a closely related 16 amino-acid peptide 
containing 53% homology with guanylin. Due to the location of its discovery and having a 
similar activity to guanylin, this new peptide was named uroguanylin (Hamra et al., 1993). 
Guanylin peptides is the common idiom used when referring to both peptides.  
Both guanylin and uroguanylin are the active peptide domains of longer proforms 
(ProGuanylin and ProUroguanylin) which present little or undetectable biological activity on 
the GC-C receptor (de Sauvage et al., 1992; Hamra et al., 1996). Uroguanylin and guanylin 
affinities to the GC-C were evaluated to be 10 and 100-fold lower, respectively, in comparison 
to the ST enterotoxin (Forte et al., 1993; Hamra et al., 1993). Recent studies showed that 
guanylin and uroguanylin peptides are able to bind to another guanylate cyclase receptor, GC-
D, that is expressed in olfactory bulb epithelium (Leinders-Zufall et al., 2007; Cockerham et al., 
2009; Duda and Sharma, 2009).  
1.3 Structure, expression and secretion of the guanylin peptides 
1.3.1 Structure of guanylin-related peptides 
To date, four known guanylin-related peptides have been identified. Guanylin and uroguanylin 
were found in multiple species ranging from rodents (Wiegand, Kato and Currie, 1992) to 
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humans (Wiegand et al., 1992; Kita et al., 1994). The two other closely related peptides, called 
lymphoguanylin and renoguanylin have not yet be identified in humans. Lymphoguanylin was 
isolated from opposum’s spleen through transcript analysis and presents 40% and 80% 
homology with guanylin and uroguanylin, respectively. Lymphoguanylin is able to activate GC-
C in a similar fashion to guanylin and uroguanylin (Forte et al., 1999). Renoguanylin was shown 
to be expressed exclusively in the intestine and kidney of eels (Yuge et al., 2003). It presents 
75% and 88% homology with guanylin and uroguanylin, respectively. In conclusion, guanylin 
and uroguanylin are closely related peptides, and peptide orthologues are highly conserved 
across vertebrates (figure 1.5) suggesting an evolutionary conserved role for these peptides. 
 
Figure 1.5: Amino Acid sequences of active guanylin and uroguanylin in different species. Amino acid 
residues identical to the human sequence are highlighted. 
 
The human genes encoding for guanylin and uroguanylin are located on chromosome 1 (1p34-
35 and 1p33-34, respectively) (Hill et al., 1995; Magert et al., 1998) and, the mouse genes are 
found on chromosome 4 (Sciaky, Kosiba and Cohen, 1994; Whitaker, Steinbrecher, et al., 
1997). Interestingly, guanylin and uroguanylin loci are in close proximity to genes that encode 
other natriuretic peptides. Indeed, the human atrial natriuretic peptide (ANP) gene is present 
on chromosome 1 in position 1p36.2 (Yang-Feng et al., 1985), as well as the brain natriuretic 
peptide (BNP) gene (Steinhelper, 1993; Arden et al., 1995). The C-type natriuretic peptide 
gene is however localised on chromosome 2 in humans (Ogawa et al., 1994). ANP and BNP 
activate receptors from the guanylate cyclase receptor family and like guanylin and 
uroguanylin, generate intracellular cGMP (Schulz, 1999).  
human P G T C E I C A Y A A C T G C
eel Y D E C E I C MF A A C T G C
pig P S T C E I C A Y A A C A G C
guinea pig P S T C E I C A Y A A C A G C
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The genes encoding guanylin and uroguanylin possess similar genomic structures with 3 exons 
and 2 introns. Both peptides are synthesised as preprohormones and post-translationally 
processed by prohormone convertases of uncertain identity to remove the signal peptide and 
produce further prohormone intermediates and, eventually, the bioactive peptide (de 
Sauvage et al., 1992; Kita et al., 1994) (figure 1.6). The preprohormone pre-ProGuanylin, 
consists of 115 amino acids and is processed to give a 94 amino acid prohormone 
(ProGuanylin) with further processing resulting in the putative bioactive guanylin protein 
consisting of a 15 amino acids (de Sauvage et al., 1992). Similarly, pre-ProUroguanylin consists 
of 112 amino acids and is processed to give an 86 amino acid intermediate with the believed 
active version of uroguanylin, consisting of a 16 amino acid peptide (Kita et al., 1994).  
Figure 1.6: Schematic overview of the assumed synthesis and processing of guanylin and uroguanylin 
peptides. Guanylin and uroguanylin have 3 exons and 2 introns. Once translated into pre-ProGuanylin and 
pro-ProUroguanylin, the signal peptide is cleaved giving a 94 amino acids ProGuanylin, and a 86 amino acids 
ProUroguanylin. Prohormone convertases are believed to cleave the proforms resulting in a 15 amino acids 
guanylin and a 16 amino acids uroguanylin. Figure adapted from Sindic et al., 2013. 
 
Both active peptides adopt similar tertiary structures owing to the presence of two disulfide 
bonds, with the configuration Cys4–Cys12 and Cys7–Cys15 for both guanylin and uroguanylin. 
These disulphide bonds were revealed to be essential for peptide function (Nokihara et al., 
1997). Furthermore, guanylin and uroguanylin share a highly conserved five amino acid C-
terminal motif (Ala-Cys-Thr-Gly-Cys) which is assumed to be required for GC-C receptor 
activation as it is the common motif between the guanylin peptides and the ST peptide (Forte, 
2004a). 
The structural difference between guanylin and uroguanylin distinguishes them in their 




















proteolytic attack and inactivation by endoproteases, such as chymotrypsin, due to the 
presence of a critical asparagine residue. In contrast, guanylin has a tyrosine residue rather 
than asparagine in the same position, rendering the peptide sensitive to degradation by 
chymotrypsin with further degradation occurring within urine (Hamra et al., 1996).  Moreover, 
the affinity of guanylin peptides to their cognate receptor, GC-C, is pH dependent. Hamra et 
al. showed that the N-termini of both peptides affects their pH dependence. Uroguanylin was 
more potent at pH 5 whereas guanylin exhibited increased potency in more basic conditions 
(pH 8) (Hamra et al., 1997). It is established that the surface of the intestinal epithelium 
presents a different microenvironment with variable pH, with the colonic lumen becoming 
more acidic due to the release of SCFAs by the microbiota (Bown et al., 1974; Daniel et al., 
1985; Chu and Montrose, 1995). Hamra et al. concluded that guanylin was potent in pH 
conditions rendering uroguanylin’s potency low and vice versa. 
1.3.2 Tissue distribution 
The predominant location of guanylin and uroguanylin expression is the intestine. Uroguanylin 
expression is higher in the proximal intestine and decreases distally along the axis of the small 
intestine and colon. In contrast, guanylin expression in the gut is highest distally (Whitaker, 
Witte, et al., 1997). Transcripts levels of mRNA were also found in the kidney. Uroguanylin 
was expressed abundantly in comparison with guanylin, and patterns of expression also 
differed. Isolation of proximal tubules and collecting duct allowed Potthast and colleagues to 
perform qPCR on uroguanylin and guanylin (Potthast et al., 2001). The investigators found that 
uroguanylin expression was highest in the proximal tubules and lowest in the other segments 
tested (glomeruli, thick ascending limbs of Henle’s loop and collecting ducts). Guanylin mRNA 
expression was detectable in the collecting duct and followed an opposite distribution when 
compared with uroguanylin expression (Potthast et al., 2001). 
Renewed research interest in the localisation of guanylin peptides occurred during the 1990s 
and early 2000s, however during this period the available reagents and utilised detection 
methods did not generate reliable and reproducible data. Uroguanylin was detected in lung, 
pancreas, stomach, salivary glands, pancreatic islet β cells in rats (Miyazato et al., 1996; 
Nakazato et al., 1998; Kulaksiz, Rausch, et al., 2001; Kulaksiz, Schmid, et al., 2001; Kulaksiz et 
al., 2004). Guanylin expression was detected in opossum’s brain and reproductive organs, liver 
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and gallbladder (Fan et al., 1997; Jaleel et al., 2002; Schwabe and Cetin, 2012). Details of their 
localisation and used methods will be discussed further in chapter 7.  
The GC-C receptor is primarily localised on the apical brush border membrane of intestinal 
and colonic epithelium (Krause’ et al., 1994; Nandi, Bhandari and Visweswariah, 1997; Qian et 
al., 2000). Qian et al. found that GC-C mRNA levels were relatively uniform in all regions of the 
intestine. However, Krause et al. showed that the distribution of GC-C expression decreased 
distally along the axis of the small intestine and colon using both binding of radiolabelled ST 
to GC-C receptor and a cGMP accumulation bioassay of intestinal mucosa. Interestingly, GC-C 
expression was shown to be high in neonates which may explain an apparent increased 
sensitivity of this population to the effects of the heat stable E. coli enterotoxin STa (Cohen et 
al., 1988; Al-Majali et al., 2007). 
The GC-C receptor is also expressed in a number of extra-intestinal tissues. In opossum, high 
levels of GC-C mRNA have been measured in the renal cortex (London et al., 1999) and recent 
studies in rodents have identified GC-C mRNA expression in the mediobasal hypothalamus 
(Valentino et al., 2011). The GC-C was also identified in midbrain dopamine neurons (Gong et 
al., 2011) as well as in the hypothalamus and, more specifically, arcuate nucleus in mice (Kim 
et al., 2016). Subsequent studies have suggested an integral role for this receptor in the 
regulation of food intake and energy homeostasis (Valentino et al., 2011; Cintia Folgueira et 
al., 2016). 
1.3.3 Site-directed secretion of ProGuanylin and ProUroguanylin 
After the discovery of the guanylin peptides and their role in intestinal water and electrolyte 
homeostasis, research focused mainly on the possible roles for these peptides in the kidney.  
Such studies focused on the mechanisms by which guanylin peptides access the kidney and 
the factors that regulate their secretion from intestinal epithelial cells. In order for these 
peptides to activate distant targets expressed in the kidney or the brain, they must be secreted 
into the circulation. Using immunoassays and Reversed-Phase High-Performance Liquid 
Chromatography (RP-HPLC), Kinoshita et al. found that uroguanylin and ProUroguanylin 
circulate in the bloodstream with ProUroguanylin identified as the predominant circulating 
form (Kinoshita, Fujimoto, et al., 1997; Kinoshita et al., 1999). Through the use of Ussing 
chambers, subsequent studies found that both ProGuanylin and guanylin were detected on 
the basolateral side of the membrane upon stimulation with several different stimulants 
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including bombesin, bethanechol, 8-Br-cGMP and carbachol (Martin et al., 1999). To date, this 
study is the only one to provide experimental evidence supporting bidirectional secretion of 
guanylin peptides from intestinal epithelial cells. Secretion from the luminal side would affect 
the water and salt homeostasis locally, and basal secretion may exert an endocrine effect on 
distant organs (such as kidney and brain). Martin et al. suggested that guanylin was mainly 
secreted from the luminal side with the concentration of guanylin 6-fold higher than levels 
measured from the basolateral membrane of the Ussing chambers. To date, the sole source 
of circulating guanylin peptides is believed to be the intestine. 
1.4 Physiology of guanylin peptides 
1.4.1 Guanylin and uroguanylin as intestinal natriuretic peptides  
The role of the guanylin peptides in the gastrointestinal tract became of interest when 
intraluminal guanylin and uroguanylin were shown to activate the GC-C receptor localised in 
the brush border membrane of enterocytes. Both guanylin and uroguanylin were shown to 
stimulate transepithelial chloride secretion in a T84 assay model (Hamra et al., 1993; Kita et 
al., 1994; Nokihara et al., 1997). An early study by Carrithers et al. supported natriuretic roles 
of the guanylin peptides by demonstrating that sodium chloride intake increased Guca2a 
mRNA expression in rat intestine (Carrithers et al., 2002). Human data corroborated these 
findings with uroguanylin plasma levels and urinary secretion higher in healthy participants on 
a high-salt diet compared to those on a low salt diet (Kinoshita, Fujimoto, et al., 1997). 
In the intestine, the binding of uroguanylin to the GC-C receptor leads to the secretion of Cl-, 
HCO3- and Na+ as well as water in the lumen (figure 1.7) via activation of the cystic fibrosis 
transmembrane regulator anion channel (CFTR) (Cuthbert et al., 1994).  
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Figure 1.7: Proposed signalling pathways of the guanylin peptides in the intestine. Guanylin peptides activate 
the GC-C receptor on the luminal side leading to the generation of cGMP. Intracellular cGMP subsequently 
binds and activates 3 downstream effectors: cGMP-dependent protein kinases (PKGs), phosphodiesterases 
(PDEs) and cAMP-dependent protein kinases (PKAs). The increasing concentration of cGMP inhibits the Na+/H+ 
exchanger type 2 (NHE2) and activates the protein Kinase G type II (PKG2). Activation of the cGMP also 
stimulates the Protein Kinase A (PKA) in two different ways. Firstly, it can activate PKA directly. Secondly it can 
activate PKA indirectly by the inhibiting the phosphodiesterase III (PDE3). This inhibition will lead to an increase 
in cAMP which will in turn activate PKA. Finally, PKA and PKGII will both phosphorylate the CFTR leading to an 
efflux of Cl- in the lumen. This extracellular Cl- secretion will stimulate the Cl-/HCO3-exchanger. The amount of 
electrolyte will increase in the intestinal lumen and the increased osmolarity will reduce the water absorption 
from the lumen to the blood. Figure adapted from Rahbi et al., 2012. 
 
The GC-C receptor is activated following binding of either the STa toxin or the cognate ligands 
guanylin or uroguanylin to the extracellular domain of the GC-C. The guanylate cyclase 
catalytic domain leads to an increased intracellular concentration of cGMP. cGMP, in turn, 
stimulates the opening of the CFTR resulting in an increased secretion of chloride and 
bicarbonate via two different mechanisms; the first is phosphorylation by cGMP-dependent 
protein kinase II (PKGII) (French et al., 1995; Vaandrager, Bot and De Jonge, 1997) or by cAMP-
dependent protein kinase II (PKAII) (Forte et al., 1992; Chao et al., 1994). cGMP inhibits 
phosphodiesterase III (PDEIII), which hydrolyses cAMP into AMP, increasing intracellular cAMP 
which consequently activates PKAII (Vaandrager et al., 2000). Activity of cGMP activity does 
not only stimulate chloride and bicarbonate secretion in the lumen, but also acts as an 
inhibitor of the sodium/hydrogen exchanger (NHE2) (Toriano et al., 2011). The increased 



































1.4.2 Uroguanylin a new satiety hormone  
Guanylyl cyclase and its signalling product cGMP are involved in the control of food intake and 
satiety in two invertebrates; Drosophila (Kaun et al., 2007) and C. elegans (You et al., 2008). A 
role for uroguanylin in the regulation of energy homeostasis and as a novel regulator of the 
gut-brain axis has been suggested (Valentino et al., 2011). Mice lacking GC-C (GC-C-/-) were 
found to be hyperphagic and heavier compared with wild-type (WT) mice. Furthermore, GC-
C-/- mice exhibited cardiac hypertrophy, hyperleptinemia, hyperinsulinemia and impaired 
glucose tolerance. Systemic administration of a GC-C ligand STa induced satiety in WT but not 
GC-C-/- mice. These findings coupled with the detection of RNA expression of the GC-C receptor 
in the mediobasal hypothalamus supported GC-C activation as a mechanism to induce satiety. 
Intestinal secretion of ProUroguanylin was stimulated upon food consumption which 
subsequently induced satiety. As no endogenous ligand for the GC-C receptor was found in 
the hypothalamus, the authors concluded that food consumption induced secretion of 
ProUroguanylin from intestinal epithelial cells into the systemic circulation followed by 
proteolytic cleavage within the hypothalamus, by an unknown proteolytic enzyme, into the 
active peptide uroguanylin.  
Data published in 2015 found similar results for uroguanylin and contributed towards its 
potential role in energy homeostasis. The chronic central infusion of uroguanylin decreased 
adiposity and body weight in diet-induced obesity (DIO) mice without causing a change in food 
intake. Centrally administered uroguanylin induced browning of the white adipose tissue 
(WAT) to promote brown adipose tissue (BAT) thermogenesis. Finally faecal output was 
increased through the parasympathetic nervous system when uroguanylin was centrally 
infused and compared in mice that received a surgical vagotomy (Cintia Folgueira et al., 2016). 
The same lab found that mice fasted for 48hrs showed significantly reduced levels of 
uroguanylin in plasma compared to mice fed ad libitum. Plasma levels of uroguanylin returned 
to baseline when the animals were fed again or following leptin challenge (C. Folgueira et al., 
2016). In leptin deficient ob/ob mice, uroguanylin levels were unchanged after fasting but 
leptin treatment increased the uroguanylin levels to levels observed in WT mice fed ad libitum. 
The authors concluded that ProUroguanylin was a nutritional status regulator but that it was 
leptin dependent (C. Folgueira et al., 2016).  
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In humans, recent clinical studies have found decreased uroguanylin levels in obese 
adolescent and adult subjects when compared to healthy participants (A. Rodríguez et al., 
2016; Di Guglielmo, Perdue, et al., 2018; Di Guglielmo, Tonb, et al., 2018). However transcript 
levels of both GUCA2A and GUCA2B were significantly higher in the jejunal division site of 
patients following Roux-en-Y gastric bypass surgery when compared to levels before the 
operation (Fernandez-Cachon et al., 2018). 
However, results from Begg et al. have questioned the link between central administration of 
uroguanylin and food intake or body weight change in lean mice. GC-C-/- mice were not 
hyperphagic and heavier compared with wild-type animals. Mice lacking the Guca2b gene 
(Guca2b-/-) were found to have a slight increase in adiposity and body weight, in addition to 
glucose intolerance. The methodology of this work was different to the previously described 
studies, which could explain the different results obtained. For example, the use of lean rats 
for GC-C agonist studies, feeding regime, and animal sex all differed from the original protocol 
(Begg et al., 2014).  
1.4.3 Guanylin peptides and crypt-villous proliferation 
As mentioned previously in 1.1.2, the intestinal epithelium undergoes continuous 
regeneration via stem cells at the base of the crypt-villus axis following a cycle of proliferation, 
differentiation and metabolic maturation before apoptosis (Bjerknes and Cheng, 1999; Barker, 
van de Wetering and Clevers, 2008; Clevers, 2013). There is an increasing number of 
publications recognising a relationship between GC-C receptor expression and a potential 
anti-proliferative action in the intestine. For instance, in GC-C-/- mice, the length of the crypts 
from duodenum to colon were considered longer when compared to WT mice (Li, Lin, et al., 
2007). Hyperplasia caused by proliferating cells was associated with an increase in cell 
migration and apoptosis in GC-C-/- mouse colon. Enterocyte proliferation was also observed 
when compared with cells from the secretory lineage (Li, Lin, et al., 2007). In a subsequent 
study, deletion of GC-C in mice carrying an adenomatous polyposis coli (APC) mutation, a 
tumour suppressor gene, increased the incidence of tumours within the colon as well as 
altering the genomic integrity of the tumour (Yang et al., 1997; Fodde and Smits, 2001). 
However in the small intestine, GC-C deficiency increased tumorigenesis through enhanced 
proliferation without modification of genomic integrity (Li, Schulz, et al., 2007). Additional 
observations suggest that cGMP production increases expression and activity of the tumour 
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suppressor PTEN (Phosphatase and tensin homolog) and therefore inhibits the v-akt murine 
thymoma viral oncogene homolog 1 (AKT) signalling (Lin et al., 2010a; Gibbons et al., 2013). 
AKT inhibition would reverse the tumorigenic Warburg metabolic phenotype in human and 
murine colon cancer cells through coordinated regulation of cell cycle, metabolism, 
chromosomal instability and/or cell death (Robey and Hay, 2009; Ward and Thompson, 2012).  
Therefore, reduced GC-C receptor signalling is assumed to have impaired epithelial cell 
function that increases the susceptibility to intestinal tumorigenesis and colorectal cancer. 
These data suggest that the GC-C receptor may serve as a tumour repressor, but surprisingly 
its expression is conserved and over-expressed in some colorectal tumours (Schulz et al., 
2006). A plethora of publications highlight the fact that the expression of guanylin and 
uroguanylin are commonly absent in colorectal cancer. The loss of gene transcripts happens 
early on in the transformation process and could play a role at an early stage of carcinogenesis 
(Zhang, 1997; Cohen, Hawkins and Witte, 1998; Steinbrecher et al., 2000, 2002; Notterman et 
al., 2001; Glebov et al., 2006). Guanylin peptide loss was subsequently defined in adenomas, 
as well as in adenocarcinomas. In a cohort of more than 280 volunteers with stage I–III 
colorectal cancer, guanylin mRNA and protein expression were lost or significantly lower (100-
1000 fold lower) in cancerous tissues compared to healthy adjacent tissues for more than 85% 
of the volunteers (Wilson et al., 2014). The deficiency of guanylin and uroguanylin expression 
may silence the GC-C, which would normally act as a tumour suppressor and interrupt the 
homeostatic mechanisms that regulate the colorectal epithelium. In conclusion, the guanylin 
peptides may impact crypt-villous proliferation through activation and maintenance of the GC-
C receptor. 
1.4.4 Uroguanylin, a controversial role in the gastrointestinal-renal natriuretic signalling axis 
In 1975, it was demonstrated that human kidney presented a greater natriuretic response to 
an oral load of sodium compared with an equivalent amount of sodium delivered 
intravenously (Lennane et al., 1975; Carey, 1978). This led to the hypothesis that the 
gastrointestinal tract complements the action of the Renin-Angiotensin-Aldosterone System 
and the Atrial Natriuretic Peptide (ANP) in the monitoring of a natriuretic response to 
postprandial salt absorption. Renewed interest in the role of the gastrointestinal tract in the 
maintenance of salt and water homeostasis increased following the discovery of the action of 
guanylin peptides in the intestine.  
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It was established that guanylin peptides promote natriuretic, kaliuretic and diuretic effects in 
mice in a dose and time dependent manner. Using a sealed-urethra mouse model, it was 
shown that the injection of uroguanylin or guanylin increased renal sodium excretion while 
glomerular filtration rate (GFR), plasma creatinine concentration, urine osmolarity, heart rate, 
and blood pressure remained constant (Carrithers et al., 1999). In another study, uroguanylin 
knockout mice were found to have an impaired salt excretion (Lorenz et al., 2003).  
While researchers largely agree on the natriuretic effect of guanylin peptides in kidney, the 
mode of action and origin of the peptides are more controversial topics. Researchers have 
proposed both a similar mechanism to the one found in the intestine, and an alternate GC-C 
independent pathway. Corroborating the first hypothesis, highly expressed GC-C receptor was 
observed in opposum’s kidney (London et al., 1999) and there is a strong correlation between 
urinary excretion of uroguanylin and the cGMP response to high-salt diet (Kinoshita, Fujimoto, 
et al., 1997). However, GC-C-/- mice presented a uroguanylin-induced natriuretic renal effect 
(Carrithers et al., 1999, 2004) and GC-C transcript expression was undetectable in rat kidney 
((Qian et al., 2011). 
Furthermore, the source of guanylin peptides that would mediate renal action has been 
subject to debate. The fact that uroguanylin transcript levels are undetectable in the kidney 
(Forte, Fan and Hamra, 1996; Li et al., 1997) and the presence of proforms in plasma (Moss et 
al., 2008) with indication that ProUroguanylin was processed as the active peptide in the 
kidney (Qian et al., 2008) has substantiated this theory. However rats and mice fed a high-salt 
diet did not exhibit significant differences in uroguanylin or ProUroguanylin plasma despite 
having higher levels of uroguanylin in urine, therefore supporting a renal origin of uroguanylin 
(Fukae et al., 2002; Elitsur et al., 2006).  
In 2012, a study by Preston and colleagues suggested that a gastrointestinal-renal axis that 
controls renal natriuresis may not exist in humans. The authors found no difference in the 
cumulative or hourly natriuretic response to oral versus intravenous sodium administration 
(Preston et al., 2012). Whilst no difference in intestinal salt secretion was detected, this study 





1.5.1 Molecular genetics of familial diarrhoea and meconium ileus syndromes 
The intestinal natriuretic action of the guanylin peptides and the role they play in water and 
electrolyte homeostasis might be of crucial importance to gut transit. Indeed, studies have 
reported that genetic mutations in the GC-C receptor alter gastrointestinal transit, resulting 
in syndromes characterised by either diarrhoea or meconium ileus.  
Fiskerstrand et al. studied 32 members of a Norwegian family that were affected by chronic 
diarrhoea and compared them to 14 family members that were not affected. After performing 
exome sequencing, a heterozygous missense mutation (c.2519G→T) was found in the GC-C 
receptor of all affected family members. Functional studies of the mutant GC-C were 
performed using transfected HEK293T cell lines and a cGMP functional assay. This mutation 
caused an overproduction of cGMP which likely triggers hyperactivation of CFTR resulting in 
increased chloride and water secretion from enterocytes to the gut lumen leading to chronic 
diarrhoea. For the same guanylin or uroguanylin concentration, the mutant GC-C was more 
active and resulted in abnormal levels of cGMP in the intestinal cells. Family members affected 
by the mutation appeared to have predispositions to small bowel obstruction or oesophageal 
hernia  (Fiskerstrand et al., 2012).  
In a study of four unrelated volunteers suffering from congenital sodium diarrhoea (CSD) 
syndromes, missense mutations in the GC-C sequence were detected by whole-exome 
sequencing and chromosomal microarray analyses (Müller et al., 2015).  All mutations were 
functionally studied in transfected HEK293T cells. All mutations enhanced intracellular cGMP 
to endogenous and exogenous ligands; this was not a consequence of increased ligand-
receptor binding, but rather was due to hyperactivation of the mutant receptors (Müller et 
al., 2015). 
Finally, meconium ileus is a condition where the content of infant distal ileum and cecum is 
extremely sticky and causes the bowel to be blocked at birth. More than 80% of cases are 
caused by mutations of the CFTR (Rosenstein and Langbaum, 1980) and 15-20% of infants with 
cystic fibrosis develop meconium ileus (Eggermont, 1996). However, 20% of new-borns 
suffering meconium ileus had no clinical evidence of cystic fibrosis (Fakhoury et al., 1992). Two 
independent studies identified loss of function mutations in GUCY2C (GC-C gene) in two 
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unrelated Bedouin and one Lebanese family, with infants presenting with meconium ileus but 
no other features suggestive of cystic fibrosis (Romi, Cohen, Landau, Alkrinawi, Yerushalmi, 
Hershkovitz, Newman-Heiman, Garry R. Cutting, et al., 2012; Smith et al., 2015). In the 
Bedouin kindred, a homozygous missense mutation in the extracellular domain of the GC-C 
receptor led to reduced synthesis of cGMP and a reduction of the CFTR activity (Romi, Cohen, 
Landau, Alkrinawi, Yerushalmi, Hershkovitz, Newman-Heiman, Garry R. Cutting, et al., 2012). 
In the Lebanese kindred, a homozygous truncating mutation cleaved the guanylate cyclase 
catalytic domain and abrogated the production of cGMP and therefore CFTR activity (Smith et 
al., 2015).  
1.5.2 Role of guanylin in colorectal cancer 
Intestinal epithelium is a remarkable dynamic structure experiencing a nearly complete cell 
renewal every 4-5 days (Heath, 1996). This epithelial homeostasis and continuous 
regeneration are controlled by important processes such as proliferation, differentiation, 
metabolic reprogramming and genomic integrity (Barker, 2014). Defective differentiation 
along the secretory lineage of epithelial cells, accelerated cell cycle and hyper proliferation, 
genomic instability in intestinal epithelial cells (increasing DNA double strand breaks, loss of 
heterozygosity, and point mutations on genes central to tumorigenesis including APC and β-
catenin), are all factors that increase dysregulation of cell metabolism and are the foundation 
of the Warburg phenotype (Bertram, 2000; Hanahan and Weinberg, 2000, 2011; Ward and 
Thompson, 2012). The Warburg phenotype is based on the observed change that cancer cells 
change their more efficient oxidative phosphorylation metabolism to anaerobic glycolysis 
pathway (Warburg, 1956). 
As mentioned in 1.4.3, guanylin and uroguanylin gene expression is commonly lost in 
colorectal tumours (Wilson et al., 2014) while their receptor GC-C is over-expressed (Schulz et 
al., 2006) and the loss of cognate ligands would silence the receptor. It is hypothesised that 
the GC-C and its ligand signalling axis plays a role in the regulation of the regenerative 
processes, and could function as a tumour suppressor to maintain the integrity of the 
intestinal epithelium  (Li, Lin, et al., 2007; Li, Schulz, et al., 2007; Lin et al., 2010b). The loss of 
guanylin and uroguanylin could act at an early stage of the carcinogenesis (Zhang, 1997; 
Cohen, Hawkins and Witte, 1998; Steinbrecher et al., 2000, 2002; Notterman et al., 2001; 
Glebov et al., 2006). It has been previously shown that STa and uroguanylin have 
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antiproliferative actions on the adenocarcinoma cell line T84 (Kunwar Shailubhai et al., 2000; 
Pitari et al., 2001, 2003). Additionally, supplementation of uroguanylin in food and water has 
been shown to decrease intestinal tumorigenesis in a mice carrying the APC mutation (Kunwar 
Shailubhai et al., 2000).  
Today, epidemiological evidence suggests an association between obesity and an increased 
risk of several cancer types, and high prediagnosis BMI was associated with increased 
mortality (Campbell et al., 2015; Renehan, Zwahlen and Egger, 2015). The emerging role of 
the GC-C receptor on energy homeostasis and food intake as well as its role on crypt-villous 
proliferation might suggest that this receptor is at the intersection between obesity and 
colorectal cancer. One of the first studies to suggest such a role was published by Lin et al. 
who showed that guanylin mRNA in human colon was inversely correlated with BMI in 
morbidly obese participants (BMI over 35) showing a 80% decrease in GUCA2A transcripts. 
Furthermore, they observed that mice on a high fat (HF) or high calorie (HC) diet did lose 
guanylin expression in the colon. The loss of the GC-C signalling pathway (via the loss of 
guanylin expression) resulted in abnormal intestinal epithelium with increased β-catenin 
expression mirroring a result observed in GC-C-/- mice. Interestingly, GUCA2A levels were 
restored after 4 weeks of replacing the HF or HC diet to a lean diet. The hypercaloric diets 
increased the endoplasmic reticulum (ER) stress markers Binding immunoglobulin protein 
(BiP) (Lee, 2005) and the CCAAT/-enhancer-binding protein homologous (CHOP) protein 
(Wang et al., 1996) in the intestinal epithelium. Lin et al. suggest that the reversible calorie-
dependent loss of guanylin is induced by ER stress and the unfolded protein response in 
colonic epithelium (Lin et al., 2016). However, in this study, the researchers only focused on 
guanylin and omitted to discuss the expression of uroguanylin, the second endogenous ligand 
of the GC-C receptor. Silencing of the GC-C would only be concluded if both ligands are 
downregulated or lost. 
1.5.3 Role of uroguanylin in kidney disease and hypertension 
Due to the potential natriuretic role of guanylin peptides in the kidney, few studies have been 
performed on participants presenting kidney diseases. Kinoshita et al. found that blood 
pressure and plasma uroguanylin levels were higher in the case of chronic glomerulonephritis 
patients as well as in patients suffering from chronic renal failure (Kinoshita, Fujimoto, et al., 
1997; Kinoshita et al., 1999). These studies found that there was a strong correlation between 
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of guanylin and creatine levels in plasma, with creatine being a marker used for routine 
analysis of kidney function (Gowda et al., 2010).  
A study in uroguanylin knock out (KO) mice showed that animals lacking uroguanylin had an 
impaired ability to excrete an enteral load of NaCl. KO mice were also hypertensive and this 
increase in blood pressure was independent of the degree of oral salt intake (Lorenz et al., 
2003). 
1.5.4 Therapeutic targeting of the GC-C receptor 
The gut motility function of the GC-C signalling axis has instigated the development of drugs 
by pharmaceutical companies to treat chronic digestive diseases. Analogues of guanylin 
peptides and the enterotoxin STa are being developed and are currently in clinical trials as 
potential drug therapies to treat chronic constipation conditions. For instance, irritable bowel 
syndrome (IBS) associated with constipation and chronic idiopathic constipation (CIC) can 
have a detrimental impact on quality of life (Koloski, Talley and Boyce, 2000; El-Serag, Olden 
and Bjorkman, 2002; Sun et al., 2011) with more than 15% of the general population affected 
by such disorders in Western countries (Lovell and Ford, 2012). Abdominal and stomach pain 
as well as bloating are common side effects of constipation associated with IBS (Heidelbaugh 
et al., 2015). Linaclotide, a poorly absorbed GC-C agonist, is the first drug to be approved by 
both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 
2012, and is distributed by Allergan under the licensed name Linzess to treat IBS with 
constipation and chronic constipation with no known cause (Corsetti and Tack, 2013). 
Plecanatide is the second GC-C agonist drug on the market that was approved by the FDA in 
2017. The drug is manufactured by Synergy Pharmaceuticals, Inc and is sold under the name 
Trulance for the treatment of CIC and IBS (Brenner et al., 2018). A second product in 
development from Synergy Pharmaceuticals is dolcanatide, which has higher stability in the 
intestinal proteolytic milieu, and is currently in development to treat ulcerative colitis. Both 
linaclotide and plecanatide were shown to reduce visceral and abdominal pain but 
precipitated diarrhoea as a side effect in 10% of the patients (Shah, Kim and Schoenfeld, 2018).  
Association of chronic constipation with the development of colorectal cancer has been a 
subject of controversy. However a meta-analysis performed on 9 previously published studies 
highlighted an increased risk of colorectal cancer linked to constipation with an odds ratio of 
1.48 and a 95% confidence intervals of 1.32-1.66 (Sonnenberg and Müller, 1993). Since the 
27 
 
role of GC-C on colorectal cancer has been studied, linaclotide and plecanatide have been 
proposed as a preventive strategy to the development of colorectal cancer (Scarpignato and 
Blandizzi, 2014). The first human study on the bioactivity of linaclotide was performed with 
the purpose to use it for colorectal cancer chemoprevention (Weinberg et al., 2017). 
Observations were made that in patients responding to linaclotide with a cGMP 
pharmacodynamic response, there was a reduced crypt proliferation in the small and large 
intestine when measured by Ki67 immunohistochemistry assessment (Hoos et al., 2001; Li et 
al., 2015; Weinberg et al., 2017). 
1.6 Aims of thesis 
Guanylin and uroguanylin are peptides produced by the intestinal epithelium with proposed 
roles in salt and water homeostasis. While the downstream signalling pathway has been 
elucidated in the intestine, understanding the role of guanylin peptides in healthy and disease 
states, the regulation of their secretion and their localisation in the digestive system has been 
limited by the lack of specific antibodies against the active human peptides and their 
prohormone precursors. The aim of this project was to address these deficiencies. 
With this in mind, in the first part of my thesis, I established and validated novel high 
throughput monoclonal antibody-based immunoassays to enable the quantification of 
guanylin peptide proforms ProGuanylin and ProUroguanylin (Chapter 3). I produced 
antibodies against the historically defined active versions of the peptides and used these to 
investigate their presence in human biological samples and redefined their sequence (Chapter 
4). Subsequently, the specificity of these immunoassays was assessed on human plasma 
samples and reference ranges of guanylin peptides in healthy volunteers in fasting and post-
prandial states, as well as in healthy and disease states (Chapter 5). In vitro cell based assays 
and ex vivo experimental systems combined with these immunoassays were used to 
investigate the effects of salt, gut and vagal stimuli on the secretion of the guanylin and 
uroguanylin (Chapter 6). Finally, I generated a transgenic reporter mouse model expressing a 
fluorescent protein under the control of the guanylin promoter to examine the localisation of 
guanylin-expressing cells in the gastrointestinal tract (Chapter 7).  
Overall, this work has shed new light on the secretion and localisation of the guanylin peptides 
in mouse and human in the digestive system.  
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Chapter 2: Materials and Methods 
2.1 Production of the hormone proforms: ProGuanylin and ProUroguanylin 
2.1.1 Construction of the propeptide expression vectors 
Recombinant propeptides were expressed as thioredoxin fusion proteins with the following 
configuration: Propeptide - AviTag – PreScission protease cleavage site – linker – His6 Tag – 
Thioredoxin. The AviTag peptide (GLNDIFEAQKIEWHE) allows site-specific biotinylation on the 
lysine residue by BirA and the PreScission protease cleavage site (LEVLFQVGP) allows the 
removal of the His6 tag and Thioredoxin after affinity purification. 
DNA constructs encoding the human propeptides -either ProGuanylin (accession number 
Q02747) or ProUroguanylin (accession number Q16661)- Avi Tag and protease site were 
commercially synthesized (GeneArt, ThermoFisher) with restriction sites NcoI on the 5’ and 
BglII on the 3’ end for cloning into a T7 RNA polymerase-based expression vector pET-32a 
(Novagen, Madison, WI). Double restriction digestion with BglII (NEB, #R0144S) and NcoI 
enzymes (NEB, #R0193S) were performed according to the manufacturer’s instructions 
followed by T4 DNA ligation (NEB, #M0202S) and transformation into DH5α E. coli strain (in 
house). Refer to appendix 1 for schematic of the pET-32a constructs. 
2.1.2 Expression of ProGuanylin and ProUroguanylin 
The production of soluble ProGuanylin in E. coli was described in Lauber et al., 2003. This 
method was used to produce 25mg of ProGuanylin for the hybridoma generation, screening 
and assay development.  
The expression vector for ProGuanylin was transformed into Origami2 (DE3) (Novagen Merck 
Millipore #71408-3) followed by selection on a 2xTYAG plate at 37˚C overnight (ON). One 
colony was used to inoculate a 5mL LB starter culture containing 200µg/mL ampicillin followed 
by ON incubation at 280rpm at 37˚C. The starter culture was subsequently used to inoculate 
a 400mL culture flask at an optical density (OD) of 0.1. The culture was grown to an OD of 0.8, 
followed by addition of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubation at 
30˚C for 4hrs. Cells were harvested by centrifugation at 4000rpm at 4˚C for 15 minutes. 
The above method was optimised for ProUroguanylin as the protein was largely insoluble in 
E. coli. Variables including duration of expression, temperature, IPTG concentration and 
bacterial strains were assessed by SDS-PAGE. The optimised protocol is described below. 
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The expression vector for ProUroguanylin was transformed into Arctic Express (DE3) (Agilent 
#230192) followed by selection on a 2xTYAG plate at 37˚C ON. A colony was used to inoculate 
a 5mL LB starter culture containing 200µg/mL ampicillin followed by ON incubation at 280rpm 
at 37˚C. The starter culture was subsequently used to inoculate a 400mL culture flask at an OD 
of 0.1. The culture was grown to an OD of 0.6, followed by addition of 0.5mM IPTG and 
incubation at 12˚C ON. Cells were harvested by centrifugation at 4000rpm at 4˚C for 15 
minutes. 
2.1.3 Purification of soluble ProGuanylin and ProUroguanylin 
Cell pellets were resuspended in 25mL of 2xphospate buffered saline (PBS) (Gibco #70011044) 
per gram of weight of cells with 2xPBS buffer containing SigmaFast Protease inhibitor cocktail 
tablet EDTA free (1 tablet per 100mL), 0.2mg/mL of lysozyme (Merck Millipore #71412-3) and 
benzonase (Merck Millipore #01654, 50U/mL). Cells were lysed on ice by sonication in pulsed 
mode: six rounds of 30s bursts with a one-minute delay (intensity at 150W). The lysate was 
clarified by centrifugation in a 45ti rotor (Beckman) at 40,000rpm at 4˚C for 2hrs. The 
supernatant was filtered through a 0.22µm membrane. 
The filtered supernatant was loaded on a HiTrap Chelating HP column (GE #17-0408-01) pre-
immobilized with Cobalt solution and pre-equilibrated with 2xPBS. The column was washed 
with 2xPBS followed by a wash step with 50mM imidazole in 2xPBS. A gradient elution (50mM 
to 1M) was performed to elute the proteins. Eluate fractions containing the fusion protein 
were analysed by SDS PAGE. The desired fractions were pooled, and buffer exchanged in 
1xPBS (Gibco #10010023) using PD10-columns (GE #17-0851-01). Protein concentrations were 
determined by spectrophotometry (Nanodrop1000 Thermo Scientific). 
To remove the C-terminal His6-thioredoxin tag, fusion proteins were incubated with 
PreScission protease (GE # 27-0843-01) at room temperature (RT) for 3hrs. A subtractive 
purification using the Cobalt column pre-equilibrated in 2xPBS was performed. The flow-
through containing the purified proforms was further purified by Superdex 75 2660 (GE) size 
exclusion chromatography on an Akta purifier (GE). Fractions containing monomeric proteins 
were pooled and concentrated using a centrifugal concentrator (Sartorius #VS2011) to a final 
concentration of 1mg/mL before being snap-frozen in liquid nitrogen. 
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2.1.4 Purification of ProUroguanylin from inclusion bodies 
The pellet from the ultracentrifugation of the lysate above (refer to 2.1.3) was resuspended 
in 8M urea. The solution was clarified by centrifugation at 20,000rpm at RT for 10 minutes and 
filtering through a 0.22µm membrane (Stericup, Thermo Scientific #5670020). The 
supernatant was incubated with 5mL of Ni-Sepharose 6 Fast Flow medium (GE #17-5318-03) 
pre-equilibrated in 2xPBS. The solution was incubated for 1hr at RT with a magnetic stirrer. 
The nickel beads were washed with 20 volumes of 8M Urea in 2xPBS pH7.4, followed by 20 
volumes of 2xPBS. Proteins were eluted with 1M imidazole in 2xPBS. The His6 thioredoxin tag 
removal was performed as described in 2.1.3. 
2.1.5 Characterisation of ProUroguanylin and ProGuanylin 
SDS-PAGE and mass spectrometry were used to determine the size and purity of proteins. 1µg 
and 5µg of proforms were analysed on a 12% SDS-PAGE gel, run at 200V for 40 minutes. The 
gel was stained with Instant Blue (Expedeon #ISB1L) for 1hr before destaining with deionized 
water for 30 minutes. MALDI-TOF mass spectrometry in the positive ion mode was performed 
on a Shimatzu Biotech AXIMA Assurance instrument using Shimadzu MALDI-MS software 
version 2.8.4, Shimadzu chips and EAM-1 matrices (Bio-Rad). Samples for MALDI-TOF MS 
analyses were prepared by diluting protein samples into a saturated EAM-1 matrix solution 
consisting of acetonitrile, water, trifluoroacetic acid (ratio 50:50:0.5). These samples were 
applied to the chip surface. 
An ELISA was also performed to confirm the protein identities. 96-well microtiter plates (Nunc) 
were coated with 5µg/mL of the proforms and incubated ON at 4˚C. The plates were blocked 
using 3% Marvel/PBS for 1hr at RT. Polyclonal antibodies against the proforms were diluted at 
a starting concentration of 5µg/mL for ProUroguanylin (Ab171982) and 1 in 10 for ProGuanylin 
(Ab14427-50) (initial concentration unknown). Serial dilutions (1:4) was performed over 8 
points on the assay plate followed by incubation at RT for 1hr. After washing 3 times with PBS-
Tween (2%), 50µL of a 1:5000 dilution of horseradish peroxidase (HRP) conjugated goat anti-
rabbit IgG (Sigma #A2074) was added for ProGuanylin, and goat anti-mouse IgG (Jackson 
Immuno Research #115-035-164) for ProUroguanylin. Following incubation at RT for 1hr, 
plates were washed 3 times with PBS-Tween (2%). 50µL of Tetramethylbenzidine (TMB) 
substrate (Sigma #T0440) was added to each well. The reaction was terminated after 10 
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minutes by adding 50µL of 0.5M sulphuric acid. Absorbance at 450nm was measured using an 
Envision plate reader (PerkinElmer). 
2.1.6 Preparation of proforms for immunisation and antibody screening 
The limit of endotoxin lipopolysaccharides (LPS) allowed in an immunising antigen is 80EU/mg. 
Above this limit, the purified protein was subjected to endotoxin removal using Polymyxin B 
resin. This resin has a specific interaction with endotoxin (Vesentini et al., 2010). The resin was 
packed onto a column and pre-equilibrated with 30 column volumes of PBS before incubation 
with the purified ProGuanylin or ProUroguanylin. Subsequently the proteins were eluted with 
endotoxin-free 1xPBS by gravity flow. 
To perform the primary screen of the hybridoma clones and IgG characterisation, biotinylated 
proforms were necessary. 2mg of each proform was enzymatically biotinylated using the BirA 
enzyme (Avidity LLC #BirA500) according to manufacturer’s instructions. The efficiency of 
biotinylation was controlled by MALDI TOF mass spectrometry according to the protocol 
described 2.1.5. 
2.2 Hybridoma campaign 
2.2.1 Immunisation 
Female CD1 mice aged 6-8 weeks were injected subcutaneously with 100µg of one of the 
following molecule: recombinant ProGuanylin, recombinant ProUroguanylin, Acetyl-Guanylin 
(human)-AEEAc-Lys(succinyl-KLH) amide (KLH-Guanylin) and Acetyl-Uroguanylin (human)-
AEEAc-Lys(succinyl-KLH) amide (KLH-Uroguanylin) (Bachem #4092212 and #4092213, for KLH-
Guanylin and KLH-Uroguanylin, respectively) in Freund’s complete adjuvant (Sigma #F5881). 
Three subsequent boosts of 100µg each were administered through subcutaneous injection 
on day 7, 14 and 22 after the first immunisation in Freund’s incomplete adjuvant (Sigma 
#F5506). Four days after the last injection, mice were sacrificed, and lymph nodes and spleen 
harvested. All animal research has been regulated under the Animals (Scientific Procedures) 
Act 1986 Amendment Regulations 2012, following ethical review by the Babraham Institute 




2.2.2 Serum titre determination 
Peripheral blood was collected 6 days before immunisation, 14 and 21 days post-
immunisation and serum recovered by centrifugation using serum separator tubes 
(Microvette #20.1280). ELISA was performed to assess the levels of immune response to the 
antigens. Antigens, either biotinylated-Guanylin (Bachem #4092214) or biotinylated-
Uroguanylin (Bachem #4092215) were coated on plates at 1µg/mL at 4˚C ON. The plates were 
blocked using 3% Marvel/PBS at RT for 1hr. Serum samples were diluted in 3% Marvel/PBS 
and serial dilutions (1/200 over 5 points) applied onto assay plates in duplicate and incubated 
for 1hr at RT. After washing 3 times with PBS-Tween (2%), 50µL of a 1:5000 dilution of HRP 
conjugated goat anti-mouse IgG (Jackson Immuno Research #115-035-164) was added. 
Following incubation at RT for 1hr, plates were washed 3 times with PBS-Tween (2%). 50µL of 
TMB substrate (Sigma #T0440) was added to each well. The reaction was terminated after 10 
minutes by adding 50µL of 0.5M sulphuric acid. Absorbance at 450nm was measured using an 
Envision plate reader (PerkinElmer). 
2.2.3 Hybridoma generation 
Cells were isolated from lymph nodes and/or spleens by mechanical disruption using the 
Gentle MACS dissociator (Miltenyi). Cells were fused with SP2/0 myeloma cells (ATCC) using a 
BTX electrofuser (ECM2001) before resuspending them in semi-solid media (CloneMatrix 
concentrate, Genetix), DMEM (Gibco), 20% FCS (SAFC), 2% GlutaMAX (Gibco), 1% sodium 
pyruvate (Sigma), 100U/mL penicillin, 100µg/mL streptomycin (Gibco), 10% hybridoma 
cloning factor (Roche), 2% oxaloacetate/pyruvate/insulin (Sigma), 2% hypoxanthine/azaserine 
(Sigma), containing FITC conjugated anti-mouse IgG monoclonal antibody (Jackson 
ImmunoResearch # 115-095-1649). Media and cells were plated into omni trays (Nunc) and 
cells were incubated at 37˚C, 7.5% CO2-enriched atmosphere. After 16 days of incubation, 
secreting IgG colonies were picked by ClonePix robot (Molecular Devices) and inoculated onto 
96 well plates (Costar) containing selection media (DMEM, 20% FCS, 2% glutaMAX, 100U/mL 
penicillin, 100µg/mL streptomycin, 10% hybridoma cloning factor, 2% 
oxaloacetate/pyruvate/insulin, 2% hypoxanthine and thymidine (Sigma)). After growing the 




2.2.4 Clones selection by HTRF assay  
A Homogeneous Time Resolved Fluorescence (HTRF) biochemical assay was developed to 
measure the binding of IgGs (in hybridoma conditioned supernatants) to the four biotinylated 
targets using Europium cryptate conjugated streptavidin (Cisbio #610SAKLB) as the donor and 
AlexaFluor 647 conjugated goat anti-mouse Fc IgG (Jackson #115-605-164) as the acceptor. 
Test samples were incubated for 15hrs at RT with 2.5nM biotinylated-antigens premixed with 
1nM Streptavidin-cryptate, and 7.5nM AlexaFluor 647 conjugated goat anti-mouse Fc IgG. The 
fluorescence was measured on an EnVision plate reader using a 320nm excitation filter and 
665nm and 590nm emission filters. The raw data was initially analysed using the equation 665 
nm / 590 nm x 10,000 and was then expressed as % ΔF using the equation (sample ratio - 
negative control ratio / negative control ratio x 100). Samples with a binding signal greater 
than 100% ΔF were taken forward for further analysis. 
2.2.5 cDNA preparation and variable chain sequencing 
The method used to sequence the hybridoma clones is described in Percival-Alwyn et al., 
2015. Briefly, heavy and light chain variable regions mRNA were isolated using Oligo (dT)25 
magnetic beads (Thermo Fisher Scientific #61002). SP2/0 MOPC abVκ mRNA was removed by 
targeted digestion with RNaseH (NEB # M0297L) at 37˚C for 1hr. Superscript III reverse 
transcriptase (Invitrogen SuperScript III kit #18080085) was used to transcribe the purified 
mRNA into cDNA at 44°C for 1hr. Poly(G) was added to the cDNA by incubation at 37°C for 1hr 
with dGTP (GE  #28-4065-23) and terminal transferase (NEB #M0315L). Variable light and 
heavy chain DNA were amplified with oligo(dC)25 and specific primers to the CH1 or kappa 
constant domain (IgG77R and KconsR respectively) using Taq polymerase (Thermo #SP-
0956/b) (details of the primers used in appendix 2). The chain termination method was used 
to sequence the PCR product. 
 2.2.6 IgG purification 
From the primary screen results, hybridomas were selected and grown for 10 days at 37°C 
under a 7.5% CO2-enriched atmosphere in HL-1 serum free media (Lonza #77201) 
supplemented with additives: 2% HybER™-Zero (Statens Serum Institute #71800) and 2% 
GlutaMAX (Gibco #35050-038). ProPlus resin bed Phytips (Phynexus #PTP-92-20-07) were 
used to purify the IgGs from the supernatants. Phytips were pre-equilibrated in PBS before 
capturing the IgG from the supernatant. The Phytips was washed 4 times after sample capture 
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with PBS before eluting the IgGs with an acidic elution buffer (100mM HEPES, 140mM NaCl, 
pH3). The eluate was neutralized by 200mM HEPES pH8. IgG concentrations were determined 
by measuring the OD280 using the EnVision plate reader. 
2.3 Phage display selection 
2.3.1 Soluble selections on naïve libraries 
Phage libraries and magnetic streptavidin beads were blocked in 500μL 3% Marvel/PBS on a 
rotating disk at RT for 1hr, 20rpm. The phage libraries were subsequently deselected against 
the streptavidin beads on a rotary mixer at RT for 1hr, 20rpm. The phage libraries were 
captured with the relevant biotinylated antigen (biotinylated-Guanylin or biotinylated-
Uroguanylin) in a 500µL final volume on a rotary mixer at RT for 1hr, 20rpm. A de-selection 
step was performed by adding 1μM free uroguanylin or guanylin to the relevant selection to 
prevent cross reactivity. Each selection was mixed with 50μL of blocked beads and 
equilibrated for 5 minutes before being transferred to a Kingfisher mL tube rack. Beads were 
washed 4 times from unbound phage in 0.1% PBS-Tween using the Kingfisher mL automated 
wash programme and released into 200μL of 10μg/mL trypsin in 0.1M sodium phosphate 
buffer. The bound phage was eluted by trypsin treatment on a rotary mixer at 37 °C for 30 
minutes, 20rpm. Eluted phage was used to infect 1-5mL of TG1 cells, in the logarithmic phase 
of growth and incubated at 37°C for 1hr, 150rpm. Selection outputs were plated onto 2xTYAG 
bioassay plates and incubated overnight at 30°C. Single colonies representing each 
bacteriophage were picked into 96-well plates and incubated at 30°C ON, 25rpm.  The rest of 
the cells were harvested in 2xTY with 17% glycerol, and stored at -80°C.  
2.3.2 Selection rescue 
For each selection, the bacterial scrape was used to inoculate 25mL of 2xTYAG in a 250mL 
flask to a starting OD600 of 0.1. Cells were grown to logarithmic phase at 280rpm at 37°C, 
before being infected with M13KO7trp helper phage at a multiplicity of infection (MOI) of 10. 
Cells were incubated at 37°C for 1hr, 150rpm. Cells were centrifuged at 3200rpm for 10 
minutes and resuspended in 400mL of 2xTYAK media for growth at 25°C ON, 280rpm. 
After overnight incubation, 1mL of culture was spun at 13000rpm for 5 minutes and put on 
ice until used for further selection. Input and output titres of phage were calculated for each 
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round of selection. To assess the stringency of the selections, a negative selection with no 
antigen was also performed at each round.  
2.3.3 Phage ELISA 
The single colonies picked in 96-well plates during the soluble selections were designated as 
“masterplates”. They were duplicated using a sterilised 96-pronged replicator into deep 96-
well daughter plates containing 500μL 2xTYAG. The colonies were grown at 37°C for 5hrs, 
280rpm before being infected with K07 M13 helper phage to a MOI of 10. The plates were 
incubated at 37°C for 1hr, 150rpm. The media was changed to 2xTYAK and cells were grown 
at 25°C ON, 280rpm. 
Nunc Maxisorp plates were coated with 50μL biotinylated-Guanylin or biotinylated-
Uroguanylin at 2.5μg/mL overnight at 4°C. Plates were rinsed 3 x in PBS to remove unbound 
antigen, the plates and phage were then blocked in 3% Marvel-PBS at RT for 1hr. The plates 
were washed 3 times in PBS and 50μL of phage were added per well and incubated at RT for 
1hr before being washed with 3x with PBS/0.1% Tween. 50μL of anti-M13-HRP (Amersham 
#27-9421-01) diluted 1/5000 in 3% Marvel-PBS at was added to each well and incubated at RT 
for 1hr. Plates were further washed 3x with PBS-Tween 0.1%. 50µL of TMB substrate (Sigma 
#T0440) was added to each well. The reaction was terminated after 10 minutes by adding 
50µL of 0.5M sulphuric acid. Absorbance at 450nm was measured using an Envision plate 
reader (PerkinElmer).  
2.3.4 Sequencing of clones and further selection process 
88 positive clones of each selection that were not cross-reactive according to the Phage ELISA 
were sequenced and ranked. Clones were streaked out into single colonies on 2xTYAG plates 
and incubated at 30°C overnight. The scFv part of the DNA was amplified by PCR using specific 
primers pair (fdtetseq and pUC19reverse) before being sequenced using PCR L-link and 
mycseq10 primers (detailed in appendix 2).  
Crude or purified monomeric preparations of scFvs were used in subsequent ELISA and 
competition ELISA to control the binding to the biotinylated and non-biotinylated version of 
the guanylin peptides. The scFv expression was induced by addition of 1mM IPTG to 2xTY 
medium at 30°C for 3hrs and the His-tagged scFv was purified from the extract using a nickel 
agarose column (Qiagen #30250). Monomeric scFv samples were purified using Superdex 75 
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10/300 GL (GE Healthcare #17517401) chromatography with an AKTA protein purifier and 
UNICORN software.  
2.4 Phage display library generation 
2.4.1 Preparation of a stop template DNA of the parents 
Sequence diversification is introduced into the best antibodies by a targeted mutagenesis on 
the complementarity determining regions (CDR). As no mutagenesis reaction is 100% efficient, 
the sequence of the parent antibody will be expressed and displayed on phage alongside the 
mutant variants. Although their fraction in a mutant library might be as low as a few percent, 
parent clone molecules will easily outnumber any given variant. To overcome this problem for 
targeted libraries, stop codons are first introduced into the parent clone. The codons are 
placed in the area to be randomised, so that any mutated antibody variant will have replaced 
the stop codons by codons for amino acid residues and any non-mutated parent sequences 
will have retained the stop codons. When such a library is expressed the non-mutated parent 
sequences will be truncated and not be displayed and selected for. 
Stop template primers were designed for the CDRs heavy chain CDR 3 (HCDR3) and light chain 
CDR 3 (LCDR3) of clones AB1000093 and AB1000107 (not displayed for MedImmune 
confidentiality). The stop template mutations were added to the sequence using the 
QuikChange Site-Directed Mutagenesis kit (Stratagene #200524) according to manufacturer’s 
instructions. 10µL of the mutated and restricted DNA from the mutagenesis reaction was 
transformed into 100µL chemically competent CJ236 cells. After incubating DNA with cells for 
5 minutes on ice, the mix was transformed on pre-warmed 2xTYAGC plates and incubated at 
37°C ON. A single clone was restreaked on a plate and incubated at 37°C to ensure clonal 
purity. A new single colony was used to inoculate 3mL of 2xTYAGC media and the DNA was 
purified using a Miniprep kit (Qiagen #27104) according to manufacturer’s instructions. 
2.4.2 Production of uracil containing single stranded DNA (dU-ssDNA) 
CJ236 colonies containing the stop template were grown in 5mL 2xTYAGC at 37°C to the 
logarithmic phase. Cells were infected with wild-type M13KO7 helper phage to a MOI of 10 
and incubated at 37°C for 10 minutes. 1mL of media was used to inoculate 30mL of 2xTYAKU 
media (100 μg/mL ampicillin, 50μg/mL kanamycin, 0.25 μg/mL uridine) and cells were cultured 
at 37°C ON, 300rpm. Cells were centrifuged at 26,890g at 2°C for 10 minutes. 1/5 volume of 
37 
 
20% (v/v) PEG8000/2.5M NaCl were added to supernatants and incubated for 10 minutes at 
RT. Phage samples were pelleted at 11,950g at 2°C for 2 mins, and the phage pellet was 
resuspended in 0.5mL PBS. Debris were pelleted with a final centrifugation at 13,000rpm for 
5 minutes.  The dU-ssDNA template was purified using QIAprep Spin M13 kit (Qiagen # 27704) 
and eluted in 100µL. The DNA concentration was measured by absorbance at 260nm and the 
quality of the ssDNA was assessed on a 1% TAE agarose gel. 
2.4.3 Kunkel mutagenesis 
For each library a single mutagenic primer was designed to randomise blocks of up to 6 
consecutive amino acids using NNS codons within degenerate oligonucleotides. Two libraries 
were designed for each CDR HCDR3 and LCDR3 of the clones AB1000093 and AB1000107. 
0.7μg of each mutagenic oligonucleotide was phosphorylated at 37°C for 1hr using T4 
polynucleotide kinase. Each reaction was performed in 1 x TM buffer, 1mM ATP, 5mM DTT, in 
a final volume of 20μL. The phosphorylated oligonucleotides were annealed to 20μg of dU-
ssDNA, using 1 x TM buffer, in a 250μL final volume. The reaction was incubated at 90°C for 2 
minutes, 50°C for 3 minutes followed by 20°C for 5 minutes. To the template mix, 21.5μL 
containing 30 units T4 DNA ligase, 30 units T4 DNA polymerase, 0.33mM ATP, 0.83mM dNTPs 
and 5mM DTT final concentration. The mix was incubated at 20°C for 3 hours. Each reaction 
was affinity-purified to 50μL water using the DNA High PCR product purification kit (Roche 
#1732676). 
2.4.4 Preparation and electroporation of electrocompetent TG1 cells with libraries 
A single TG1 colony was used to inoculate 60mL of 2xTY media at 30°C ON, 300rpm. 400mL of 
media was inoculated to an OD600 of 0.1 and grown to the logarithmic phase at 30°C, 300rpm. 
Cells were incubated on ice for 30 minutes before being centrifuged at 2700g at 2°C for 15 
minutes. Cells were resuspended in 300mL ice-cold Milli-Q water. The centrifugation and wash 
steps were repeated before resuspending the cells in 50mL Milli-Q water, cells were 
centrifuged at 2210g at 4°C for 10 minutes. The centrifugation and wash steps were repeated 
once again before resuspending the cells in 5mL of Milli-Q water before being electroporated 
immediately.  
35µL of mutagenesis reaction was mixed with 1.6 mL of electrocompetent TG1 cells. 4 x 400μL 
of cells were electroporated per library in a 0.2cm cuvette using the standard electroporation 
settings of 2.5kV field strength, 200Ω resistance, 25µF capacitance. Immediately after 
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electroporation, 1mL 2xTYG was added to each cuvette and cells were transferred to a 50mL 
Falcon tube and incubated at 37°C for 1hr, 150 rpm. Cells were plated on a 2xTYAG bioassay 
plate and incubated overnight at 30°C. A dilution series of each library were plated on 2xTYAG 
petri dishes to determine the number of transformants. Libraries were scraped into 10mL 2xTY 
with 17% glycerol and libraries were stored at -80°C. 
2.5 Ribosome display lead optimisation 
2.5.1 Building of a ribosome library  
Preparation of the Parental scFv DNA Construct for Ribosome Display 
The parent clone in pCANTAB6 was streaked onto a TYAG agar plate and grown at 37˚C 
overnight. A single colony was used to inoculate 15mL of 2xTYAG for overnight growth at 30˚C, 
300rpm. The plasmid DNA was purified using the QIAamp Mini kit (Qiagen #51304) according 
to manufacturer’s instructions. The above plasmid DNA and pUC-RD D3 vector were digested 
using the NEB enzymes NcoI and NotI at 37˚C for 90 minutes and the digestion product 
separated on a 1% agarose/TAE electrophoresis gel. Both vector and insert were purified using 
the Roche DNA purification kit (#1732676) according to manufacturer’s instructions. The NotI-
NcoI cut pUC-RD D3 vector and the NotI-NcoI cut parent scFv were ligated using a 1:5 ratio. 
The ligation was performed using the T4 ligation kit (NEB #M0202S) in a 30µL ligation reaction 
and the reaction was incubated 1hr at room temperature. 10µL of ligation product was 
transformed into 100µL chemically competent TG1 cells by heat-shock. The cells were 
incubated on ice for 30 minutes and heat-shocked at 42˚C for 45 seconds and placed back on 
ice for 2 minutes. 900µL 2xTYG was added to the reaction and shook at 37˚C for 1hr, 120rpm. 
The transformed cells were plated onto 2xTYAG agar plate. 
Construction of Error–Prone Mutagenesis Libraries 
The error-prone PCR is performed using the Diversify PCR Random Mutagenesis kit (Clontech 
#630703). The error rate can be adjusted by modifying manganese sulphate and dGTP 
concentrations. The conditions were chosen for the highest error rate (8.1 nucleotide changes 
per 1000bp) according to manufacturer’s instructions (8mM MnSO4, 2mM dGTP) with 10ng of 
scFv in pUC-RD D3 in a 50µL final volume. The scFv-coding region of antibodies AB1000107 
and AB1000001 were amplified by PCR using primers MycRestore and germline VH gene 
specific primer SDCAT-CG (refer to appendix2). Two rounds of error-prone PCR using the 
following program: the thermal cycle was programmed for 3 minutes at 94°C as initial 
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denaturation, followed by 25 cycles of 30 seconds at 94°C for denaturation, 120 seconds at 
68°C for annealing and extension. In between the two rounds of error-prone mutagenesis, the 
PCR products were separated on a 1% agarose/TAE gel and purified using the Roche DNA 
purification kit (#1732676) following the manufacturer’s instructions. 
A short non-structured region of the gene III sequence of filamentous phage was amplified by 
PCR for use as a ‘tether’ to allow protein display outside of the ribosomal tunnel. 10ng of 
pCANTAB6 was used as template to amplify the Gene III tether with the primers geneIIIfor2 
and MycgeneIIIshortadapt using the PCR Master mix from Abgene (#SP-0488). The thermal 
cycle was programmed for 3 minutes at 94°C as initial denaturation, followed by 25 cycles of 
30 seconds at 94°C for denaturation, 30 seconds at 55°C for annealing and 105 seconds at 
72°C for extension and final extension at 72°C for 5 minutes. The PCR product was separated 
on 1.5% agarose/TAE gel and purified using the Roche DNA purification kit following the 
manufacturer’s instructions.  
A recombinatorial PCR to add gene III tether to the scFv coding sequence was performed using 
the PCR Master mix (Abgene #SP-0488) with 200ng of gel-purified SDCAT/mycrestore product 
and 200ng of gel-purified gene III tether. The first 5 cycles were performed without the use of 
primers and the thermal cycler was programmed for 3 minutes at 94°C as initial denaturation, 
followed by 5 cycles of 30 seconds at 94°C for denaturation, 30 seconds at 50°C for annealing 
and 105 seconds at 72°C for extension. At the beginning of the 5th annealing step, the PCR was 
paused and SDCAT family specific and T7te primers (see appendix 2) were added to the 
reaction mix and the programme resumed. The thermal cycler was programmed for 3 cycles 
of 30 seconds at 94°C, 30 seconds at 30°C and 105 seconds at 72°C followed by 15 cycles of 30 
seconds at 94°C, 30 seconds at 50°C and 105 seconds at 72°C and a final extension at 72°C for 
5 minutes. The PCR products were separated on a 1% agarose/TAE gel and the amplified 
fragment was gel purified using the Roche DNA purification kit following the manufacturer’s 
instructions. The final ribosome display construct was reamplified to bulk up the converted 
scFv DNA using the PCR Master mix from Abgene (#SP-0488) with a new set of primers T7B 
and T6te (refer to appendix 2). The thermal cycle was programmed for 3 minutes at 94°C as 
initial denaturation, followed by 25 cycles of 30 seconds at 94°C for denaturation, 30 seconds 
at 55°C for annealing and 105 seconds at 72°C for extension and final extension at 72°C for 5 
minutes. 5µL of PCR sample was checked on a 1% agarose/TAE gel for size and purity. 
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In vitro Transcription and mRNA Translation 
The PCR sample was transcribed using the Ribomax Large Scale RNA production system 
(Promega #P1300) in a 50µL final volume. The transcription reaction was incubated at 37˚C 
for 2hrs. The DNA was removed using RNA qualified (RQ1) RNAse-free DNAse and the mRNA 
was purified using ProbeQuant G50 micro column (Amersham Biosciences #27-5335-01) 
according to manufacturer’s instructions. 
30µg of mRNA was cell-free translated using an in-house S30 E. coli extract. The translation 
mastermix was made of 38.5µL of 2M potassium glutamate, 26.6µL of 0.1mM magnesium 
acetate, 7µL of 5mg/mL Protein Disulphide Isomerase (PDI, Sigma #P3818), 77µL of Premix X 
(250mM Tris-acetate pH 7.5, 1.75mM of each amino acid, 10mM ATP, 2.5mM GTP, 5mM 
cAMP, 150mM acetylphosphate, 2.5mg/mL E. coli tRNA, 0.1mg/mL folinic acid, 7.5% PEG 
8000) and 140µL of S30 E.coli extract. 300µL of the mastermix was added to 30µL mRNA on 
ice and mixed gently by pipetting up and down. The tube was transferred immediately to a 
37˚C heat block for 9 minutes. The 330µL translation reaction was transferred into a pre-
chilled microfuge tube containing 1250µL chilled heparin-block buffer (0.05M Tris-acetate pH 
7.5, 0.15M NaCl, 0.05M magnesium acetate, 0.1% Tween-20, 2.5mg/mL heparin from Sigma 
#H9399) on ice to stabilise scFv-ribosome-mRNA complexes. 
2.5.2 Selection and Capture of Specifically Bound scFv-Ribosome-mRNA Complexes 
Ribosome display selections were performed as described in Groves and Nickson, 2012. 
Briefly, magnetic streptavidin beads were blocked in 1% de-biotinylated Marvel/PBS (final 
concentration) on a rotating disk at RT for 1hr, 20rpm before. 500µL of stabilised scFv-
ribosome-mRNA complexes was mixed with 1% de-biotinylated Marvel/PBS and 50µL of the 
biotinylated antigen was added per library for overnight incubation at 4°C. Streptavidin 
magnetic beads were washed four times in HB buffer before capturing the antigen-bound 
complexes for 5 minutes at 4°C. Beads were washed 5 times with 800µL HB buffer to remove 
non-specifically bound complexes using the Kingfisher mL automated wash programme and 
released into 200μL water containing 10mg/mL S. cerevisiae RNA. Amplification of mRNA was 
performed by RT-PCR using Superscript II Reverse Transcriptase (Invitrogen, 18064-014) with 
T8te primer and a SDCAT VH family specific primer (SDCAT-CG for AB1000107 selections and 
SDCAT-CC for AB1000001 selections) (see appendix 2) in 20µL final volume with 12.25µL 
coming from the ribosome-bead-mRNA complexes. The mix was incubated at 42°C for 30 
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minutes before being amplified by PCR using 2x PCR master mix (Thermo CM-250 custom mix) 
with SDCAT-specific and T8te primers. The PCR was performed as follows: 94˚C for 3 minutes 
followed by 30 cycles at 94˚C for 30 seconds, 55˚C for 30 seconds and 72˚C for 105 seconds, 
and a last step at 72˚C for 5 minutes.  
2.5.3 Further processing of the selection Output mRNA  
To process outputs for a further round of selection, another round of PCR had to be performed 
on 50-200ng gel purified PCR using T7B and T6te primers. This PCR was performed using Vent 
DNA polymerase in a 50µL final volume with 25 cycles of 94˚C for 30 seconds, 62˚C for 30 
seconds and 72˚C for 105 seconds. PCR was completed with a last step at 72˚C for 5 minutes. 
To screen for the activity of the different PCR variants, 50ng of each PCR products were 
enzyme restricted with NcoI and NotI (NEB) and ligated into pCantab6 using T4 DNA ligase 
(Promega) according to manufacturer’s instructions. 
2.6 Characterisation of the antibodies 
2.6.1 IgG conversion 
Variable genes from antibodies of interest were amplified using PCR and cloned into pEU 
expression vectors. The heavy chain variable genes were digested with BssHII and BsmBI, then 
inserted into pEU23.4 mu IgG1. Light chain variable genes were digested with ApaLI and PacI, 
then inserted into pEU22.3 murine Kappa vector or pEU21.3 murine lambda vector. DNA quick 
ligase (NEB) was used for ligation reactions, and Z-competent DH5α cells were transformed. 
Successful cloning was confirmed using PCR with primers targeting the pEU backbone, 
products were loaded in a 1% agarose gel, which was ran at 130V for 20 minutes to check for 
the presence of an insert and confirmed using DNA sequencing. The DNA was later purified 
for positive clones using the QIAgen Midi Prep Plus Kit. 
For antibody expression, DNA constructs of heavy and light chain variable genes were 
transfected into G22 cells using polyethylenimine (PEI) Max (Polysciences Inc). The transfected 
cells were incubated for 1 week at 34°C with shaking at 140rpm, 5% CO2 and 70% humidity. 
Supernatant was harvested by centrifugation at 500g for 30 minutes at 4°C and filtered using 
a 0.22 µm membrane. MabSelect Sure resin (GE Healthcare Bio-sciences, Marlborough, USA) 
was used for purification, and antibody was eluted with 0.1M sodium citrate (pH3) in the high 
throughput method. Desalting was then performed using PD10 columns (GE Healthcare Bio-
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sciences). A quality control check of the antibody was performed by SDS-PAGE. The gels were 
stained with InstantBlueTM to visualise the protein bands. 
2.6.2 Specificity ELISA on the clones 
96-well microtiter plates (Nunc) or streptavidin coated plates (Costar) were coated with 
5µg/mL of proforms or biotinylated-Guanylin (Bachem #4092214) or biotinylated-Uroguanylin 
(Bachem #4092215) and incubated ON at 4˚C. The plates were blocked using 3% Marvel/PBS 
at RT for 1hr. scFvs or antibodies were tested as a single point or serially diluted into the assay 
plates in duplicate over 8 points and incubated for 1hr at RT. After washing 3 times with PBS-
Tween (2%), 50µL of a 1:5000 dilution of HRP conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch #115-035-164) was added. Following incubation at RT for 1hr, plates were 
washed 3 times with PBS-Tween (2%). 50µL of TMB substrate (Sigma #T0440) was added to 
each well. The reaction was terminated after 10 minutes by adding 50µL of 0.5M sulphuric 
acid. Absorbance at 450nm was measured using an Envision plate reader (PerkinElmer). 
2.6.3 Competition ELISA  
Competition ELISA was performed to confirm the specificity of scFv or IgG binding to the 
peptides as opposed to the tags (KLH and biotin). In other words, binding specificity was 
assessed based on the ability of free peptides in the solution to compete with immobilized 
tagged-peptides (which was used in the hybridoma screening). Plates were coated with 
biotinylated-peptides or biotinylated-proforms at 5µg/mL and incubated at 4˚C ON. Plates 
were blocked using 3% Marvel/PBS for 1hr at RT. The concentration of IgG or scFv that gave 
80% of the maximum absorbance in a standard ELISA was incubated for 1hr at RT with a serial 
dilution of free guanylin (Bachem #H.2996.1000) or free uroguanylin (Bachem #H.2166.1000), 
from 0.21nM-3.3µM. After washing 3 times with PBS-Tween (2%), 50µL of a 1:5000 dilution 
of goat anti-mouse IgG (Sigma #Ab17198) was added. Following incubation at RT for 1hr, 
plates were washed 3 times with PBS-Tween (2%). 50µL of TMB substrate (Sigma #T0440) was 
added to each well. The reaction was terminated after 10 minutes by adding 50µL of 0.5M 
sulphuric acid. Absorbance at 450nm was measured using an Envision plate reader 
(PerkinElmer). 
2.6.4 Epitope binning to identify antibody pairs 
Antibodies were covalently bound to the surface of ester coupled pre-activated SensEye G 
Easy2Spot (SSens #1-09-04-006) using a Continuous Flow Microspotter (CFM) (Wasatch 
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Microfluidics). CFM uses a network of microchannels to cycle ligand solutions over a surface 
plasmon resonance (SPR) surface. A flow prints microarray spots by directing 70μL plugs of 
antibodies from a 96-well microplate into a fluidic manifold. The antibody solutions are 
arranged into a 4×12 array of 48 micro flow cells on the surface of the SPR substrate. The CFM 
cycles the solutions back and forth at 60μL/min.   
The antibody plate contained the 90 IgGs prepared at 5µg/mL in 10mM NaOAc pH4.5 (GE 
Healthcare #BR-1003-50) and they were cycled for 15 minutes. Once the printing was done on 
the SensEye sensor, it was loaded into the SPRi reader (MX96, IBIS Technologies). 1M 
ethanolamine-HCl was injected across the SensEye sensor for 15 minutes to quench the excess 
reactive ester before washing it with system buffer. A sensor picture was used to define the 
reaction spots and the interstitial reference spots.  
For the affinity measurement, a standard injection cycle of analyte (proforms or active 
peptides) followed by a regeneration was used. Antigens were injected at a concentration of 
100nM and serially diluted 1 in 2 over 8 points for 3 minutes. Subsequently buffer was injected 
to define the dissociation rate. The sensor was regenerated using 10mM phosphoric acid pH2 
for 1 minute. The data was analysed using Scrubber2 (BioLogic Software). 
For epitope binning, both antigens and antibodies were flowed over the sensor, and injected 
immediately after one another before continuing with regeneration. Proforms were injected 
at 100nM for 3 minutes, followed by the antibodies at 7.5μg/mL for a further 5 minutes and 
then the sensor was regenerated using 10mM phosphoric acid pH2 for 1 minute. The data was 
analysed using SprintX (Ibis Technology). 
2.6.5 Affinity measurement using Surface Plasmon Resonance (SPR) 
Binding constants of the proforms, guanylin and uroguanylin were determined using a Biacore 
T100 instrument. Antibodies were immobilised at 10μg/mL on a CM3 chip by amine coupling 
to a density of 450RU. Serial dilutions of ProGuanylin, ProUroguanylin, guanylin and 
uroguanylin were prepared in the running buffer (PBS pH7.4, 0.05% Tween 20). The compound 
solutions were injected onto the surface of the chip at a flow rate of 50μL/min, contact time 
was 180 seconds and dissociation time 400 seconds. Sensorgrams were analysed using the 




2.7 Immunoassay to measure ProGuanylin and ProUroguanylin 
2.7.1 Human samples 
Studies on volunteers were performed by Dr. Claire Meek, Dr. Geoffrey Roberts, Dr. Benjamin 
Challis, and Pr Jørgen Jensen. 
The study on healthy volunteers in the fasting and postprandial state was given ethical 
approval by the local research ethics committee (Reference 13/EE/0195). 
The study on volunteers that undertook a gastrectomy and small bowel transplant was 
approved by the local National Health Service Research Ethics Committee and conducted in 
accordance with the ethical standards of the Helsinki Declaration of 1975 (Reference 
16/EE/0338). 
The study on volunteers that fasted over 7 days was approved by the Ethics committee at 
Norwegian School of Sport Sciences (Reference 15-220817). 
The study on volunteers that presented a different range of osmolality was given ethical 
approval by the local research ethics committee (Reference 14/EE/1247). 
The study on neuroendocrine tumour volunteers was approved by the local research ethics 
committee (Reference 14/EE/1059) 
All human organoids studies were approved by local ethical review committee (Reference 
09/H0308/24). 
Glucose tolerance test or Liquid meal test 
Following an overnight fast, participants were given a 50g, 75g or liquid standardised meal 
test (SMT). The SMT consisted of a 230mL bottle of Ensure plus, a balanced nutritional 
supplement containing 11g fat, 13g protein and 50g carbohydrate. Participants were also 
given 250ml of water after the meal was consumed. Blood samples were collected 
immediately prior to glucose/food ingestion, and at 15, 30, 45, 60, 90, 120 minutes post-
ingestion. 
Plasma samples 
Blood was collected into EDTA and lithium heparin tubes and samples were immediately 
centrifuged for 10 minutes at 3500g at 4oC. Plasma aliquots were snap frozen on dry ice and 
stored at -80oC within 30 minutes. 
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Serum samples  
Blood samples were taken and allowed to clot for 10 minutes after phlebotomy. Samples were 
then centrifuged for 10 minutes at 3500g at 4oC, separated and frozen on dry ice and stored 
at -80oC within 30 minutes. 
2.7.2 In-house developed MSD assay  
Antibodies AB1000011 and AB1000025 (anti-ProUroguanylin and -ProGuanylin respectively) 
were diluted to 50ng/µL and 5µL, respectively, coated on an assay plate (MSD #MA6000) and 
incubated at RT overnight. Plates were blocked using 1% PBS/BSA for 2hrs at RT. After washing 
3 times with washing buffer of PBS-Tween (0.05%), 25µL of samples were added to each well 
and incubated for 2hrs at RT. Following incubation, plates were washed 3 times with washing 
buffer and 25µL of a second Sulfo-Tag labelled anti-proforms antibodies AB1000010 and 
AB1000028 prepared at 1µg/mL in Diluent 41 (MSD) was added per well for 1hr at RT. Once 
washed with washing buffer, 150µL of Read buffer 2X was added to each well before reading 
the plate immediately using a MSD Workbench. A standard curve was constructed by fitting a 
sigmoidal function to the absorbance obtained from the known proforms concentrations 
using MSD discovery software. The concentration of experimental samples was assessed by 
interpolating them to a standard curve using MSD discovery software as well.  
2.7.3 Biovendor kit 
ProGuanylin and ProUroguanylin were measured using the commercially available ELISA kits 
(Biovendor) following the manufacturer’s instructions. Absorbance was measured at 450nm 
and 630nm using a Perkin Elmer 1420 multilabel counter (Perkin Elmer). Readings at 450nm 
were subtracted by the readings at 630nm. A standard curve was constructed by fitting a 
sigmoidal function to the absorbance obtained from the known proforms concentrations 
included in the kits. The concentration of experimental samples was measured by 
interpolation from the standard curve using GraphPad Prism software version 7. 
2.8 Secretion assays 
2.8.1 Solutions and chemicals 
Standard saline solution contained 138mM NaCl, 4.5mM KCl, 4.2mM NaHCO3, 1.2mM 




Modified saline solutions were used for some experiments. ‘Buffer138 Na+ free’ solution 
contained 138mM N-Methyl-D-glucamine (NMDG), 4.5mM KCl, 1.2mM KH2PO4, 4.2mM 
KHCO3, 2.6mM CaCl2, 1.2mM MgCl2, 10mM HEPES. ‘Buffer138 Cl- free’ solution contained 
138mM Sodium D-gluconate, 4.5mM Potassium D-gluconate, 4.2mM NaHCO3, 1.2mM 
NaH2PO4, 5.2mM Calcium D-gluconate, 2.4mM Magnesium Gluconate, 10mM HEPES. 
Lysis buffer contained 50mM Tris–HCl, 150mM NaCl, 1% IGEPAL-CA-630, 0.5% deoxycholic 
acid and supplemented with complete EDTA-free protease inhibitor cocktail (Roche). 
Unless stated, all drugs and chemicals were obtained from Sigma (Poole, UK). Forskolin, 
isobutyl-1-methylxanthine (IBMX), phorbol 12-myristate 13-acetate (PMA), were dissolved in 
DMSO. Peptone, NaCl, mannitol, taurodeoxycholate (TDCA), bombesin acetate and carbachol 
were dissolved in water. Where DMSO is used as a solvent, the working concentration never 
exceeded 0.2 % (v/v).  
2.8.2 Cell culture 
Caco2-TC7 cell line 
The Caco-2 cell line is a human intestinal cell line established from colonic adenocarcinoma 
and mature into enterocytes upon confluence. The TC7 cell line is a subclone of the Caco-2 
cell line which was generated from Caco-2 at late passage (Caro et al., 1995). TC7 cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, 4.5g/L glucose) supplemented with 
10% Foetal Bovine Serum (FBS), 100units/mL penicillin, 100μg/mL streptomycin and 2mM L-
glutamine. TC7 cells were incubated at 37°C, 5% CO2 in 75 cm2 flasks. The culture media was 
changed every 3 days. Every 5 days cells were trypsinised with 1X trypsin-EDTA, diluted and 
reseeded. 
Organoids set up, maintenance and differentiation 
Human tissues were obtained from the Human Research Tissue Bank at Addenbrooke's 
Hospital (Cambridge, UK) and processed within the same day.  
Duodenal and colonic intestinal organoids were established from one human donor each by 
Dr Goldspink (Goldspink et al., 2017) using a modified protocol from Sato et al., 2009. Briefly, 
tissues were washed in ice cold PBS and chopped into 2-3mm pieces. Tissue pieces were 
incubated for 5 minutes in ice cold 30mM EDTA in PBS and transferred to cold PBS before 
shaking vigorously for 20s. The incubation in EDTA and shaking steps (in new cold PBS 
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fractions) were repeated 4 times. Fractions presenting crypts were filtered through a 70μm 
cell strainer (Thermo Fisher) to remove villi. The crypts were centrifuged at 200g for 3 minutes, 
resuspended in Cultrex PathClear Reduced Growth Factor BME (Bio-Techne) and 20μL drops 
were polymerised at 37°C for 30 minutes in 48-well plates (Nunc). 250μL organoid medium 
(100μg/mL mouse Noggin (R&D), 50μg/mL human EGF (Invitrogen), 2mM L-Glutamine 
(Invitrogen), 100units/mL Pen/100µg/mL Strep (Invitrogen), 1x B27 (Invitrogen), 1x N2 
(invitrogen), 1mM NAC (Sigma), 10nM Gastrin (Sigma), 10mM nicotinamide, 500nM A83-01 
(Tocris), 10nM SB202190 (Sigma), 10μM ROCK inhibitor y27632 (Tocris), Wnt-3a and R-
Spondin-1 (RSPO1) conditioned medium were used and generated following the 
manufacturer’s instructions (ATCC and Trevigen, respectively) and adapted according to  Fujii 
et al., 2015.  
To maintain the organoid cell line, medium was changed every 3 days, with organoids 
passaged every 10 days. For the passage of the organoids cell lines, domes were harvested in 
1X TrypLE (Life technologies) and trypsinised at 37°C for 10-15 minutes, cells were centrifuged 
at 300g for 3min, resuspended in BME and 20μl drops were polymerised at 37°C for 30min. 
250μL organoid medium was added per well. 
Organoids were maintained in an undifferentiated state by the high concentration of Wnt-3a 
conditioned medium. To differentiate the organoids, wells were rinsed 3 times with Advanced 
DMEM/F12 medium over the course of an hour and 250μL of differentiation medium was 
added (15% RSPO1 conditioned medium, 100μg/mL human Noggin (R&D), 50μg/mL human 
EGF (Invitrogen), 2mM L-Glutamine (Invitrogen), 100units/mL Pen, 100µg/mL Strep 
(Invitrogen), 1x B27 (Invitrogen), 1x N2 (invitrogen), 1mM NAC (Sigma), 10nM Gastrin (Sigma) 
in Advanced DMEM/F12 medium) per well. Medium was changed every day for 7-10 days 
before experiments. 
Air Liquid interface (ALI) monolayer cultures 
ALI cultures were set up in 24 well plates (Costar) with 0.4μm pore cell inserts (BD Falcon) with 
a transparent PET membrane ideal for observing cell cultures as adapted from Wang et al., 
2015. TrypLE dissociated organoids (Cf. section on organoids maintenance) were seeded onto 
BME-coated transwells on the apical surface at 2 x 104 cells in WENR media (media on both 
apical and basolateral side). This media was replaced after 24hrs. Differentiation was induced 
at day 3 with differentiation media (See above Organoids differentiation) changed every other 
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day. Once cells had formed a confluent monolayer, air liquid interface was initiated with the 
removal of the media from the apical side. The cultures were grown for 2 weeks with 
periodical removal of mucus produced on the apical side and media on the basolateral side 
was changed every other day.  
2.8.3 ProGuanylin and ProUroguanylin secretions 
For ProGuanylin and ProUroguanylin secretion experiments, TC7 were seeded for 9 days on a 
24-well plate or human organoids were seeded into BME domes in 48-well plates and 
differentiated for 8-9 days as previously described. The wells were washed 3 times in warm 
basal medium containing 1mM glucose and 0.1% BSA. Test agents were dissolved in the same 
basal medium and 250μL applied for TC7 secretions, or 150μL applied for organoid secretions. 
For organoid secretions, treatments were added to the organoids domes and incubated at 
37°C for 4hrs, 8hrs, or 24hrs. Supernatants were removed from the organoids and spun at 
350g at 4°C for 10 minutes, transferred to a fresh Lo-bind tube (Eppendorf) and snap frozen 
on dry ice. 
For experiments that required cell lysates to measure total proforms or total protein levels, 
the cells were lysed in 150μL of lysis buffer on ice for 30 minutes. Lysates were collected and 
centrifuged at 10,000g at 4°C for 10 minutes and the supernatants was snap frozen until 
measurement. 
To isolate RNA, the cells were lysed with TRI-Reagent (Sigma), collected and snap frozen until 
RNA extraction (see section 2.10.1). 
Proforms were measured using the MSD assay (see section 2.7.2). Proforms secretions were 
calculated first as the amount produced in pg/mL and secondly as fold change produced in 
comparison to wells treated with the basal condition.   
2.8.4 BCA assay to measure total protein levels 
BCA assay were performed on cell lysis (Thermo Fisher) according to manufacturer’s 
instructions. Briefly, 25µL of each standard or unknown sample were pipetted into a 96 
microplate (Costar). 200µL of the WR mix (WR ratio = 1:8) was added to each well and mixed 
thoroughly. The plate was incubated at 37°C for 30 minutes. The absorbance was measured 
at 562nm on a plate reader (Tecan M1000). 
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2.9 Ussing Chamber 
Human tissue (ascending colon) was obtained through Addenbrooke’s Hospital Tissue Bank 
from patients undergoing partial colectomy. After histological verification, the piece of 
intestine was transported in ice-cold L-15 medium to level 2 biosafety cabinet. It was washed 
with Ringer solution containing 120mM NaCl, 3mM KCl, 0.5mM MgCl2, 1.2mM CaCl2, and 
23mM NaHCO3, with 10mM glucose. Serosa and most of the muscular layer were stripped 
away with fine forceps. The segment was mounted in an Ussing chamber (EM-LVSYS-4 system 
with P2400 chambers and P2405 slider; Physiologic Instruments). The active epithelial surface 
area of each segment was 0.25cm2. Both parts of the Ussing chambers were filled with Ringer 
solution, maintained at 37°C, and continuously bubbled with 5% CO2/95% O2 (vol/vol). The 
transepithelial potential difference was continuously monitored under open circuit 
conditions, using a DVC 1000 amplifier (WPI) and recorded through Ag-AgCl electrodes and 
150mM NaCl agarose bridges. Recordings were collected and stored using a DVC 100 amplifier 
(WPI) connected to a Digidata 1440A A/D converter and AxoScope 10.4 acquisition software 
(Molecular Devices). First, transepithelial resistance and potential difference were allowed to 
stabilise for 20 to 30 minutes. During this period, transepithelial resistance was assessed by 
measuring voltage changes in response to 45μA pulses lasting 2.5 seconds, applied every 100 
seconds. After stabilization of the electrical parameters, solutions from both sides were 
removed. Both sides of the chamber were refilled with 1.2mL of fresh Ringer solution 
containing 10mM glucose, 0.1% fatty acid–free BSA, 10μM amastatin and 500 kIU/mL 
aprotinin. To prevent extensive foam formation, Infacol (Forest Laboratories) was added to 
the both compartments (1:100000 dilution). At 15, 45 and 90 minutes after the solution 
exchange, samples (120μL) were taken from both compartments and assayed for 
ProGuanylin/ProUroguanylin content. Fresh solution was added to replenish volumes lost by 
sampling. At 45 minutes after the second pair of samples was taken, forskolin (10μM) and 
IBMX (100μM) were added bilaterally. Reported secretion values were normalised for 1cm2 of 
the tissue and a 60-minute secretion period. 
2.10 Measurement of transcript levels 
2.10.1 mRNA extraction 
Tissue or cells were homogenised in TRI-Reagent, and RNA was extracted using an adjusted 
manufacturer’s (Sigma) protocol. Homogenised tissues/cells were transferred to new 
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microcentrifuge tubes and incubated at RT for 5 minutes. 50μL of chloroform was added, the 
mix was shaken vigorously before incubating it at RT for 15 minutes. Tubes were centrifuged 
at 12,000g at 4˚C for 15 minutes and the aqueous layer was carefully transferred into a clean 
microcentrifuge tube. 500μL of isopropanol was added to each tube; they were mixed 
thoroughly and incubated at RT for 10 minutes. To pellet the RNA, tubes were centrifuged at 
12,000g at 4˚C for 10 minutes the supernatant removed. 1mL of 70% ethanol was used to 
wash the pellet and the tubes were centrifuged at 12000g at 4˚C for 15 minutes. The pellets 
were air-dried at RT and RNA was dissolved into 20μl of RNAse free water. The RNA was 
treated with DNAseI (Ambion) according to manufacturer’s instructions. Following a 20 
minutes incubation at 37˚C, DNAse inactivation reagent was added to each tube. After 2 
minutes incubation, the samples were centrifuged at 12,000g for 2 minutes. RNA samples 
were transferred to new tubes and snap frozen on dry iced before being stored at -80˚C. 
2.10.2 Reverse Transcription 
2μg of RNA was reverse transcribed with random primers via High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher) according to manufacturer’s protocol. Reverse transcription 
was performed in a 20μL final volume with a first step at 25°C for 10 minutes, followed by 
37°C for 2hrs and a final step of 85°C for 5 minutes. cDNA was stored at -80°C and used neat 
in subsequent PCR reactions. 
2.10.3 Quantitative RT-PCR 
Quantitative PCR were performed using 1μL of cDNA template, 5μL of TaqMan Fast Universal 
PCR Mastermix (AppliedBiosystems), 3μL of RNase-free water and 1μL of FAM-dye labelled 
TaqMan Gene expression assay probe (Applied Biosystems) (see appendix 3 for probes). Each 
reaction was incubated at 90˚C for 2 seconds followed by 40 cycles of 90˚C for 1 second 
followed by 60˚C for 20 seconds using ABI QuantStudio 7 qRT-PCR machine. Available 
sequences for the TaqMan probes are shown in appendix 3. 
2.11 LDH assay  
Cell culture supernatant and lysate samples were assessed using a Lactate Dehydrogenase 
Activity Assay Kit (Sigma–Aldrich) adapted from manufacturer’s instructions. Briefly, 
supernatants were diluted 1 in 5 and cell lysis samples were diluted 1:11 in cold LDH assay 
buffer. Samples were centrifuged at 10,000g at 4˚C for 15 minutes to remove insoluble 
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materials. 50μL of each sample was pipetted into a 96-well flat bottom plate (Costar) as well 
as the NADH standards. 50μL of master reaction mix was added to each well and the plate was 
incubated at 37 ˚C for 30 minutes before OD was measured at 450nm and 690nm. OD690 was 
subtracted to OD450 as well as the background. Data was plotted as a percentage of LDH 
activity in the supernatant over the total LDH activity in cell lysate and supernatant. 
2.12 Mass Spectrometry to analyse peptides levels 
2.12.1 Preparation of samples for Mass Spectrometry 
Peptides from tissue homogenates, plasma, organoid secretion, and intestinal content 
samples were extracted in 80% acetonitrile (ACN) in water. Samples were spun at 12,000g for 
10 minutes and the supernatants were transferred to new Lo-bind tubes (Eppendorf). Samples 
were dried using a SPE Dry evaporator system (Biotage) and resuspended in 200µL 0.1% formic 
acid (FA) in water. The samples followed a solid phase extraction (SPE) step to purify the 
peptides. Samples were loaded on a HLB PRIME µElution plate (Waters) and washed first with 
0.1% FA in water. Samples were washed by addition of 200µL of 5% methanol and 1% acetic 
acid in water. The samples were eluted by addition of 2 x 25µL of 60% methanol 10% acetic 
acid in water.  
To remove disulphide bonds and obtain linear peptides, samples were reduced and alkylated. 
Eluted samples were dried using SPE Dry evaporator system. Peptides were reconstituted in 
200µL of 10mM DTT in 50mM ammonium bicarbonate solution and incubated at 60˚C for 1hr. 
40µL of 100mM iodoacetamide (Sigma) in 50mM ammonium bicarbonate solution was added 
to the samples and incubated in the dark at RT for 30 minutes. 25µL of 1% FA in water was 
added to the samples to acidify the samples. 
For samples that were trypsinised, the enzyme digest was performed before the addition of 
1% FA in water. This step was done by addition of 10µL of trypsin (Promega #V511C 20µg in 
40µL) at 100µg/mL. 
2.12.2 Nano-LC-MS 
Method as described in Kay et al., 2017: “Peptide extracts were analysed using a Thermo 
Fisher Ultimate 3000 nano-LC system coupled to a Q Exactive Plus Orbitrap mass spectrometer 
(ThermoScientific, San Jose, USA). The analysis was performed using nano-flow-based 
separation and electrospray approaches due to the low amount of material present in the 
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samples. The extracts were injected onto a peptide trap column (0.3 × 5mm; ThermoFisher 
Scientific) at a flow rate of 20μL/min and washed for 10 minutes before switching in line with 
a nano easy column (0.075 × 250mm; ThermoFisher Scientific) flowing at 300nL/min. Both 
nano and trap column temperatures were set at 45°C during the analysis. The buffers used for 
nano-LC separations were A: 0.1% formic acid in water (v/v) and B: 0.1% formic acid (v/v) in 
80:20 ACN/water. Initial starting conditions were 2.5% B (equating to 2% ACN), and held for 5 
minutes. A ramp to 50% B was performed over 145 minutes, and the column then washed 
with 90% B for 20 min before returning to starting conditions for 20 minutes, totalling an 
entire run time of 190 min. Electrospray analysis was performed using a spray voltage of 1.8 
kV, the tune settings for the MS used an S-lens setting of 70 v to target peptides of 
higher m/z values. A full scan range of 400–1600 m/z was used at a resolution of 75,000 
before the top 10 ions of each spectrum were selected for MS/MS analysis. Existing ions 
selected for fragmentation were added to an exclusion list for 30 s. 
The acquired LC/MS files were searched using Peaks 8.0 software (Waterloo, ON, Canada) 
against the mouse and human Swissprot databases (downloaded on 06/May/2016). A no-
digest setting was used, which enabled peptides of up to 65 amino acids in length to be 
matched, and precursor and product ion tolerances were set at 10 ppm and 0.05 Da, 
respectively. A fixed post-translational modification of carbamidomethylation was applied to 
cysteine residues, whilst variable modifications included methionine oxidation, N-terminal 
pyro-glutamate, N-terminal acetylation and C-terminal amidation. A false discovery rate value 
of 1% was used to filter the results, with a minimum of 1 unique peptide also required.” 
Raw data files were analysed using Xcalibur (v4.0) (Thermo Fisher Scientific). Peptide peak 
areas were obtained by integrating the area under the peak of an extracted ion 
chromatogram. 
2.13 Transgenic mice generation 
All experimental procedures were approved by local ethical review bodies and were 
performed in accordance with the Animal (Scientific Procedures) Act 1986, Home Office 
guidelines, local establishment guidelines. Experiments were performed under Fiona Gribble’s 
project licence (70/7824). C57BL/6 mice were purchased from Charles River UK.  
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The 3 exons coding for Guca2a (Guanylin) from the start codon to the stop codon in the 
murine-based BAC RP23-104G3 (Source Bioscience) was initially replaced by a counter-
selection cassette RpsL-neo (GeneBridges) and subsequently by the Venus (EYFP) sequence 
(Rekas et al., 2002) using Red/ET recombination technology (Genebridges). The RpsL/Neo 
(FSD001/FSD002) or Venus (FSD003/FSD004) sequences were amplified by PCR with Phusion-
polymerase adding Guca2a-gene specific 3′ and 5′ sequences (see appendix 2 for primers). 
Homologous recombination was performed by co-transformation of the PCR product and the 
plasmid pRedET (which provides the recombination enzymes) into DH10B E. coli strain 
containing the BAC vector. Positive recombinants were isolated using appropriate antibiotic 
selection and characterised by PCR. The identity and correct positioning of the introduced 
Venus sequence was confirmed by direct sequencing using oligonucleotides FSD045-FSD076 
in appendix 2 and restriction analysis using the ZraI enzyme (NEB) for DNA fingerprinting. 
The 3 exons coding for Guca2b (Uroguanylin) in the murine-based BAC RP23-440N21 (Source 
Bioscience) was replaced by the counter-selection cassette RspL/Tet fused to the Venus 
sequence. The Venus (FSD033/FSD034) and RpsL/Tet (FSD035/FSD036) sequences were 
amplified by PCR to add the homology arms to RpsL/Tet and Venus respectively. The final 
RpsL/Tet-Venus product was amplified by PCR using the FSD037 and FSD038 primers 
combination. The RpsL/Tet counter-selection cassette was later removed using an 
oligonucleotide (FSD039) covering the 3’ promoter sequence and the 5’ Venus sequence. 
Similarly, homologous recombination was performed by co-transformation of the PCR product 
and the plasmid pRedET into DH10B E. coli strain containing the BAC vector. The identity and 
correct positioning of the introduced Venus sequence was confirmed by direct sequencing 
using oligonucleotides FSD110-FSD127 and restriction analysis using the XhoI enzyme (NEB) 
for DNA fingerprinting. 
The large construct Maxi-Prep (Qiagen) was used to purify the BAC DNAs for microinjection. 
It was diluted to 1ng/μL into the injection buffer (10mM Tris-HCl (pH 7.5), 0.1mM EDTA, 
100mM NaCl, 0.03 mM spermine, and 0.07mM spermidine). The Central Biomedical Services 
(Cambridge University) performed the pronuclear injection of C57BL/6 mice ova which were 
implanted into pseudopregnant females. Integration of the transgene was screened by PCR 
on the pups’ ear clips after extracting the DNA by proteinase K digestion using the primers 
GFPF1 and GFPR1. Out of two Guanylin-Venus founders, only one passed the transgene to 
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their offspring (mouse 26) and presented detectable fluorescence. It was backcrossed to a 
C57BL/6 background up to 5 generations. 
2.14 Immunohistochemistry 
Tissues were fixed in 4% paraformaldehyde (PFA) (Alfa Aesar) ON at RT, dehydrated in 15% 
for 6hrs and finishing with 30% sucrose ON at 4˚C. Tissues were embedded in OCT (VWR) prior 
to slicing. Tissues sections were blocked in 10% donkey serum, 0.05% Tween-20 and 1% BSA. 
Slides were stained with primary antisera of interest in the same blocking solution ON at RT 
(Appendix 4). Slides were washed in blocking solution and incubated with appropriate 
secondary antisera diluted 1:300 and Hoescht diluted 1:1300 for 1hr. Tissue stained with 
secondary antisera only served as controls. Coverslips were mounted with hydromount (Fisher 
Scientific). Images were taken using a Leica TCS SP8 X confocal microscope with Leica 
Application Suite X software. 
2.15 Whole mounted tissue immunostaining 
The following method was adapted from that developed by Winton and Ponder, 1990. Excised 
tissues were stripped of adipose tissue and muscle layers (removal of the muscle layer greatly 
reduces immunofluorescent background). tissues were pinned onto 3% agar filled petri dishes, 
cut open and washed with PBS using a plastic pipette. The colons were then fixed for 3hrs at 
room temperature using 4% PFA (Alfa Aesar) and subsequently washed with PBS. Residual 
mucus was removed from the fixed tissue by incubation with 50mL of demucifying solution 
for 20 minutes at RT followed by 4x PBS washes. The fixed colons were transferred to 50mL 
Falcon tubes containing blocking solution (PBS with 0.1% Triton-X 100 and 10% goat serum) 
and left ON at 4°C. The following morning tissues were incubated for 4hrs at room 
temperature with primary antibodies to GFP diluted in wash solution containing 1% goat 
serum and 0.1% Triton-X 100 in PBS. Tissues were placed in wash solution ON. Tissues were 
incubated with goat secondary antibody (1:300) for 3 hours at room temperature. Following 
further washing ON at 4°C, tissues were incubated with 1:2000 Hoescht nuclear stain (in PBS) 
for 30 minutes at RT followed by 1hr period of PBS washes. Finally, tissues were divided in half 
and mounted onto microscope slides using Hydromount (National Diagonistics). 
Wholemounts were imaged using the Axio Scan.Z1 system (Zeiss). Tiles of extended depth of 
focus (EDF) images were taken for the labelled channel using a PlanApoChromat 20x/0.8 M27 
objective, a Hamamatsu Orca Flash camera and an inbuilt autofocus function. The depths used 
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for the EDF images were customised for the wholemount and depended on tissue thickness. 
Following acquisition, the tiled images were stitched together with shading correction. 
2.16 Primary murine intestinal single-cell suspension for fluorescence-activated cell 
sorting 
Guanylin-Venus mice were killed by cervical dislocation and the gut collected into ice-cold 
Leibovitz-15 (L-15) medium. 4 distinct parts of 3 cm corresponding to the duodenum, jejunum 
and ileum as well as the colon were treated separately. Each intestine part was opened 
longitudinally, rinsed in phosphate buffered saline. The outer muscle layer was removed. Each 
epithelium was digested in 10mL with 15mM EDTA (or 30mM for colon) and 1 mM DTT in Ca2+-
free PBS for 7 minutes at RT. Tissue pieces were transferred in 15mL Ca2+-free PBS with 10μM 
ROCK inhibitor y27632 (Tocris) and shaken for 30 seconds. The incubation steps in EDTA 
solution followed by the shaking steps were repeated 5 times. The tissue pieces were 
transferred into a 10mL Trypsin 0.25% EDTA, 100mg/mL DNAseI and incubated at 37°C for 5 
minutes. Cells were spun at 500g at 4°C for 5 minutes and resuspended into 10mL of washing 
solution (of Hanks' buffered salt solution (HBSS) supplemented with 10% FBS and 5μM ROCK 
inhibitor y27632) and filtered using both 100µm and 50µm cell filters. 150µL of the washing 
solution containing an anti-CD45-PE antibody (1/500) (Thermo Fisher #MA110233) and 
incubated on ice for 1hr. Cells were spun at 500g at 4°C for 5 minutes, resuspended in 200µL 
of the washing solution containing DAPI and incubate for 5 minutes. A final centrifugation was 
performed, and cells were resuspended in 500µL of the washing solution containing 5µM 
DRAQ5 (Fisher Scientific #15530617). Cells were transferred to a 5mL polypropylene 
12*75mm FACs tube (Falcon #352063). Single cell suspensions were separated immediately 
by flow cytometry using a MoFlo Beckman Coulter Cytomation sorter (Coulter Corp., Hialeah, 
FL) by the Flow Cytometry Core Facility at the Cambridge Institute for Medical Research. Side 
scatter, forward scatter, and pulse-width gates were used to exclude debris aggregates and 
doublets. Dead cells were excluded using DAPI staining and live cell-shape remains were 
removed by DRAQ5 staining. Cells were sorted and collected into a positive (YFP+) population 
with high green fluorescence and non-fluorescent negative cells population for each tissue. 
Cells were sorted into lysis buffer for mRNA extraction 
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2.17 RNA sequencing 
Total RNA from FACS-isolated cells was extracted using RNAeasy Micro Plus kit (Qiagen) 
according to the manufacturer's instructions. The Bioanalyser RNA Pico kit (Agilent) was used 
to assess the quality and quantity of the RNA extracted. RNA samples with RNA integrity 
number values between 8.6 and 10 were used. Libraries were prepared and amplified using 
SMARTer Pico V2 Mammalian prep kit (Takara) from 10ng of RNA. Libraries were single-end 
50 base pair sequenced at CRUK Cambridge on the Illumina HiSeq 4000 platform. The average 
total number of reads in each sample was 32.3 million with an average of 21.4 million mapping 
once to the mouse genome GRCm38 using STAR (Dobin et al., 2013). Read counts per gene 
was determined using STAR and differential gene expression was determined using DESeq2. 
2.18 Statistical analysis 
Statistics on samples was performed using GraphPad Prism 7.04 (GraphPad Software, La Jolla, 
CA, USA), with a threshold for significance of p = 0.05. Specific details for the statistical analysis 




Chapter 3: Generation of monoclonal antibodies against ProGuanylin 
and ProUroguanylin and development of an immunoassay 
3.1 Introduction 
3.1.1 Lack of tools to study ProGuanylin and ProUroguanylin  
Understanding the physiology and pathophysiology of the guanylin peptides in health and 
disease states has been limited by the lack of specific monoclonal antibodies against the active 
peptides and their prohormone precursors.  
Commercially available antibodies from the main commercial distributors (Abcam, Santa Cruz 
antibodies) are polyclonal and do not distinguish between the proforms and the bioactive 
versions of the guanylin-related peptides. The only available kit used routinely referred to in 
the published literature was developed by Biovendor which cost £683 per kit. 
Not only are reliable antibodies difficult to find but recombinant versions of prohormone 
precursors ProGuanylin and ProUroguanylin are not commercially available. The production 
of ProGuanylin solubly-expressed in E. coli was described in Lauber et al. This method was 
optimised to produce ProUroguanylin (Lauber et al., 2002). 
3.1.2 Generation of antibodies by hybridoma campaign 
Since 1975 hybridoma campaigns have been widely used to create monoclonal antibodies 
based on the techniques originally described by Köhler and Milstein (Köhler and Milstein, 
1975). A campaign is initiated by repeatedly immunising a mouse with a target antigen which 
will trigger an immune response. B cells from the spleen (or lymph nodes in our case) are then 
isolated and fused with an immortal myeloma cell line. The fused cells have the capacity of 
dividing perpetually and the ability to produce antibodies. The hybridoma cells secrete 
antibodies in the media that can subsequently be assayed in ELISA or other immunoassays to 
determine the antibody specificity (figure 3.1). 
Other approaches are available to produce antibodies against a specific target and these 
include phage display, ribosome display, yeast display and computational methods. However, 
a hybridoma campaign is considered a fast and efficient method to produce and identify large 
numbers of IgG antibodies usually with nanomolar (nM) or subnanomolar affinity to their 
targets due to the in vivo round of selection and affinity maturation. 
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MedImmune has a state-of-the-art technology platform to produce and characterise 
monoclonal antibodies in a short and efficient way. The Clonepix FL machine for instance is 
able to pick hybridoma colonies growing in semi-solid media and check for monoclonality.  
 
Figure 3.1: Hybridoma process for the generation of antibodies against Guanylin or Uroguanylin. Female 
CD1 mice were immunised with a series of antigen injections over 28 days. Antibody-producing B cells from 
lymph nodes or spleen were fused with a myeloma (B cell cancer) by electrofusion. IgG-secreting hybridomas 
were selected and incubated for 15 days in semi-solid media containing an anti-IgG-FITC antibody, and 
subsequently picked by Clonepix FL. Colonies were grown for a further 3-5 days before being screened for 
activity. The positive clones were cherry-picked, sequenced, and then small-scale IgGs were expressed, and 











To generate novel monoclonal antibodies against ProGuanylin and ProUroguanylin by: 
a) Designing and producing ProGuanylin and ProUroguanylin in E. coli. 
b) Generating hybridoma antibodies by mice immunisation. 
c) Screening the clones of interest in ELISA assays and epitope binning to find pairs of 
compatible antibodies to detect ProGuanylin or ProUroguanylin. 




3.2 Results  
3.2.1 Production of the ProGuanylin and ProUroguanylin 
3.2.1.1 Generation of ProGuanylin and ProUroguanylin fusion proteins 
C-terminally His6 –tagged ProGuanylin was expressed in Origami 2 (DE3) and affinity purified 
following the protocol of Thomas Lauber et al. 25mg of ProGuanylin was obtained at a yield 
of 5.6mg/L. The same protocol was used to overexpress and purify ProUroguanylin with 
limited success due to poor solubility when expressed in E. coli. Therefore, the expression and 
purification protocol for ProGuanylin was adapted and optimised. Sixty-eight expression 
conditions were tested in attempt to generate sufficient quantity of protein for subsequent 
experiments. Expression in Arctic Express (DE3) at 12˚C overnight with 0.5mM IPTG was found 
to yield the highest quantities of ProUroguanylin as determined by SDS-PAGE (figure 3.2). On 
review of the literature, this adapted method is the first to describe production of soluble 
ProUroguanylin. However, the protein yield was poor (30.5µg/L). Therefore, to achieve the 
quantities required for immunisation and screening the production was scaled up. In all, a 




Figure 3.2: Assessment of the optimal condition for ProUroguanylin expression by SDS-PAGE. 
Expression assessed in (A.) Origami 2 (DE3) at 18˚C, (B.) Shuffle T7 at 18˚C, (C.) SHuffle T7 Express LysY 
at 18˚C, (D.) Arctic Express at 12˚C and (E.) in Origami 2 (DE3)0.1mM IPTG at 18˚C in presence of 
chaperones (pKJE7, pGro7 or pTf16) . For (E.) only soluble fractions were analysed by SDS-PAGE. 
Protein expression was examined at 4hrs, 5hrs, 6hrs, 7hrs and overnight following induction with 
varying concentrations of IPTG (0.1mM, 0.5mM, and 1mM). The expected value for the protein of 
interest (ProUroguanylin - Avi Tag - Prescission protease cleavage site – linker - His6 Tag – Thioredoxin) 
is 29.4kDA. The arrow represents the condition that was chosen to produce the soluble version of 
ProUroguanylin: expression in Arctic Express (DE3) at 12˚C overnight with 0.5mM IPTG. 
 
It was apparent that adopting this soluble protocol would not yield enough ProUroguanylin 
therefore, in order to generate the required 5mg of protein for immunisation, an alternative 
protocol was developed. Since the correct conformation of the protein was not essential for 
immunisations in mice, a significant larger quantity of the protein was isolated and purified 














































L    1     2      3     4      5     6     7     8 1 – Insoluble – 4H  
2 – Insoluble – 5H
3 – Insoluble – 6H
4 – Insoluble – O/N
5 – Soluble – 4H
6 – Soluble – 5H
7 – Soluble – 6H
8 – Soluble – O/N
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B. Expression in SHuffle T7 at 18˚C
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4h   5h 6h    4h  5h  6h   4h   5h  6h   4h  5h   6h
pGro7 pTf16
1 – Insoluble – 4H  
2 – Insoluble – 5H
3 – Insoluble – 6H
4 – Insoluble – 7H
5 – Insoluble – O/N
6 – Soluble – 4H
7 – Soluble – 5H
8 – Soluble – 6H
9 – Soluble – 7H
10 – Soluble – O/N
1 – Insoluble – 4H  
2 – Insoluble – 5H
3 – Insoluble – 6H
4 – Insoluble – O/N
5 – Soluble – 4H
6 – Soluble – 5H
7 – Soluble – 6H
8 – Soluble – O/N
1 – Insoluble – 4H  
2 – Insoluble – 5H
3 – Insoluble – 6H
4 – Insoluble – O/N
5 – Soluble – 4H
6 – Soluble – 5H
7 – Soluble – 6H
8 – Soluble – O/N
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from inclusion bodies. Using this approach, 9.3mg of ProUroguanylin was purified from the 
inclusion bodies with an average yield of 520µg/L. This was a sufficient quantity to pursue 
immunisations and screening for the ProUroguanylin protein. 
Endotoxins or lipopolysaccharide (LPS) are the membrane components of Gram-negative 
bacteria and are immunogenic. The purified proforms -soluble ProGuanylin and 
ProUroguanylin from inclusions bodies were found to contain high levels of endotoxins 
(>200EU/mg) and not suitable for immunisation (80EU/mg allowed for immunisation). 
Endotoxin levels were reduced by using polymyxin B agarose (Sigma P1411). The interaction 
between polymyxin B and endotoxin (LPS) is specific (Vesentini et al., 2010). After incubation 
with the resin, the endotoxin levels were reduced to 8.96EU/mg and 75.8 EU/mg for 
ProGuanylin and ProUroguanylin, respectively.  
3.2.1.2 Characterisation of the ProGuanylin and ProUroguanylin 
The proforms were characterised using SDS-PAGE and MALDI-TOF mass spectrometry to 
determine size and purity. Observed masses on mass spectrometry were consistent with the 
presence of AviTag on ProGuanylin and ProUroguanylin (12307.9Da and 11454.0Da, 
respectively) (figure 3.3). The proteins were both >95% pure, appeared monomeric by SDS-
PAGE and single species by mass spectrometry. The ELISA using commercially available 
antibodies (Abcam #Ab14427-50 for ProGuanylin and #Ab171982 for ProUroguanylin) further 




Figure 3.3: Characterisation of the proforms of ProGuanylin and ProUroguanylin by Mass Spectrometry. 
MALDI-TOF mass spectrometry of (A.) ProGuanylin and (B.) ProUroguanylin in the positive ion mode was 
performed on a Shimatzu Biotech AXIMA Assurance instrument using Shimadzu MALDI-MS software version 










Figure 3.4: Characterisation of the proforms of ProGuanylin and ProUroguanylin by SDS PAGE and ELISA. 
SDS PAGE was performed on 1μg and 5 μg of (A.) ProGuanylin and (B.) ProUroguanylin to control their quality. 
The expected molecular weights for ProGuanylin and ProUroguanylin are 12.3kDa and 11.5kDa, respectively. 
Both proforms are recognised by commercially available polyclonal antibodies in (C.). 
 
To enable screening, proforms purified from the soluble fractions were specifically 
biotinylated on the AviTag by BirA enzymatic reaction (Cull and Schatz, 2000) (Avidity 




Figure 3.5: Assessment of biotinylation efficiency by Mass spectroscopy. ProGuanylin and ProUroguanylin 
were enzymatically biotinylated using BirA enzyme. (A.) shows the mass spectra for ProGuanylin before (red) 
and after (blue) biotinylation. (B.) shows the mass spectra for ProUroguanylin before (red) and after (blue) 
biotinylation. 
 
3.2.2 Generation of monoclonal antibodies 
3.2.2.1 Mouse immunisation and hybridoma generation 
Mice were immunised with 100µg of ProGuanylin or ProUroguanylin following a 28-day 
immunisation schedule. Serum titres (prebleed, day 13 and day 20) were measured using an 
66 
 
ELISA that detected binding to biotinylated-proforms. Strong serum titres were obtained for 
the mice immunised with ProGuanylin and ProUroguanylin (data not shown).  
For antibody production, hybridomas were generated from lymphocytes extracted from 
immunised mice that presented the highest serum titres among each group. To identify IgG-
secreting colonies, fusions were plated into a semi-solid media containing a FITC-labelled 
antibody against IgG. ClonePix FL was used to identify IgG-secreting colonies. Percentages of 
IgG secreting for the two immunising antigen groups are shown on table 3.1. 
 
Table 3.1: Summary of the hybridoma campaign to ProGuanylin and ProUroguanylin targets. All IgG-
secreting hybridomas were picked and IGs screened in the primary screens. The table contains the final results 
of binders after characterisation. 
3.2.2.2 Screening of hybridoma clones 
All of the IgG-secreting hybridoma colonies were tested for binding to the four biotinylated 
targets in a HTRF direct binding assay. Among the 814 IgG supernatants tested, 35 clones were 
found to bind to biotinylated-ProGuanylin and 10 clones bound to biotinylated-
ProUroguanylin (table 3.1). The 45 hybridoma supernatants that were positive in the HTRF 
assay were sequenced and IgG-purified using a small-scale automated plate-based method. 
To assess the sequence diversity of the panel of antibodies, the variable region CDR3 was 
sequenced. 42 out of 45 clones presented a unique sequence, equivalent to 93.3% diversity. 
The specificity of the 45 antibodies was confirmed using an ELISA assay against each potential 
target: biotinylated-ProGuanylin, biotinylated-ProUroguanylin, biotinylated-Guanylin, 
biotinylated-Uroguanylin, Guanylin-KLH, Uroguanylin-KLH and KLH only (those last targets are 
developed more in Chapter 4). The ELISA was performed at a single sample dilution. From the 
35 antibodies directed against ProGuanylin, 26 showed exclusive binding to ProGuanylin. Five 
out of 10 antibodies directed against ProUroguanylin showed exclusive binding to 
ProUroguanylin (figure 3.6). 
ProGuanylin ProUroguanylin
Hybridoma colonies 5691 4077
IgG secreting colonies 754 60
% of IgG secreting colonies 13.2% 1.4%
HTRF binders to biotinylated antigens 35 10
% of binders/IgG secreting colonies 4.6% 16.7%





























































































































































































3.2.3 Determination of the specificity and binding of the panel of antibodies 
3.2.3.1 Affinity measurement and identification of antibody pairs by Epitope binning 
All 45 antibodies identified by primary screens were covalently conjugated to a SensEye for 
affinity measurements and epitope binning assay using IBIS-MX96, which is based on surface 
plasmon resonance. From the panel of 45 antibodies, 25 clones did not bind the SensEye and 
were subsequently excluded from further analysis. It was likely that these antibodies were not 
compatible with the surface chemistry of SensEye. The binding of each antibody to its target 
(either ProGuanylin or ProUroguanylin) was analysed. The KD was measured for 11 of the 16 
antibodies and demonstrated binding to ProGuanylin and binding to ProUroguanylin for 3 out 
of the 4 antibodies (table 3.2). Some antibodies presented a high affinity to their targets such 
as AB100030 (KD=597pM) and AB100033 (644pM) due to low off-rates. The KD of AB100011 
was impossible to determine as the binding was biphasic with an initial fast off-rate followed 
by a second slower off-rate phase. However, the kd was measured on the slower off-rate 
phase and was the lowest among the panel of antibodies. 
 
Table 3.2: Affinity results of the panel of antibodies to their targets measure using the IBIS-MX96. 
ProGN means ProGuanylin and ProUGN means ProUroguanylin. 
 
The IBIS technology was also used to perform epitope binding to identify antibody pairs that 
bind different epitopes on the same antigens. Having antibody pairs will enable the 
development of assays to detect proform and active peptides of guanylin and uroguanylin. A 
signal will be detected only when two antibodies bind to non-overlapping epitopes. The 
epitope binding results are presented in figure 3.7 and demonstrate identification of several 
antibody pairs capable of detecting ProGuanylin. The coated antibodies AB100030 and 
AB100025 appeared most promising with a diversity of potential secondary antibody: 
AB100037, AB100038, AB100028, AB100031 and AB100041. Out of the 4 antibodies that 
showed binding to ProUroguanylin, only one pair of antibodies was able to detect 
ProUroguanylin: AB100010 and AB100011. The signal was stronger when AB100010 was 
covalently bound to SensEye compared to AB100011 but that could be due to a difference in 
conjugation efficiencies to SensEye. 
AB100010 AB100011 AB100012 AB100013 AB100020 AB100021 AB100023 AB100024 AB100025 AB100027 AB100028 AB100030 AB100032 AB100033 AB100034
Target ProUGN ProUGN ProUGN ProUGN ProGN ProGN ProGN ProGN ProGN ProGN ProGN ProGN ProGN ProGN ProGN
ka 2.46E+05 9.45E+04 1.08E+05 9.75E+05 1.70E+05 1.36E+06 1.56E+05 1.03E+06 3.42E+05 1.55E+05 1.74E+06 7.40E+05 1.94E+06 4.73E+05
kd 1.74E-03 5.40E-04 1.99E-03 2.03E-03 1.84E-02 1.24E-02 5.41E-02 3.19E-03 4.66E-03 1.10E-02 9.89E-03 1.04E-03 2.35E-02 1.25E-03 7.72E-03
Rmax 96.34 36.08 34.9 149.9 33 57.96 66.37 85.91 63.8 58.83 49.66 76.58 37.63 82.86
KD 7.09nM 21.03nM 18.8nM 18.9nM 75nM 39.81nM 20.50nM 4.521nM 32.11nM 63.84nM 597.21pM 31.76nM 644.55pM 16.34nM




Figure 3.7: Epitope binding of antibodies to propeptides using SPR technology IBIS MX96 to identify 
antibody pairs. Each of the composite sensorgrams A-L represents the binding of free ProGuanylin in the flow 
cell to the covalently immobilised antibody (labelled on the top of each composite sensorgram), followed by 
individual binding events of secondary antibodies 1-6 to ProGuanylin. Similarly, M-N represent the binding of 
free ProUroguanylin in the flow cell to the covalently immobilised antibody, followed by individual binding 
events of secondary antibodies 7-8 to ProUroguanylin. The identities of the secondary antibodies are: 1/ 




Four of the antibodies implicated in a potential pair to detect ProUroguanylin and ProGuanylin 
did not bind to the SensEye and therefore the affinity to the proforms was not measured. It 
was decided to perform another experiment using a Biacore instrument - based on surface 
plasmon resonance as well. Eight of the antibodies involved in pairs detecting the ProGuanylin 
or Proguanylin were covalently bound to a CM3 chip by amine coupling. Different 
concentrations of the ProGuanylin and ProUroguanylin allowed the measurement of the 
binding constants using a 1:1 binding model. The sensorgram presenting the binding of 
AB1000010 and AB1000011 to ProUroguanylin and AB1000025, AB1000028, AB1000030, 
AB1000031, AB1000037 and AB1000041 to ProGuanylin are presented in figure 3.8 and the 
binding constants are summarised in table 3.3. 
 
Table 3.3: Affinity results of the panel of antibodies to ProGuanylin or ProUroguanylin. Affinity 
measurement was performed using the IBIS and Biacore T100 instrument. The data was analysed using 










AB1000010 ProUroguanylin Hybridoma selection 7.09E-09 6.17E-09
AB1000011 ProUroguanylin Hybridoma selection N/D 2.94E-09
AB1000025 ProGuanylin Hybridoma selection 4.52E-09 3.64E-09
AB1000028 ProGuanylin Hybridoma selection 6.38E-08 2.89E-09
AB1000030 ProGuanylin Hybridoma selection 5.97E-10 1.12E-09
AB1000031 ProGuanylin Hybridoma selection N/D 6.99E-10
AB1000037 ProGuanylin Hybridoma selection N/D 8.04E-10
AB1000041 ProGuanylin Hybridoma selection N/D 1.06E-09
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Figure 3.8: Determination of the antibodies’ affinity to ProGuanylin of ProUroguanylin using Biacore.  
Kinetic binding experiment with antibodies A. AB1000010 B. AB1000011 C. AB1000025 D. AB1000028 E. 
AB1000030 F. AB1000031 G. AB1000037 H. AB1000038 on the Biacore T100 instrument (Response Units (RU) 
as function of time). The antibodies were immobilised at 10μg/ml on the CM3 chip. The flow rate was 
50μl/min, the contact time was 180 seconds while the dissociation time was 400 seconds. The data was 
analysed using the Biacore T100 evaluation software using a 1:1 binding model and the fit is represented by 
the black line. 
In (A.) ProUroguanylin was used at a concentration ranging between 2.5nM and 160nM. In (B.) ProUroguanylin 
was used at a concentration ranging between 2.5nM and 20nM. In (C.) and (E.) ProGuanylin was used at a 
concentration ranging between 7.81nM and 62.5nM. In (D.) ProGuanylin was used at a concentration ranging 
between 7.81nM and 31.25nM. In (F.) ProGuanylin was used at a concentration ranging between 1.25nM and 
10nM. In (G.) ProGuanylin was used at a concentration ranging between 1.25nM and 20nM. In (H.) 
ProGuanylin was used at a concentration ranging between 7.81nM and 15.63nM. 
 
All tested antibodies presented a high affinity (nanomolar affinity) for either ProGuanylin or 
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A. AB1000010 B. AB1000011
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However, the Biacore T100 evaluation software was unable to fit the curves properly using a 
1:1 binding model. This is probably due to bivalent binding and, therefore, the KD needs to be 
interpreted with some reservation, although it does provide an estimation of the affinity. 
Biacore sensorgrams frequently exhibit deviation of the first-order kinetics and different 
causes can explain such a result (Kalinin, Ward and Winzor, 1995; Morton, Myszka and 
Chaiken, 1995; O’Shannessy and Winzor, 1996). The antibody could have a multivalent 
property and recognize two or more parts of the target (ProGuanylin or ProUroguanylin) 
invalidating the first-order binding model. Another potential cause would be the 
heterogeneity of the antibody or the target. It can be assumed that the proforms exist as a 
homogeneous solution as it presented a 1:1 binding model fit with some of the antibodies. 
Even though the antibodies were purified by affinity followed by size exclusion 
chromatography, potential degradation of the antibodies with time would modify the 
homogeneity of the solutions. Finally, a potential explanation of the bivalent binding would 
be the masking of potential sites by the proform. 
A common approach to overcome bivalent binding to measure the affinity of antibodies to 
their targets is to perform the experiment using the Fab or the scFv part of the antibody 
(Muller-Loennies et al., 2000). This methodology was however not pursued as it would have 
been time consuming and the affinity measurement was not essential for the completion of 
the project. 
3.2.3.2 Development of an immunoassay for the measurement of the proforms 
To compare the different possible pairs of antibodies that were identified by epitope binning 
for ProGuanylin, each potential pair of antibodies were tested in the Meso Scale Discovery 
(MSD) electrochemiluminescence assay which measures the light emitted when a voltage is 
applied. The MSD immunoassay has been regularly evaluated against competitor 
immunoassays (Becton Dickinson Cytometric Bead Array, ELISA) and has proven a more 
reliable, accurate and with a broader dynamic range assay to measure cytotoxins (Chowdhury, 
Williams and Johnson, 2008; Dabitao et al., 2011), pharmacodynamic responses in tumours 
(Gowan et al., 2007) or incretin hormones (Bak et al., 2014; Meek et al., 2016). 
In order to perform a MSD assay, one of the 2 antibodies involved in a pair is used to coat the 
MSD plate while the second antibody is labelled with a Sulfo-tag. Antibodies AB1000025 and 
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AB1000030 were both used as capture antibodies and were coated on a plate. Antibodies 
AB1000028, AB1000031, AB1000037 and AB1000041 were labelled with a Sulfo-Tag and used 
as detection antibodies. Three concentrations of ProGuanylin were used with each antibody 
configuration and the pair that gave the highest MSD response was the pair formed by 
AB1000025 and AB1000028-Sulfo-Tag (figure 3.9 A).  The antibody pairs were also tested in 
the reverse configuration where AB1000028 was used as the capture antibody and Sulfo-Tag 
labelled AB1000025 used as the detection antibody. This new configuration was not as 
effective as the pair with AB1000025 as the capture antibody (figure 3.9 B).  
The best combination of antibodies to detect ProUroguanylin was easier to find as only two 
antibodies worked as a pair (AB1000010 and AB1000011). Both were labelled with the Sulfo-
tag and used as capture antibody. Three concentrations of ProUroguanylin were used with 
each antibody configuration and both antibody configurations gave similar MSD response 
(figure 3.9 C). 
The final assay to detect ProGuanylin gave a range of detection from 200-200,000pg/ml and 
intra-assay CVs of <5%. The final assay to detect ProUroguanylin gave a range of detection 





Figure 3.9: Assessing the best pair of antibodies to capture and detect ProGuanylin or ProUroguanylin in 
the Meso Scale Discovery assay. (A). MSD response to set concentration of ProGuanylin with all potential 
antibody combinations. (B.) Assessment of the limit of detection of ProGuanylin by the AB1000025 and 
AB1000028 antibody pair with either the AB1000025 coated to the plate and AB1000028 tagged or vice versa. 
(C.) Assessment of the limit of detection of ProUroguanylin by the AB1000010 and AB1000011 antibody pair 
with either the AB1000025 coated to the plate and AB1000028 tagged or vice versa. 
 
3.3 Discussion 
3.3.1 Expression of the ProGuanylin and ProUroguanylin 
A method to produce ProGuanylin in solution was previously been described by Lauber et al. 
This method was used to express soluble ProGuanylin in bacteria and purify it from the 
cytoplasm by affinity purification. However, when using the same protocol for 
ProUroguanylin, the protein was mainly expressed in inclusion bodies. This was not an 














different physical and chemical properties which could lead to a different expression 
behaviour. 
In order to obtain soluble ProUroguanylin from E. coli expression, a diverse range of 
expression conditions were thoroughly analysed: different bacteria strains engineered to help 
the expression of proteins in solution, temperature, expression time, and IPTG concentration 
for induction of the protein expression were tested. After optimisation of soluble expression, 
the protein yield was very low. Moreover, the purification was done in 3 steps: 
ProUroguanylin-(His)6Tag-TRX was affinity purified followed by the cleavage of (His)6Tag-TRX 
from the proform and purified again to remove (His)6-thioredoxin tag. Each purification step 
generated protein loss leading to a total loss of 60% at the end of the process. Hence, in total 
only 40% of the material required for the immunisations could be produced as soluble and so 
other approaches needed to be investigated.  
To immunise mice, recombinant proteins are vortexed in Freund’s Complete Adjuvant or 
Incomplete Freund’s Adjuvant which is a denaturant. This step will unfold the proteins. As 
maintaining protein conformation is not a prerequisite for immunisations, it was decided to 
produce the protein from the inclusion bodies, in an aggregated state. For the isolation of 
specific antibodies against ProUroguanylin, ProUroguanylin aggregates were used for 
immunisation and soluble ProUroguanylin was only used for the screening and 
characterisation in order to isolate binders recognising the native ProUroguanylin. 
If time was not a limiting factor, different strategies could have been developed in attempt to 
express higher levels of ProUroguanylin in the soluble fraction. First, redesigning the DNA 
vector to increase the size of the His6-tag to a His10-tag would have helped protein binding to 
the purification column during the affinity purification. Another strategy to achieve such a 
result would have been to place the His-tag at the C- or N-terminus of the protein. The poor 
binding of the protein to the affinity column could also be explained if the protein was 
produced as soluble aggregates (Dümmler, Lawrence and de Marco, 2005). Soluble aggregates 
do not bind properly to an IMAC column, but addition of mild detergents may help to 
dissociate the soluble aggregates and increase the efficiency of the protein binding to the 
column. Finally, the use of different expression hosts might have achieved an improved 
soluble expression profile. 
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In addition, other solubilisation tags could have been used to assist in the proper folding of 
the protein instead of the thioredoxin-tag such as a poly(NANP) tag. Other solubilisation tags 
have a dual role as affinity tags and could have replaced both His-tag and thioredoxin-tag such 
as MBP and GST. To improve the purification step removing the solubilisation and purification 
tags, different cleavage sites could have replaced the PreScission protease cleavage site to use 
different enzyme with higher yield such as enterokinase, Factor Xa, or Thrombin. A final 
strategy would have been to develop a purification method from the inclusion bodies. 
However, for this strategy it would have been necessary to develop assays to control the 
conformation of the protein. 
3.3.2 Results of the hybridoma campaign 
A hybridoma campaign is considered a fast and efficient method to find large numbers of 
antibodies in IgG format usually with nanomolar or subnanomolar affinity to their targets.  The 
goal of this work was to find pairs of antibodies directed specifically to the proforms in order 
to perform assays to detect them in human samples. The hybridoma campaign was successful 
in finding pairs of antibodies against ProGuanylin and ProUroguanylin. Several options can be 
used to quantify ProGuanylin as AB1000030 and AB1000025 managed to bind the target 
which was consecutively recognised by AB1000037, AB1000038, AB1000028 or AB1000031. 
To quantify ProUroguanylin, one pair of antibodies was found to bind in a sandwich format: 
AB1000010 and AB1000011.  
Both assays have a broad range of detection. When comparing the MSD assay to the 
commercially available kit, Biovendor states that their ProGuanylin ELISA to be able to detect 
between 0.31-10ng/ml of protein, whereas this newly-developed MSD assay is able to 
measure levels of ProGuanylin ranging from 0.2-200ng/ml. Biovendor states that their 
ProUroguanylin ELISA kit is able to detect between 0.8-40ng/ml, but the newly developed 
MSD assay is able to measure levels of ProUroguanylin ranging from 0.3-200ng/ml.  
In conclusion, the hybridoma campaign was successful in producing monoclonal antibodies 
against ProUroguanylin and ProGuanylin. Both proforms have now at least one pair of 
antibodies that can be used to measure quantitatively their concentrations in human 
biospecimens. The Biovendor protocol supplied for both assays also recommends diluting the 
plasma or serum samples to be in the calibration range. An advantage of the broad dynamic 
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range of the MSD assay is that no further dilution of serum or plasma samples is required, 





Chapter 4: Generation of monoclonal antibodies against the bioactive 
peptides guanylin and uroguanylin 
 
4.1 Introduction 
4.1.1 Historically known active peptides and antibodies availability  
Human guanylin and uroguanylin are both expressed on chromosome 1 and translated as pre-
prohormones consisting of 115 and 112 amino acids, respectively (Hill et al., 1995; Magert et 
al., 1998). The 21 amino acid signal peptide is cleaved leading to the formation of ProGuanylin, 
a 94 amino acid peptide (Kuhn et al., 1995). Following secretion from the cell, ProGuanylin is 
cleaved further by an unknown proteolytic process resulting in guanylin, a 15-amino acid 
biologically active peptide (de Sauvage et al., 1992; Mark G Currie et al., 1992). Similarly, 
following cleavage of the signal peptide, the uroguanylin pre-proform, is processed to yield an 
86 amino acid peptide, ProUroguanylin (Hamra et al., 1996), which is released from the cell 
and processed further into a 16-amino acid peptide called uroguanylin (Kita et al., 1994; 
Miyazato et al., 1996). A second 24-amino acid peptide version was isolated and characterised 
as another potential peptide derived from the ProUroguanylin sequence; and called GCAP-II 
(Hess et al., 1995). 
Whilst the biological activity of the proforms is debated (Kuhn et al., 1993; Schulz et al., 1999), 
the bioactive guanylin and uroguanylin peptides potently activate the GC-C receptor.  
To date, the most commonly employed methods for measuring and studying these peptides 
include radioimmunoassay (RIA), electrospray mass spectrometry and cGMP assays. No 
monoclonal antibodies are commercially available that bind specifically to the guanylin and 
uroguanylin peptides.  
4.1.2 Generation of antibodies by phage display 
Phage display is a commonly used technique for the isolation and maturation of antibodies to 
a target using M13 bacteriophage. The M13 bacteriophage displays on its surface 5 coat 
proteins that are directly encoded by genes packaged within the bacteriophage. Genes can be 
cloned and enclosed in the bacteriophage resulting in expressed proteins that are displayed 
on the bacteriophage surface (Smith, 1985). In the case of antibody phage display, phage 
libraries were generated in which genes encoding for single chain variable fragment (scFv) 
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were cloned in a phage display vector. ScFvs are fusion proteins encoding the variable regions 
of the heavy (VH) and light (VL) chains of the antibody. Both chains are connected by a flexible 
linker to form the scFv and the structure can be used for antibody phage display. 
Consequently, scFvs fused to the pIII coat protein are expressed on the M13 bacteriophages 
(McCafferty et al., 1990). 
MedImmune has produced libraries containing between 1010-1011 different phages, that were 
engineered to isolate clones against all targets which can be a protein, a peptide or DNA 
(Tristan J. Vaughan et al., 1996; Lloyd et al., 2008). The most common way to select for clones 
of interest is through an in vitro binding incubation in which the phage library binds to a target 
of interest. Unattached phages are washed off before elution of the phage of interest and 
propagating them for further rounds of selection (figure 4.1). After several rounds of selection, 
clones can be screened, and their identity determined by sequencing. Initial characterisation 
of the panel of clones is done by phage ELISA in which phages bind to a target coated on a 
plate. The specific binding is detected by an anti-phage antibody which will give a “yes-no” 
answer. Characterisation of the binding is studied by the production of a soluble scFv, which 
can be used in competition assays. The resulting VH and VL sequences of interest are 






Figure 4.1: Phage Display selection process for the selection of clones against Guanylin or Uroguanylin. M13 
bacteriophage expresses a single scFv fused to the pIII protein -determined by the sequence of the phagemid. 
The phage libraries are selected by binding to the biotinylated targets which are separated using magnetic 
streptavidin beads. Following their elution from the beads, bacteriophage infect TG1 bacterial cells. The 
bacteriophage infected cells are rescued allowing the cells to produce a new pool of phagemids of interest 
that can be used subsequently in further rounds of selections. The positive clones from the screening were 
cherry-picked, characterised in ELISA and competition ELISA, sequenced, and then small-scale IgGs were 
expressed and purified. IgGs were further characterised. Figure adapted from Clackson and Lowman, 2004. 
 
4.1.3 Options to optimise epitope binding 
Several options are available to optimise the affinity of an antibody to its target. Phage display 
is, again, a common tool to improve the affinity of an antibody to its target and can typically 
be increased by up to 1000-fold (Schier, McCall, et al., 1996). Targeting mutations to the 
complementary determining regions (CDRs) is a preferential way to increase the affinity as 
they are responsible for antigen binding. The CDR3 is usually the major determinant of 
antibody-binding specificity, and the varied length and biochemical properties of VH CDR3 is 
the main contributor to the sequence diversity (Zemlin et al., 2003; Barderas et al., 2008). 
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Affinity maturation by targeted mutagenesis on the VH CDR3 and VL CDR3 is a common method 
to mature the affinity of an antibody to its target (Yang et al., 1995). 
Another common method to optimise the binding of an antibody to its target is ribosome 
display.  This technique is based on in vitro translation that prevents the newly synthesised 
protein (scFv) from leaving the ribosome by removal of the stop codon that causes stalling. 
Therefore, the encoding gene sequence (mRNA) and scFv peptide are linked together in a 
ribosomal complex, coupling phenotype and genotype. Those complexes are used in selection 
against an immobilised target and similarly to phage display the unbound scFv-mRNA-
ribosomes complexes are washed off. The mRNA isolated and purified can be used in 
subsequent rounds of selection (figure 4.2) As well as performing rounds of selection, 
mutations can be introduced into the mRNA sequences using low-fidelity DNA polymerase 
and can be performed between rounds of selection, conferring a directed evolution of 
proteins for higher binding affinity. For example, antibodies optimised against insulin showed 
a 40-fold improvement compared to its progenitor by accumulating point mutations during 






Figure 4.2: Ribosome display process for the selection of clones against guanylin or uroguanylin. After 
performing Error Prone mutagenesis on the parental scFv, the mutated DNA was transcribed in vitro. The 
mRNA was translated using a cell-free system allowing the generation of a stabilised mRNA-ribosome 
displaying a scFv by removal of the stop codon causing stalling. Selections were performed on the complex by 
binding to the immobilised target biotinylated-Guanylin or biotinylated-Uroguanylin. After washing away the 
non-binding complexes and disrupting the ribosome complex, the mRNA was reverse transcribed, and the 
signal amplified by PCR. Several rounds of selection were performed with decreasing levels of target antigens. 
Once the round of selections performed, the DNA was cloned back into phage libraries to perform some 
screening. Diagram adapted from Groves and Osbourn, 2005. 
 
4.1.5 Liquid chromatography and mass spectrometry as a new powerful tool in peptidomics 
Liquid chromatography coupled to mass spectrometry (LC-MS) is used in the detection and 
quantification of peptides. It is an analytical technique that uses the physical separation 
capabilities of liquid chromatography (LC) with the mass analysis capabilities of mass 
spectrometry (MS), and can detect the mass-to-charge ratio (m/z) of charged particles or ions 
within a sample.  
Samples are injected into a chromatography column that will separate according to physico-
chemical properties (for example, size, charge, hydrophobicity). The most widely used variant 
is the reverse-phase (RP) mode of the partition chromatography technique, which separates 
analytes according to their hydrophobicity. The more hydrophobic an analyte, the longer it 
will take to elute. Once eluted, the analytes introduced into a MS system are ionized by 
application of high temperature in combination with a voltage resulting in the ions moving 
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from the liquid to gas phase. The gaseous analytes are then applied to an analyser that will 
determine the mass-to-charge value of the analyte (Kebarle, 2000). The mass-to-charge value 
is a unique signature of a peptide/analyte. 
An analyte can be analysed further by Tandem-MS/MS. In this method, the gaseous analyte is 
fragmented by collision with atoms of an inert gas (helium or nitrogen). Fragmented analytes 
will re-enter the MS analyser and the new mass-to-charge ratio re-evaluated. The 
fragmentation occurs in between amino acid residues and the sequence of the peptide can be 
assessed using analysis software (PEAKS). 
In conclusion, mass spectrometry is a powerful tool to assess which peptides are present in a 
sample and can analyse all peptides in the same sample. Recently, LC-MS/MS is becoming a 
prominent method to assess the peptides in a sample as well as to quantify them (Chambers 
et al., 2014; Cox et al., 2016; Kay et al., 2017). 
4.1.4 Aims 
To generate novel monoclonal antibodies for the bioactive versions of the human guanylin 
and uroguanylin peptides by:  
e) Generating hybridoma antibodies by immunisation of mice. 
f) Naïve phage display using biotinylated-Guanylin or biotinylated-Uroguanylin. 
g) Screening the clones of interest in ELISA assays and competition ELISA. 
h) Affinity maturation of the lead clones to improve affinity to their targets by phage or 
ribosome display. 
i) Developing an IP method to pull out the peptides from human samples and measure 




4.2.1 Generation of a monoclonal antibody against guanylin by a hybridoma campaign 
As described in Chapter 3, a hybridoma campaign was performed to generate specific 
antibodies to the historically known active peptides. Mice were immunised with 100µg of KLH-
Guanylin and KLH-Uroguanylin over a 28-day immunisation programme. Serum titres 
(prebleed, day 13 and day 20) were measured by ELISA for binding to biotinylated peptides. 
Low serum titres were obtained for the mice immunised with KLH-Guanylin or KLH-
Uroguanylin (data not shown). This result was not unexpected since KLH is a high molecular 
weight (MW) and immunogenic protein, most of the immune response would be targeted 
against it. Conversely only a small fraction of the immune response would be directed against 
the peptides linked to it because they are composed of very small numbers of amino acids 
(guanylin: 15 amino acids; uroguanylin: 16 amino acids). 
Hybridomas were generated from lymphocytes extracted from all immunised mice as no 
difference could be made between serum titres among each group. IgG-secreting colonies 
were then picked and screened for their specificity to guanylin and uroguanylin. The 
percentages of IgG secreting for the two immunising antigen groups are shown in table 4.1. 
 
Table 4.1: Summary of the hybridoma campaign to guanylin and uroguanylin targets. All IgG-secreting 
hybridomas were picked and IgGs screened in the primary screens. The table contains the final results of 
binders after characterisation. 
 
4.2.2 Screening of hybridoma clones and specificity  
All IgG-secreting hybridoma colonies were tested for binding to the biotinylated targets in a 
HTRF direct binding assay. Among the 1337 IgG supernatants tested, 9 clones bound 
biotinylated-Guanylin, whereas no clones bound biotinylated-Uroguanylin (table 4.1). It was 
possible that due to the small size of guanylin and uroguanylin, biotinylation of the peptides 
may have affected their conformation or sterically hindered binding of antibodies to the 
KLH-Guanylin KLH-Uroguanylin
Hybridoma colonies 2598 3358
IgG secreting colonies 376 961
% of IgG secreting colonies 14.4% 28.6%
HTRF binders to biotinylated antigens 9 0
ELISA binders to KLH peptides 10 26
Binder after primary screen 19 26
% of binders/IgG secreting colonies 2.7% 2.7%
Binders  after further characterisation 1 0
85 
 
peptides, leading to the low or null number of binders observed. An ELISA using the KLH 
conjugated peptides was used as an alternative assay to screen for potential binders. The 
ELISA identified 26 binders to KLH-Uroguanylin and 10 additional binders to KLH-Guanylin. 
The specificity of the 45 antibodies was confirmed using an ELISA assay against each potential 
target and negative controls: biotinylated-Guanylin, biotinylated-ProGuanylin, biotinylated-
ProUroguanylin, biotinylated-Uroguanylin, Guanylin-KLH, Uroguanylin-KLH and KLH only. The 
ELISA was performed at a single sample dilution (figure 4.3). Four out of 9 antibodies for the 
biotinylated-Guanylin showed specificity against its antigens. All binders to KLH peptides were 
cross-reactive to KLH-Guanylin and KLH-Uroguanylin. The antibody AB1000001 (raised against 
KLH-Guanylin) was able to bind the biotinylated-Guanylin, but also able to bind the coated 
biotinylated-ProGuanylin. 





To identify antibodies directed against guanylin and uroguanylin, the ten strongest cross-reactive 
binders to KLH-Guanylin and KLH-Uroguanylin were analysed in a competition ELISA. An increasing 




























































































































































































































































































































































































































































































of coated KLH-Guanylin or KLH-Uroguanylin. None of the antibodies that were isolated from the KLH-
peptide screening bound the free peptides (figure 4.4 B and C). This finding may be explained if these 
clones recognise epitope(s) at the C-termini of the peptides where they bind KLH. This is further 
supported by the observation that the C-termini of the two peptides are almost identical. 
 
Figure 4.4: Characterisation of guanylin peptides antibodies isolated from the hybridoma campaign. A. 
Competition ELISA performed on the strongest binders to biotinylated-Guanylin. Serially diluted 
concentrations of free guanylin were used to compete against a constant concentration of coated 
biotinylated-Guanylin. AB100001 in pink binds Free guanylin. B and C. Competition ELISA performed on the 
strongest binders to peptide-KLH. Serially diluted concentrations of free peptide were used to compete 
against a constant concentration of coated peptide-KLH. None of the antibodies bind free guanylin or free 
uroguanylin. 
 
A similar competition ELISA was performed on the clones binding to biotinylated-Guanylin 
(selected from the HTRF assay). An increasing concentration of free guanylin was used to 
compete against a constant concentration of coated biotinylated-Guanylin. The titratable 
effect of free guanylin was only observed in AB1000001, indicating specific binding. No 
titratable effect was observed for the eight other antibodies. This suggests that biotinylation 
was a critical structural determinant of the epitope recognised by these antibodies (figure 
4.4C).  


































The cross-reactivity of AB1000001 to guanylin and ProGuanylin in the single-point specificity 
was further investigated. An ELISA was performed with fixed amount of biotinylated-
ProGuanylin or biotinylated-Guanylin captured on the plate against a titration of AB1000001 
(figure 4.5A and B). The dose-dependent signals observed for both ProGuanylin and guanylin 
indicated that AB1000001 recognises both antigens. However, when AB1000001 was coated 
to the plate followed by incubation with dilution series of biotinylated-ProGuanylin or 
biotinylated-Guanylin, in solution dose dependent binding was detected only for biotinylated-
Guanylin (figure 4.5C and D). In conclusion, AB1000001 is specific for guanylin when it is in 
solution and not bound to an assay plate. The binding to ProGuanylin when immobilised was 
most likely an in vitro artefact as a result of biotinylated-ProGuanylin presenting non-
conformational epitopes. 
Figure 4.5: Specificity characterisation of AB1000001 for guanylin and ProGuanylin. In A. and B., biotinylated-
Guanylin or biotinylated-ProGuanylin was immobilised to a streptavidin plate and incubated with a dilution 
series of AB1000001, followed by antimouse IgG HRP detection. In C. and D., AB1000001 was immobilised to 
a Maxisorp plate and incubated with a dilution series of biotinylated-Guanylin or biotinylated-ProGuanylin, 
followed by streptavidin-HRP detection. 
 
Despite the high number of clones screened, no specific antibodies against uroguanylin were 
found using the hybridoma technique, and only one antibody AB1000001 was specific to 
guanylin.  
Clones that bound to biotinylated-Guanylin, Guanylin-KLH or Uroguanylin-KLH were identified 
in the primary screen. After further detailed characterisation, the binders to Guanylin-KLH and 
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Uroguanylin-KLH were found to be cross-reactive and did not bind the free peptide. It is highly 
possible that the clones that bound Guanylin-KLH and Uroguanylin-KLH were binding the link 
between the KLH and the peptide. Identity between human peptides and mouse endogenous 
peptides is high: 93% and 81% for guanylin and uroguanylin, respectively. Therefore, the mice 
immune response during the hybridoma campaign would generate antibodies against non-
identical parts of the peptides. The main immune response was directed against the KLH or 
the peptides’ C-terminal epitope linked to KLH. Also, the C-termini of the peptides have a 
strong identity between guanylin and uroguanylin which may account for the cross-reactivity. 
4.2.3 Lead isolation of guanylin and uroguanylin binders by Naïve Phage Display Selection 
Antibodies targeting guanylin or uroguanylin were generated using a naïve phage display 
selection approach. Three naïve bacteriophage libraries were used: Bone Marrow Vaulttrp 
(BMVtrp) library which was isolated from bone marrow, Combined Spleentrp (CStrp) isolated 
from spleen and DP47trp a library based on the VH CDR3 framework of the DP-47 gene 
segment, the most frequently used VH gene segment in the VH gene rearrangements 
(Brezinschek et al., 1997). 
Libraries were selected for 2 rounds, with the first round of selection performed using 100nM 
of biotinylated human guanylin (or uroguanylin) followed by a second round of selection using 
50nM biotinylated human guanylin (or uroguanylin). To remove guanylin/uroguanylin cross-
reactive clones, de-selections were performed using 1μM of the opposite free peptide. Output 
titres were measured at each round of selection and reported in tables 4.2 and 4.3.  
Table 4.2: Round of selection and output of initial lead Isolation of clones against human guanylin by phage 
display selection. Round 1 of selection used 100nM biotinylated human guanylin and half of the libraries were 
de-selected against 1μM free human uroguanylin. Round 2 used 50nM biotinylated human guanylin and all 
libraries were subjected to a de-selection against 1μM free human uroguanylin. 
 
 
Selection performed for Lead Isolation of clones to guanyl in
Round of selection BMVtrp CStrp DP47 BMVtrp CStrp DP47
Round 1: 100nM biotinylated-Guanylin Des elected with free uroguanyl in No deselection
Output ti tre CFU/ml 3700 1900 7600 3500 4000 1500
Round 2: 100nM biotinylated-Guanylin Des elected with free uroguanyl in Deselected with free uroguanyl in
Output ti tre CFU/ml 5.50E+05 2.13E+06 2.08E+03 1.88E+05 8.40E+06 7.80E+04
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Table 4.3: Round of selection and output of initial lead Isolation of clones against human uroguanylin by 
Phage Display selection. Round 1 of selection used 100nM biotinylated human uroguanylin and half of the 
libraries were de-selected against 1μM free human guanylin. Round 2 used 50nM biotinylated human 
uroguanylin and all libraries were subjected to a de-selection against 1μM free human guanylin. 
 
The output titre is a quality control measurement of the selection method and an expected 
output titre would be 103-106 colony forming units (cfu) per ml. Selections were performed at 
a high concentration of biotinylated target, however the first round of selection gave low 
output titres. The similar step without deselection did not particularly increase the output 
titres. The second round of selection was performed with a de-selection step giving expected 
titres but most probably with a low sequence diversity. The diversity per library selection was 
not calculated due to costs. 
4.2.4 Screening of clones from the Lead isolation by phage display 
Eighty-eight scFv binders to guanylin and 176 scFv binders to uroguanylin were isolated and 
crude fractions of scFvs were prepared and analysed in a single-point binding ELISA. Positive 
clones were sequenced and ten unique binders to each target with high sequence diversity 
were expressed as scFvs by the Biologics Expression team at MedImmune. The 10 purified 
scFvs were characterised by ELISA and the scFv concentration giving 80% of the maximal 
absorbance was used to perform a competition ELISA. This assay was performed to assess 
scFvs’ ability to bind the free peptide version (figure 4.4A and 4.5A). A smaller panel of 5 clones 
were consequently selected for IgG conversion and the VH and VL sequence were cloned into 
murine pEU vectors (IgG1 format). Similar binding assays were performed on the panel of 
antibodies (figure 4.4B and 4.5B) and IC50 were calculated for the 5 IgGs. IC50 measurements 
are summarised in table 4.5.  
For the uroguanylin binders, AB1000107 antibody was the strongest uroguanylin binder with 
an IC50 of 850nM. A second antibody AB1000110 displayed a similar affinity but was cross-
reactive to guanylin (data not shown). AB1000107’s affinity to uroguanylin was low and 
required optimisation.  
Selection performed for Lead Isolation of clones to uroguanylin
Round of s election BMVtrp CStrp DP47 BMVtrp CStrp DP47
Round 1: 100nM biotinylated-Uroguanyl in Deselected with free guanylin No deselection
Output ti tre CFU/ml 3100 1100 1500 3100 1100 1500
Round 2: 100nM biotinylated-Uroguanyl in Deselected with free guanylin Deselected with free guanylin
Output ti tre CFU/ml 6.75E+05 4.74E+06 1.84E+05 1.34E+06 1.59E+06 1.82E+05
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For the guanylin binders, antibodies from the phage display’s isolation did not present a lower 
IC50 when compared to the hybridoma antibody AB1000001. The strongest guanylin binders 
from the lead isolation were AB1000092 and AB1000093 with a measured IC50 of 519nM and 
692nM, respectively. AB1000001, AB1000092 and AB1000093 antibodies did not display a 
sufficient affinity for guanylin therefore affinity maturation was required.  
Figure 4.4: Characterisation of the guanylin binders’ scFv and IgGs from the lead isolation by phage display. 
A competition ELISA was performed on the 10 leads expressed as scFv in (A.) and on the 6 leads expressed as 
IgGs in (B.) The clone represented in orange is the IgG obtained from the hybridoma campaign and used 
subsequently for lead optimisation by error-prone mutagenesis. The clone represented in pink was used 
subsequently for lead optimisation by site-directed mutagenesis. 
 
Figure 4.5: Characterisation of the uroguanylin binders’ scFv and IgGs from the lead isolation by phage 
display. A competition ELISA was performed on the 10 leads expressed as scFv in (A.) and on the 6 leads 
expressed as IgGs in (B.) The clone represented in pink was used subsequently for lead optimisation by site-
directed mutagenesis 
 
4.2.5 Affinity maturation by targeted mutation on VH and VL CDR3  
A summary of the lead optimisation of the antibodies against guanylin or uroguanylin was 
performed using different methods which are summarised in two flow charts: figures 4.7 and 
4.9. 
While AB1000001 has a stronger IC50 to guanylin compared to AB1000092 and AB1000093, 
experience at MedImmune showed that antibodies originating from a hybridoma campaign, 





AB1000092 was shorter than the VH CDR3 of AB1000093 which reduced the possibility for 
mutations. AB1000092 was subsequently discarded and affinity maturation by targeted 
mutation on the VH and VL CDR3 was performed on AB1000093 for guanylin and AB1000107 
for uroguanylin. 
For maturation, two overlapping libraries targeting the VH CDR3, and two overlapping libraries 
targeting the VL CDR3 were generated for each antibody, culminating in a total of 8 scFv phage 
libraries. Libraries were produced by Kunkel reaction, replacing 6 consecutive codons with 
NNS codons (where N=A/C/G/T and S=C/G) in the CDRs. Four rounds of selection were 
proceeded on all libraries using more stringent conditions than during the lead isolation. While 
the first round of selection was performed using a concentration of 100nM of biotinylated-
peptide, the last round of selection used a concentration of 400pM of biotinylated-peptide 
(figure 4.6).  
 
Figure 4.6: Flow chart summarising the lead optimisation by phage display selection after site-directed 
mutagenesis. Two site-directed mutagenesis were performed on each VH and VL to cover the CDR3 sequence. 
The 8 libraries were selected by phage display over 4 rounds of selection using 100nM, 20nM, 2nM and 400pM 
of biotinylated-target antigen and de-selected against 1μM free human guanylin or uroguanylin. The round 4 
was screened in Phage ELISA and positive clones were sequenced and further characterised.  
 
Output titres for the maturation selection ranged from 2.2 x105 to 8.7 x 107 and sequencing 





Table 4.4: Output titres and sequence diversity of selections from affinity maturation of AB1000093 and 
AB1000107. Rounds 1, 2, 3 and 4 of selection used 100nM, 20nM, 2nM and 400pM of biotinylated human 
guanylin or uroguanylin respectively. The % sequence diversity across each library was calculated from the 
number of unique sequences within 44 clones.  
 
All single picked clones were prepared as crude fractions of scFvs and analysed in a single-
point binding ELISA. The strongest binders were expressed as scFvs by the biologics expression 
team at MedImmune and those 11 purified scFvs were characterised by competition ELISA to 
assess their ability to bind the free peptide version (figure 4.8A and 4.10A).  
For the uroguanylin binders (figure 4.8A), the clones did not show a major improvement with 
only a two-fold improvement in IC50 compared to the parent clones AB1000107. It was decided 
to perform a maturation of the antibodies differently using an error prone mutagenesis on the 
5 clones which presented a slight improvement in IC50. AB1000126, AB1000127, AB1000128, 
AB1000131 and AB1000133) scFvs were pooled for a next step of optimisation. 
For the guanylin binders (figure 4.10A), all the clones presented an improvement compared 
to the parent clone AB1000093. While the clones coming from the VH CDR3 site-directed 
mutagenesis (AB1000136-AB1000145) had a similar improvement in affinity, the clone coming 
from the VL CDR3 site-directed mutagenesis AB1000146 had the strongest affinity 
improvement with an IC50 of 2.1nM (300-fold improvement). Five of the 10 clones that showed 
an improvement from the VH CDR3 site-directed mutagenesis (AB1000137, AB1000139, 
AB1000142, AB1000144 and AB1000145) were selected to be expressed as IgG with either the 
light chain from the progenitor clone (AB1000093) or the light chain from the clone 
AB1000146. AB1000146 light chain was also co-expressed with the parental heavy chain 
AB1000093. Due to rearranging heavy and light chains, the IgGs had to be nicknamed 
differently: Flo08-Flo18. A summary of the antibody panel is shown in table 4.5. Antibodies 
were compared in a final competition assay to assess their ability to bind the free peptide and 
Output titres (cfu/ml) Sequence diversity
Library Antigen R1 R2 R3 R4 R2 R4
93H3.1 Guanylin 2.6E+07 4.4E+07 3.4E+07 3.2E+07 100% 100%
93H3.2 Guanylin 1.4E+06 2.7E+06 1.5E+06 4.8E+05 100% 68%
93L3.1 Guanylin 2.6E+05 1.2E+07 1.0E+07 4.7E+06 100% 64%
93L3.2 Guanylin 3.3E+05 1.1E+07 6.4E+06 3.3E+06 93% 78%
107H3.1 Uroguanylin 1.3E+07 5.7E+07 4.0E+07 1.8E+07 93% 84%
107H3.2 Uroguanylin 2.2E+05 6.7E+07 4.4E+07 4.0E+06 93% 41%
107L3.1 Uroguanylin 2.2E+07 5.7E+07 4.7E+07 1.2E+07 93% 63%
107L3.2 Uroguanylin 8.7E+07 6.4E+07 3.6E+07 5.6E+06 98% 34%
94 
 
compare their IC50 (figure 4.10B). The antibody with the largest improvement was Flo13 (IC50 







Figure 4.8: Characterisation of the uroguanylin scFv and IgG binders from the lead optimisation. In (A.) a 
competition ELISA was performed on the 11 scFv leads from the site-directed mutagenesis. (B.) presents the 
panel of scFvs generated by error prone mutagenesis on the pool of scFvs with higher IC50 compared to the 
parent AB1000107 (AB1000126, AB1000127, AB1000128, AB1000131 and AB1000133) in a competition ELISA. 
In (C.) the 4 leads expressed as IgGs were compared in a final competition ELISA including the parent antibody 
AB1000107. The clone represented in orange is the parental clone used for lead optimisation. The clones 
represented in pink are the leads from each step of the optimisation. 
 
Lead Isolation by Phage Display
AB1000107 selected for Lead Optimisation
Targeted mutation of the CDR3 VH and VL of 
AB1000107 by Kunkel mutagenesis
Error Prone mutagenesis on pooled 
AB1000126, AB1000127, AB1000128, 
AB1000131 and AB1000133
Phage display selections on resultant phages
from the AB1000107 Kunkel mutagenesis 
Identification of AB1000126, AB1000127, 
AB1000128, AB1000131 and AB1000133 with 
increased IC50
Ribosome Display selection on Error Prone 
mutagenesis product
Identification of AB1000173, AB1000176, 
AB1000185, AB1000187 with increased IC50
Characterisation of the final panel of 
antibodies by Competition ELISA and Biacore
AB1000173 identified as the strongest binder
A. B.
C.
Figure 4.7: Flow chart summarising the generation 
of antibodies against uroguanylin.  
Lead isolation was performed by phage display. 
Site-directed mutagenesis of the VH and VL CDR3 
were performed on one variant followed by further 
rounds of phage display selection. The resultant 
phages with increased IC50 were pooled and error 
prone mutagenesis was performed on them. 
Ribosome display selection were performed, and 
the final characterisation identified AB1000173 as 





Figure 4.10: Characterisation of the guanylin scFv and IgG binders from the lead optimisation. In (A.) a 
competition ELISA was performed on the 11 scFv leads from the site-directed mutagenesis. In (B.) the 
antibodies generated from the VH and VL recombination from these scFvs where tested in a competition ELISA. 
In (C.) a competition ELISA was performed on 22 scFvs from the lead optimisation by error-prone mutagenesis. 
In (D.) the 3 leads expressed as IgGs were compared in a final competition ELISA including the parent antibody 
AB1000001 and the best antibodies from the lead optimisation by site directed mutagenesis Flo13.  
The clones represented in orange are the parental clones used for lead optimisation. The clones represented 
in pink are the leads from the optimisation and were used for further characterisation. 
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campaign
AB1000001 selected for Lead 
Optimisation
Error Prone mutagenesis on 
AB1000001
Ribosome Display selection on 
Error Prone mutagenesis 
product
Identification of AB1000152, 
AB1000158 and AB1000161
Characterisation of the final panel of antibodies by Competition 
ELISA and Biacore
Flo13 identified as the strongest binder
Lead Isolation by Phage Display
AB1000093 selected for Lead 
Optimisation 
Targeted mutation of the CDR3 
VH and VL of AB1000093 by 
Kunkel mutagenesis
Phage display selections on 
resultant phages from the 
AB1000093 Kunkel 
mutagenesis 
Identification of AB1000137, 
AB1000139, AB1000142, 
AB1000144 and AB1000147 
VH and AB1000146 VL with 
increased IC50
Production of antibodies with 
combined VH and VL from the 
targeted mutagenesis
Generation of antibodies Flo08 
to Flo18 with increased IC50
A. B.
C. D.

















Figure 4.9: Flow chart summarising the 
generation of antibodies against guanylin.  
Lead Isolation was performed both by 
hybridoma and a phage display campaign. 
Error prone mutagenesis was performed on 
AB1000001 identified from the hybridoma 
campaign followed by ribosome display 
selection. Site-directed mutagenesis of the VH 
and VL CDR3 was performed on the variant 
identified by phage display. VH and VL with 
higher IC50 were recombined to generate a new 
panel of antibodies. Final characterisation of 
the panel of antibodies identified Flo13 as the 




4.2.6 Affinity maturation by error prone mutagenesis on AB1000001 and affinity matured 
products of AB1000107 
The aim of the lead optimisation steps was to obtain antibodies with low nanomolar to 
subnanomolar affinity for guanylin or uroguanylin. The antibodies isolated did not present a 
high enough affinity, especially for the uroguanylin binders.  
An alternative approach had to be considered to improve the binding to the targets. When 
the site directed mutagenesis of the VL and VH CDR3 is unsuccessful to reach an affinity target, 
another commonly used method is error prone mutagenesis on the scFv sequence. In error 
prone ribosome display libraries, prior to subsequent rounds of selection, mutations are 
introduced into the mRNA using low-fidelity DNA polymerase for amplification, resulting in 
error-prone PCR. An advantage of ribosome display compared to other selections method is 
that more mutations can be introduced after each round of selection allowing directed 
evolution.  
Uroguanylin AB1000126, AB1000127, AB1000128, AB1000131 and AB1000133 scFvs 
sequences were pooled together. Those scFvs originated from the lead optimisation by phage 
display of the parent clone AB1000107 and were identified as 107pool. Three rounds of error 
prone mutagenesis were performed on the 107pool as well as the AB1000001 sequence (Cf. 
4.2.1 and 4.2.2). The mutated DNA was transcribed in vitro, and the mRNA was translated 
using a cell-free system allowing the generation of a stabilised mRNA-ribosome complex 
displaying a scFv. Three rounds of selections on the mutated 107pool or mutated AB1000001 
were performed on the complex by binding to the immobilised target biotinylated-
Uroguanylin or biotinylated-Guanylin respectively at 10nM, 2nM and 400pM. The mRNA was 
reverse transcribed, and the signal was amplified by PCR. The final amplification was enzyme-
restricted and ligated into pCantab6 vectors.  
Once transformed into E. coli, 176 clones were picked after the third round of selection and 
crude fractions of scFvs were prepared and analysed in a single-point binding ELISA. The 24 
strongest binders with specific sequences that produced a signal in the ELISA were selected 
and expressed as scFvs by the biologics expression team at MedImmune. Purified scFvs were 
characterised by competition ELISA to assess their ability to bind the free peptide version and 
measure their IC50. 
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For the uroguanylin binders, all clones showed an improvement in IC50 compared to the 
progenitor AB1000107 in the scFv competition ELISA (figures 4.8B). Four binders (AB1000173, 
AB1000176, AB1000185 and AB1000187) presenting the strongest affinity were reformatted 
into IgG and tested once again in a competition ELISA (figure 4.8C). A clone presenting 2 
changes in its VH CDR2, AB1000173, displayed the best improvement with an IC50 of 28nM.  
For the guanylin binders, three clones AB1000152, AB1000158 and AB1000161 were 
reformatted into IgG and tested in a competition ELISA (figures 4.10C and 4.10D). They 
showed a 10-fold improvement in IC50 than its progenitor AB1000001 (6.5nM, 6.6nM and 
8.7nM). However, those clones did not show a stronger affinity than the IgG Flo13, which 
came from the lead isolation/optimisation by phage display and presented an IC50 of 3.2nM. 
(Cf. table 4.5) 
4.2.7 Determination of the binding specificity of the panel of antibodies 
A panel of 4 antibodies were selected for a final affinity measurement using the Biacore T100 
instrument. Two of the antibodies binding guanylin (Flo13 and AB1000152) and two of the 
antibodies binding uroguanylin (AB1000173 and AB1000185) were covalently bound to a CM3 
chip by amine coupling. Different concentrations of the guanylin and uroguanylin allowed the 
measurement of the binding constants using a 1:1 binding model. The sensorgrams presenting 
the binding of Flo13 and AB1000152 to guanylin and AB1000173 and AB1000185 to 





Figure 4.11: Determination of the antibodies’ affinity to their targets using Biacore.  
Kinetic binding experiment with antibodies (A.) AB1000152 (B.) Flo13 (C.) AB1000173 (D.) AB1000185 on the 
Biacore T100 instrument (Response Units (RU) as function of time). The antibodies were immobilised at 
10μg/mL on the CM3 chip. The flow rate was 50μL/min, the contact time was 180 seconds while the 
dissociation time was 400 seconds. The data was analysed using the Biacore T100 evaluation software using a 
1:1 binding model and the fit is represented by the black lines. 
In (A.) and (B.) guanylin was used at a concentration ranging between 93.8nM and 1500nM. In (C.) uroguanylin 
was used at a concentration ranging between 93.8nM and 1500nM. In (D.) uroguanylin was used at a 
concentration ranging between 187.5nM and 1500nM. 
 
All tested antibodies presented a nanomolar affinity for either guanylin or uroguanylin. The 
Biacore T100 evaluation software managed to fit the curves properly using a 1:1 binding model 
for all antibodies to their target; but, the response unit was low and the signal noisy. The small 
size of guanylin and uroguanylin, 15 and 16 amino acids respectively, are responsible for the 
sensorgrams’ quality and are not uncommon in the literature for such small peptides (Zhang 
and Oglesbee, 2003). 
The first aim of this chapter was to find pairs of antibodies that would bind guanylin or 
uroguanylin in an immunoassay. Concerned by the size of the peptides and potential steric 
hindrance from each of the antibody, the plan was to use the antibodies for either 
immunoprecipitation or use of magnetic beads coated with the antibodies to isolate the 
peptides. Once isolated from serum, plasma or supernatants, levels of guanylin peptides could 
be measured by mass spectrometry. Commercially available guanylin or uroguanylin could be 
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4.2.7 New knowledge about the sequence of the murine active Guanylin peptide by mass 
spectrometry 
Concomitantly towards the end of the antibodies’ lead optimisation, the Gribble/Reimann 
group developed new protocols and techniques to study peptide levels and secretions from 
different biological sources. Kay et al. looked at peptides from human and mouse colonic 
tissues’ homogenates as well as colonic primary intestinal culture supernatants to detect 
insulin-like peptide 5 peptides and measured an increase in secretion in response to L-cell 
stimuli (Kay et al., 2017). A similar method and analysis was applied on mouse and human 
homogenates in the first instance.  
Initial analysis was performed on homogenates from mouse tissues (duodenum, jejunum, 
ileum, colon and rectum). GUC2A (guanylin) peptides were successfully detected after 
reduction/alkylation and Nanoflow-LC-MS analysis (figure 4.12). However, the method was 
not sensitive enough to detect GUC2A peptides in human homogenates. GUC2B (uroguanylin) 
peptides were not detected in either murine or human tissue homogenates. 
The database search matched peptides throughout the entire GUC2A prohormone sequence 
except for the signal peptide (amino acid residues 1-21). In figure 4.12, blue box represents a 
sequence identified by LC-MS/MS that matches the murine GUC2A sequence.  The peptides 
peak area (and therefore the concentration of peptide) is represented by the blue gradient. 
The historically known sequence from Swissprot database is highlighted by the black box 
below the protein sequence. An interesting observation originating from this peptide search 
was that the Swissprot entry for the historically known activating guanylin peptide 102-116 
was present at extremely low levels in homogenates from jejunum and colon only.  
This experiment also highlighted the presence of other GUC2A peptides at higher levels 
compared to the historically known guanylin peptide 102-116. A version of the known guanylin 
peptide supplemented by a glutamic acid (D) on the N-terminal (figure 4.13A) was found in 
murine homogenates from duodenum, jejunum, ileum and colon tissues in detectable levels 
(figure 4.12). Two other peptides distinguished themselves by the levels found across the 
tissues (based on peptide peak area): the peptide 22-49 and the peptide 60-116 (figure 4.13B 
and C). While the peptide 22-49 does not present the C-terminal sequence proposed to 




Figure 4.12: GUC2A (guanylin) peptides detected in murine homogenates. Murine homogenates of 
duodenum (A.), jejunum (B.), ileum (C.), colon (D.) and rectum (E.) were analysed by LC-MS/MS. Each blue 
box represents a sequence identified by LC-MS/MS that matches the murine GUC2A sequence.  The peptide 
peak area (log10 scale) is represented by the blue gradient. The historically known sequence from Swissprot 
database is highlighted by the black box below the protein sequence. 
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Figure 4.13: Product ion spectrum of detected peptides of GUC2A from murine ileal secretion. (A.) Product 
ion spectrum of the [M+2H]2+ ion of the GUC2A peptide 101-116 (m/z=931.845) found in culture media of 
murine ileal organoids. (B.) Product ion spectrum of the [M+6H]6+ ion of the peptide 22-49 (m/z=528.297) 
found in secretion of murine ileal organoids. (C.) Product ion spectrum of the [M+5H]5+ ion of the peptide 60-
116 (m/z=1284.821) found in lysis of murine ileal organoids. 
 
To confirm the existence of different GUC2A peptides in mouse, investigations using the LC-
MS/MS were done on different sample types: organoid secretion (culture supernatants), 
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intestinal content and plasma. Consistent with what was previously observed in tissue 
homogenates, the peptides 22-49 and 60-116 were highly represented (based on peptide 
peak area) in the supernatants and lysates of the ileal organoid’ secretion assay, as well as in 
the luminal content (figure 4.14). Another interesting highly expressed peptide was the 
peptide 60-90. In mouse plasma, only 3 peptides from GUC2A were identified:  22-39, 22-49 
and 60-116.  The historically known peptide 102-116 was not detected.  
The combination of multiple sources of tissues and fluids, studied here by LC-MS/MS differed 
from those in the literature (Currie et al., 1992) and the Swissprot database. Previously proline 
as the first amino acid was assessed by automated Edman degradation sequence analysis and 
electrospray mass spectrometry from rat jejunum. The peptides were purified by a 10 minutes 
boiling step in 1M acetic acid. Such step could have degraded the natural hormone and would 
not reflect its true sequence. The peptide extraction method used in this chapter was based 
on 80% ACN in water (v/v) which denatures the protein instead of degrading them. The mass 
spectrometry data in conjunction with the peptide extraction method argues against the 
established guanylin sequence. A strong candidate for a potential active peptide would be the 
peptide 60-116. This peptide has been the most abundant and presenting the amino acid 




Figure 4.14: GUC2A (guanylin) peptides detected in murine ileal organoid secretion intestinal content and 
serum. Secretion of murine ileal organoids and peptides were analysed in supernatant (A.) and cell lysis (B.). 
Murine luminal content for the different part of the gut was analysed in (C.) as well as murine plasma samples 
in (D.) Each blue box represents a sequence identified by LC-MS/MS that matches the murine GUC2A 
sequence. The peptide peak area (log10 scale) is represented by the blue gradient. The historically known 
sequence from Swissprot database is highlighted by the black box below the protein sequence. 
 
4.2.8 Mass spectrometry analysis on human samples to uncover the active guanylin sequence 
Due to doubts regarding the existence of the previously described murine guanylin active 
peptide sequence and establishing the true sequence of the bioactive human guanylin peptide 
similar studies were undertaken on human samples. Human colonic secretion performed in 
Ussing chambers as well as human plasma were looked at in a similar method as in 4.2.7.  
The historically known peptide described in the literature was not found in any human 
samples analysed. The longer peptide 100-115 containing an additional Aspartic acid on the 
N-terminal sequence was found in the secretion of human colonic tissue using the Ussing 
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chamber (assay performed by Juraj Rievaj, University of Cambridge) (figures 4.15A and B). 
Peptide 22-49 was the second and only peptide which was detected in the secretion samples 
(figures 4.15C and D). Those 2 peptides were also detected in human intestinal homogenates. 
These findings are summarised graphically as the levels found per tissue (based on peptide 
peak area) in chapter 7 (Cf. figure 7.10).  
Figure 4.15: GUC2A (guanylin) peptides detected in secretion of human colonic tissue in Ussing chamber. 
(A.) Mass spectrum displaying the 13C isotope pattern of the GUC2A peptide 101-116 from the peak at 53.4 
minutes and its product ion spectrum of the [M+2H]2+ ion (m/z=903.333) in (B.) found in secretion of human 
colonic tissue in Ussing chamber in the apical compartment.  (C.) is the Mass spectrum displaying the 13C 
isotope pattern of the GUC2A peptide 22-49 from the peak at 54.04 minutes and its product ion spectrum of 
the [M+5H]5+ ion (m/z=644.541) in (D.) found in secretion of human colonic tissue in Ussing chamber in the 
apical compartment.   
 
While one of the most common forms of the peptides detected in mouse was longer (amino 
acid residues 60 to 116), a similar peptide was not detected in human samples. The presence 
of the peptide 22-49 in human samples was the starting point of a hypothesis assigning a 
potential cleavage site after the arginine residue on position 49. The theorised peptide -once 
cleaved- would result in a 66 amino acid residues peptide 50-115; peptide which would be too 
long to be detected using the mass spectrometry method.  
When all previous mass spectrometry experiments performed on human serum or plasma 
from healthy volunteers failed to detect the guanylin peptides, an experiment performed by 
Dr Richard Kay (University of Cambridge) managed to detect GUC2A peptides in plasma 
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samples from healthy volunteers undergoing a long fasting (Cf. chapter 5). A proteomic 
approach was used to analyse the samples instead of a peptidomic approach -as previously 
used. In a proteomic approach, samples are cleaved with an enzyme treatment after the 
reduction-alkylation treatment. In the case of this study trypsin was used, which cuts after the 
arginine and lysine residues. An interesting outcome was the presence of 2 new peptides that 
were not previously detected: peptides 55-83, 84-93 (figure 4.16). This result was consistent 
with the previously described hypothesis, a longer hidden version of the peptide which was 
not detectable with a peptidomic approach was unveiled by proteomics. The N-terminal part 
of the hypothesised longer peptide that was not detected in this experiment was from the 
residues 50-55 which would have cleaved at the lysine residue 52, making it too small to be 
detected.  
Figure 4.16: Proteomic analysis of human plasma where GUC2A (Guanylin) peptides were analysed after 
reduction and alkylation followed by trypsin treatment. (A.) Localisation of the peptides 55-83 and 84-93 on 
GUC2A’s human amino acid sequence, identified by LC-MS/MS after trypsin treatment (B.) Product ion 
spectrum of the [M+3H]3+ ion of the GUC2A peptide 55-83 (m/z=1092.903) found in human serum. (C.) Product 
ion spectrum of the [M+2H]2+ ion of the peptide 84-93 (m/z=599.316) found in human serum. 
 
This result supported previous suspicions regarding the existence of a potential longer version 
peptide 50-115 in human plasma. If a proteomic approach allows to form a hypothesis about 
a longer form present in the plasma, a caveat of this experiment is that the use of trypsin could 
cleave the ProGuanylin form and provide an identical result. Therefore, the use of trypsin 
cleavage does not corroborate completely the theory of a longer peptide. In other words, a 
potential other explanation of the presence of peptides 55-83 and 84-93 in the proteomic 
approach would be that ProGuanylin (amino acid residues 22 to 115) could produce identical 
peptides by trypsin treatment. 
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To corroborate the theory, a strategy was employed to uncover the potential longer peptide 
by using another cleavage enzyme, cutting at different sites. Chymotrypsin, an enzyme cutting 
on the C-terminal of phenylalanine, tyrosine and tryptophan in position P1, was employed on 
the same plasma sample. Positions of cleavage sites were after residues 29, 31, 56 and 109 in 
the GUC2A sequence (without considering the signal peptide). This approach was unsuccessful 
as no GUC2A peptides were detected by mass spectrometry on the chymotrypsin-cleaved 
plasma sample. Using an enzyme to cleave peptides for a proteomic approach can make 
analysis complicated as it significantly increases the number of peptides to read by the mass 
spectrometry.  The absence of peptides in the mass spectrometry read out, does not mean 
they are not present in the sample but only that they have not been detected.  
In conclusion, the historically known peptides were not present in sufficient quantities to 
attest of their endogenous presence in mouse and human. A 57 amino acid long peptide was 
identified in mouse. This peptide is the most represented peptide in homogenates, intestinal 
content, secretion and serum samples. It encompasses the conserved C-terminal motif which 
is required for GC-C receptor activation (Schulz et al., 1999). Other smaller peptides were 
present and could be the result of further processing of this 57-amino acid peptide.  
Human levels of GUC2A and GUC2B peptides were constantly lower compared to mouse. So 
far, the longer peptide was not detected in human samples, even though some preliminary 





4.3.1 Antibody isolation by hybridoma campaign against small peptides 
A hybridoma campaign is a fast and efficient method to find large numbers of antibodies in 
IgG format with nanomolar or subnanomolar affinity to their targets. MedImmune has 
successfully produced antibodies specifically directed against peptides of 30 amino acids using 
the hybridoma platform, so it was with confidence that a hybridoma campaign was performed 
to generate antibodies against historically known guanylin and uroguanylin which are 15 and 
16 amino acids long, respectively. Despite the high number of clones screened, no specific 
antibodies against uroguanylin were found using the hybridoma technique, and only one 
antibody AB100001 was specific to guanylin. 
Clones that bound to biotinylated-Guanylin, Guanylin-KLH or Uroguanylin-KLH were identified 
in the primary screen. After more characterisation, the binders to Guanylin-KLH and 
Uroguanylin-KLH were found to be cross-reactive and did not bind the free peptide. It is highly 
possible that the clones that bound KLH-Guanylin and KLH-Uroguanylin were binding the link 
between the KLH and the peptide. Identity between human peptides and mouse historically 
known peptides is significant: 93% and 81% for guanylin and uroguanylin, respectively. 
Therefore, the murine immune response during the hybridoma campaign would generate 
antibodies against non-identical parts of the peptide and the main immune response was 
directed against the KLH.  
4.3.2 Lead isolation using display methods compared to a hybridoma approach 
Currently, antibody phage display is widely used for generation of therapeutic biologicals. For 
example, in 2002, adalimumab (Humira) was the first phage display derived antibody to be 
granted a FDA approval and was produced by CAT/Abbott laboratories (Frenzel, Schirrmann 
and Hust, 2016). Using a phage display platform has various advantages compared to a 
hybridoma platform when developing therapeutic antibodies. A first benefit compared to the 
hybridoma is the in vitro approach that can by-pass the use of animals and allow the 
development of antibodies on more complicated targets such as toxin (Garet et al., 2010). 
Another advantage of working with such a platform is the valuable selection strategies that 
can be employed on the rounds of selections. Rounds of selection can be performed using 
ortholog targets allowing scientists to look for cross reactive antibodies between species, a 
strategy which is unachievable with a hybridoma approach. For instance, a cross reactive 
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antibody was developed against a GLP1-receptor by a member of the Gribble/Reimann lab 
(Biggs et al., 2018).  
In this work, monoclonal antibodies were generated against the historically known active 
peptide guanylin and uroguanylin using naïve phage libraries. The selection process led to the 
production of large panels of potential clones, and high throughput screening techniques were 
used to screen them. Phage ELISA and sequence assessment were used for screening the 
clones. Although the time-frame to isolate guanylin and uroguanylin binders by phage display 
was much shorter than the isolation of antibodies by a hybridoma approach, the clones proved 
to have low affinity to their targets (690nM and 860nM for guanylin and uroguanylin 
respectively). Albeit low affinity to their targets, competitive ELISA demonstrated specificity 
of the antibodies to biotinylated peptides as well as the free active peptides. 
4.3.3 Affinity maturation approaches using display methods 
The low affinity of the generated antibodies to their targets were not unexpected and 
maturation was necessary to obtain the desired efficiency. Affinity maturation by display 
methods can prove to be efficient with improvement to femtomolar antigen-binding affinity 
(Boder, Midelfort and Wittrup, 2000). 
To achieve a sufficient affinity improvement, AB1000093 and AB1000107 mutant libraries 
were generated by targeting the VH and VL CDR3 by Kunkel mutagenesis. AB1000001 isolated 
from the hybridoma approach had a stronger affinity to guanylin compared to the phage 
display isolated AB1000093 but rounds of in vivo selection on the CDR3 do allow a small 
window of improvement. The new mutated libraries were processed in more stringent rounds 
of selection by decreasing the concentration of antigen: up to 400pM of antigen. A 200-fold 
improvement was reached for the guanylin antibody Flo13 when compared to the progenitor 
antibody AB1000093 and the affinity reached an IC50 value of 3.2nM. The maturation of the 
AB1000107 antibody was not as effective with only an 8-fold improvement, reaching an IC50 
of 105nM. 
Concomitantly to the affinity maturation by phage display, the antibody AB1000001 (and later 
the affinity matured AB1000107 clone) was matured by error prone mutagenesis and 
ribosome display selections. Ribosome display is used on a regular basis to mature lead 
antibodies derived from phage display or from immunised animals. This technology can evolve 
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the antibody libraries by introducing random mutations in between the selection cycles and 
therefore perform directed evolution (Groves and Osbourn, 2005). After 3 rounds of stringent 
selection on the mutated AB1000001 library, a new lead antibody was found for guanylin with 
a 12-fold improvement in IC50.  
When error prone mutagenesis and ribosome display selection were performed on the pool 
of matured clones from the phage display maturation of AB1000107, a new antibody with VH 
CDR2 modifications was found for uroguanylin with a 4-fold improvement succeeding in an 
IC50 of 28.4nM (30-fold improvement from progenitor AB1000107’s IC50). 
Plenty of different approaches using both phage display and ribosome display techniques 
could be used to improve further the affinity of the antibodies to the historically known active 
peptides. A systematic but laborious approach, sometimes employed in industry, would be to 
perform targeted mutagenesis on all CDRs and look at combination of VH and VL CDRs. 
Combinations of the highest affinity mutant heavy chains with the highest affinity mutant light 
chains provide the potential to generate new antibodies with additive affinities. A similar 
approach called CDR walking mutagenesis was proven successful and is done by maturating 
the antibody’s CDR consecutively (Yang et al., 1995).  
A relatively quicker method would be to perform more rounds of error prone mutagenesis 
followed by stringent ribosome display selection. The sequencing of those clones could show 
patterns of mutations in specific CDRs suggesting where to perform targeted CDR 
mutagenesis. It is for instance a method that could have been employed on the uroguanylin 
antibody: a 4-fold improvement obtained by 2 modifications in the VH CDR2 is a strong 
incentive suggesting that the CDR2 might be strongly implicated in the binding to Uroguanylin.  
Another approach to perform affinity maturation is chain shuffling when either the VH or the 
VL gene is replaced by random combinatorial immunoglobulin libraries (Kang, Jones and 
Burton, 1991).  
4.3.4 Conclusion on the generation of antibodies against guanylin peptides 
In this chapter, monoclonal antibodies were generated against the peptides described in the 
literature as the bioactive forms. Several techniques were used to isolate antibodies including 
a hybridoma campaign and phage display selection on naïve libraries and antibody affinities 
were improved through several rounds of maturation, using display methods such as targeted 
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mutation on VH and VL followed by phage display and error prone mutagenesis followed by 
ribosome display. Affinities were improved to reach a KD of 3.2nM and 28.4nM for antibodies 
against guanylin and uroguanylin. The affinity of the antibodies against uroguanylin is not 
considered as high enough and further maturation would need to be performed on this 
antibody to increase it. Other methods are available to perform affinity maturation of an 
antibody to its target. Yeast display is commonly used for affinity maturation which has 
generated antibodies with femtomolar affinity (Boder, Midelfort and Wittrup, 2000). This 
method can overcome some difficulties that are encountered when using the phage display 
approach. One of the limitations of the phage display method is its potential bias due to host 
infectivity by the phage as well as its toxicity on the host (Riechmann and Weill, 1993; Schier, 
Bye, et al., 1996) and its potential library bias due to expression of the library in a prokaryotic 
host. E. coli that can present difficulties to express several disulphide-bonded eukaryotic 
proteins by lack of chaperones (Boder and Wittrup, 1997; T J Vaughan et al., 1996). An 
alternative approach to the maturation of protein is the use of computational in silico 
modelling to support the affinity maturation process (Jorgensen, 2004; Clark et al., 2006; 
Thakkar et al., 2014). The maturation of an antibody is a time-consuming task and countless 
techniques have been developed to optimise the affinity to a target, however one of the main 
constraints in industry and academia is time. 
Furthermore, the goal behind this work was to establish an immunoassay involving 2 
antibodies able to bind guanylin or uroguanylin in a sandwich type of assay. So far, I managed 
to only produce a range of antibodies that were not able to bind different epitope of the 
peptides. This is probably due to the small size of the peptides (15 and 16 amino acids 
respectively), preventing the development of an immunoassay with 2 antibodies. A potential 
assay that could measure the levels of guanylin and uroguanylin would be a competitive ELISA. 
Biotinylated targets could be coated on a streptavidin plate and would compete for the 
antibody against guanylin peptides present in unknown or standard samples. A limitation of 
this type of competitive assay is supposed to be 4/5 times less sensitive. 
Concomitantly to the affinity maturation, the Gribble/Reimann lab developed a new 
peptidomic approach to look at a variety of samples allowing to describe exactly the different 
guanylin peptides present in each sample. The historically described guanylin active peptide 
was not found in several mouse and human samples (such as tissue homogenates, plasma, 
113 
 
intestinal content, and organoids secretion and cell lysate), but longer version were detected. 
The antibodies being able to target the C-terminus part of the guanylin amino acid sequence 
would potentially bind the endogenous forms. An experiment involving both an 
immunoprecipitation with the antibodies followed by LC-MS/MS would be a perfect way to 
investigate the prevalent form of peptides that bind to the antibodies and also the sequence 
of the endogenous peptides. Unfortunately, this was not pursued further. This method could 
be used as an assay to measure the different forms of guanylin peptides binding to the 
antibody.  
4.3.5 Redefining the guanylin active peptides 
This chapter has mainly focused on designing antibodies on what was thought to be the active 
guanylin peptides: guanylin (101-115) and uroguanylin (103-111). Since the discovery of 
guanylin in 1992 in rat and human by Currie and de Sauvage respectively, techniques used to 
assess the amino acid sequence have improved tremendously. One of them is LC-MS/MS mass 
spectrometry. New data using this highly sensitive method brought light to a different 
processing of the guanylin active peptide described in the literature with a different cleavage 
site on the N-terminal side of it.  
Currie was the first to describe the purification and characterisation of a 15 amino acids 
guanylin from rat jejunum (M G Currie et al., 1992). The purification was achieved on frozen 
jejunum tissue, and were thawed, minced and boiled for 10 minutes in 1M acetic acid solution. 
The peptide sequence was assessed by automated Edman degradation sequence analysis and 
electrospray mass spectrometry. The resulting sequence was a 15-amino acid peptide 
characterised by an N-terminal proline. While this sequence was rarely questioned, the 
authors acknowledged that the guanylin peptide could be the result of a truncated form that 
had bioactivity but could be derived from a larger precursor. A hypothesis on the purification 
of a 15-amino acid peptide would be that the harsh acetic acid boiling step cleaved the aspartic 
acid and proline bond. 
Once identified in rat, multiple groups tried to identify the guanylin in different species and 
de Sauvage was first to describe it in human (de Sauvage et al., 1992). After identifying the 
full-length human guanylin cDNA, it was transfected into a human embryonic kidney cell line 
which expressed the proform. Peptides were generated by trypsin or acid treatment on the 
purified ProGuanylin and the C-terminal sequence of ProGuanylin was found to activate the 
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GC-C. de Sauvage et al. highlighted that a more physiologic processing site would be after the 
basic 93rd arginine residue and emitted the hypothesis that the previously described rat 
peptide was probably not the correct N-terminal sequence.  
However, Currie’s and de Sauvage’s observations about the N-terminal sequence of the 
guanylin peptides were disregarded or unnoticed by the scientific community. Discrepancies 
on the rare reviews on guanylin quoted those papers but never mentioned a potential longer 
form of the active peptide. One paper found a 16-amino acid version of guanylin starting with 
an aspartic acid. However, they concluded that this version was not biologically active 
(Yamaguchi et al., 1995). Later, research was completed by accepting the 15-amino acid 
peptide as being the endogenous active version. No questioning on the difficulty to cleave 
between an aspartic acid and proline residue in vivo was mentioned in the literature again. 
While the mass spectrometry data produced in this chapter highlighted evidence of a different 
endogenous guanylin in mouse, no conclusions can be drawn on the longer versions yet. The 
biological activity of the longer versions (peptides 60-116 or 101-116) found in the different 
array of mouse samples need to be confirmed.  
In humans, the guanylin peptide’s current version not being found in any samples, and the 
detection of a peptide with an additional aspartic acid on the N-terminal (101-116) tends to 
refute the current understanding of the human guanylin peptide. A hypothesis emitted in this 
chapter was the presence of an even longer peptide which could not be detected by mass 
spectrometry as too long. However, more experiments need to be performed on human 
samples to confirm the presence of this longer peptide and its activity. 
When studied by mass spectrometry, human and mouse samples rarely exhibited uroguanylin 
peptides that presented the C-terminal active part and therefore the literature cannot be 




Chapter 5: Quantification of guanylin-related peptides in humans.  
5.1 Introduction 
In humans, guanylin-related peptides have not been extensively characterised due to a lack of 
validated reagents and assays required for their quantification. Only a few reports have 
described their attempt to  measure circulating levels of active guanylin and uroguanylin, with 
initial attempts done with an early developed radioimmunoassay (RIA) (Kuhn et al., 1994).  In 
healthy volunteers the authors reported a measured guanylin concentration of 40fmol/ml of 
in EDTA plasma samples (fasting status was not reported) (Kuhn et al., 1995) and 5fmol/ml for 
uroguanylin in EDTA plasma samples from fasted healthy volunteers (Kinoshita, Fujimoto, et 
al., 1997). Despite the interest in these hormones due to their potential roles in energy 
homeostasis and carcinogenesis (Valentino et al., 2011; Begg et al., 2014; C. Folgueira et al., 
2016), the lack of a reliable and user-friendly method to analyse all the guanylin-related 
peptides has prevented advancements in our understanding of their physiological and 
pathophysiological roles.  
Chapter 3 described the development of two assays that are capable of measuring both 
ProGuanylin and ProUroguanylin. In this chapter, I describe the utility of these assays in the 
measurement of ProGuanylin and ProUroguanylin in human biosamples, including serum and 
plasma. Antibodies and MSD assays were developed using ProGuanylin and ProUroguanylin 
that were produced in vitro in E. coli. Of potential concern was the potential lack of specificity 
of the antibody pairs to the endogenous proforms because the antibodies were raised against 
peptides produced in E. coli and the presence of the AVI-tag could be essential in the binding 
of the antibody pairs to the recombinant proforms (Cf. to chapter 3). It was also uncertain 
whether the binding of antibody pairs to non-specific molecules present in biological samples 
would occur.  
Another aim of this study was to compare the MSD assays I developed with the commercially 
available ELISAs that are marketed for the quantification of guanylin-related peptides in 
human samples. I also sought to compare their respective calibration ranges and, limits of 
detection. Online protocols obtained for the Biovendor kit (www.biovendor.com) displayed 
different incubation steps and sample handling requirements for ProGuanylin and 
ProUroguanylin. In light of this, one advantage of the assays I developed is the similar protocol 
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used for each prohormone which promotes user-friendliness and the ability to perform the 
assays in parallel.  
It was anticipated that the developed assays would be capable of measuring ProGuanylin and 
ProUroguanylin in human plasma and serum samples and provide approximate reference 
ranges for healthy volunteers in fasting and post-prandial states, as well as in other 
physiological and pathological situations. Earlier studies examined a potential role for guanylin 
peptides as biomarkers in patients with neuroendocrine tumours (Kuhn et al., 1995) or kidney 
disease (Kinoshita, Fujimoto, et al., 1997; Kinoshita, Nakazato, et al., 1997; Kinoshita et al., 
1999), which was also attempted as part of this study to help establish reference ranges that 
may aid disease diagnosis, response to treatment and surveillance. For example, 
establishment of reference ranges have been of value in our understanding of human gut 
peptide secretion in response to a variety of stimuli (Meek et al., 2016).   
The aims of this chapter were firstly, to test the developed MSD assays on human samples and 
compare them with the commercially available ELISA kits, specifically in terms of their 
calibration range, as well as limits of detection. Secondly, to provide reliable reference ranges 
for both ProGuanylin and ProUroguanylin in healthy, fasted human volunteers, and 
investigate effects of standardised liquid meal test or an oral glucose challenge (OGTT) on the 
circulating levels of the proforms. Finally, ProGuanylin and ProUroguanylin levels were also 
determined in subjects with midgut metastatic neuroendocrine tumours with carcinoid 
syndrome and other conditions characterised by impaired gastrointestinal function including 
following prophylactic total gastrectomy and small intestine transplant. 
To do so, studies on volunteers were performed by several clinicians (Dr Meek, Dr Roberts, Ft 
Challis and Pr Jensen) and glucose tolerance and liquid meal tests were achieved according to 
methods detailed in section 2.7.1. ProGuanylin and ProUroguanylin were measured in Serum, 
Lith Hep plasma or serum samples using both the commercially available ELISA kit and the 






5.2.1 Evaluation of the MSD assay on human plasma samples and comparison with the 
commercially available Biovendor kit  
Antibody pairs capable of detecting either ProGuanylin or ProUroguanylin and the newly 
developed MSD assays were compared to the commercially available kit from Biovendor. 
ProGuanylin levels were measured in 80 lithium heparin (Lith Hep) plasma samples (from 40 
different participants) using both the ProGuanylin ELISA kit from Biovendor and the 
ProGuanylin MSD assay. Similarly, the ProUroguanylin ELISA kit from Biovendor and the 
ProUroguanylin MSD assay were used to determine the levels of ProUroguanylin. Biovendor 
standards were tested in the MSD assays and standards from the MSD assays were tested in 
the Biovendor ELISA kits at the concentration that was used in each respective experiment. 
Measurements from all assays were done in parallel and at the same time in order to mitigate 
the effects of possible freeze/thaw degradation. The results are presented in figure 5.1. 
Interestingly, both assays were able to detect the standards from the other kit (figures 5.1 A 
and B). While MSD assays managed to read all 8 standard points from the Biovendor kits, the 
Biovendor kit was not able to detect the 3 highest MSD standard concentrations because 
these were too high and therefore above the range of detection (data not shown). The 
ProUroguanylin MSD assay was able to detect the expected standard concentrations of the 
Biovendor kit with a slope of 1.13. The Biovendor kit was not able to correctly detect the 
ProUroguanylin standard concentrations which were underestimated (slope of 0.73). 
Regarding the ProGuanylin standard concentrations, the Biovendor kit also underestimated 
the expected values of the standard concentrations with a slope of 0.39. However, the MSD 
assay measured Biovendor concentrations that were higher than expected (slope was 1.75). 
The discrepancy between measured and expected concentrations are unclear. Factor 
differences between expected and measured values were 1.75 and 0.39 for the MSD assay 
and the Biovendor assay, respectively. One potential explanation may be human error when 
reconstituting the ProGuanylin powder provided by the Biovendor kit. Another explanation is 
the different buffers used for diluting the standards. For example, MSD standards were diluted 
in PBS with BSA whereas the Biovendor standards were diluted in a proprietary diluent. 
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In conclusion both assays could detect the standards from the other kit, but the MSD assays 
were able to detect the standard concentrations more accurately than the Biovendor kits 
could detect the MSD standards. 
Figure 5.1: Comparison of the Biovendor kit with the newly developed MSD kit on human Lith Hep plasma 
samples. In (A.) and (B.), standards from each kit were tested in each other’s assay. In the Biovendor ELISA 
kits, MSD standards concentrations were higher than the detection limit of the ELISA kits assay. Slopes values 
were reported in the table underneath the plots. N = 80 Lith hep plasma samples were measured for 
ProGuanylin (C.) and ProUroguanylin (D.) using the commercially available Biovendor ELISA kit and the MSD 
assay. Obtained values and linear regression were plotted. The linear regression results are summarised in the 




Human plasma samples were measured using both the MSD assay and Biovendor kit (figure 
5.1 C, D and E). The measured ProGuanylin levels correlated well between both assays with a 
coefficient of determination (R2) of 0.84. An intriguing result was the difference in 
concentration measured by both assays: identical plasma samples presented a 2-fold 
ProGuanylin
Biovendor Vs MSD kit
ProUroguanylin
Biovendor Vs MSD kit
Slope 0.3141 ± 0.01559 0.4073 ± 0.04944

















difference depending on which assay was used. This result was expected as the standard 
concentrations presented a discrepancy between both assays. 
ProUroguanylin levels did not correlate as well between the 2 assays, when compared with 
the ProGuanylin assay (coefficient of determination (R2) of 0.47). Similarly, ProUroguanylin 
concentrations measured with the Biovendor kit were lower than proforms concentrations 
measured with the MSD assay. Again, this was expected based on differences found with the 
respective standard concentrations detected by the assays.  
In conclusion, the MSD assays appeared more sensitive and had a broader dynamic range than 
the commercially available Biovendor ELISA kits. Correlations between both assays were 
relatively good suggesting that experiments requiring relative values could be performed with 
the Biovendor kit. However, the MSD assay is capable of more accurately measuring absolute 
peptide values. As alluded to above, another advantage of the MSD assay is that proform 
assays use the same protocol, whereas the protocols of the two ELISA kits differ in terms of 
dilution and incubations time and is less user friendly. 
5.2.2 ProGuanylin and ProUroguanylin levels in fasted and fed healthy volunteers  
Range of baseline values for ProGuanylin and ProUroguanylin from healthy volunteers in fasting 
state 
The concentration ranges for ProGuanylin and ProUroguanylin were determined in fasted 
healthy volunteers. For both proforms the distribution of the data and normality were 
determined and used to assess circulating concentrations of proforms in healthy volunteers 
which allowed for comparison with disease states in future studies.  
From measured levels of both proforms in healthy volunteers, histograms were produced to 
assess the distribution of the data in fasting participants. The analysis was performed on the 
fasting state in order to remove meal-related variability. The data were tested for normality 
using a Shapiro-Wilk test and also tested for skewness and kurtosis (figure 5.2). ProGuanylin 
levels were normally distributed with a p-value of 0.69 in a Shapiro-Wilk normality test and a 
kurtosis of -0.08, whereas, ProUroguanylin levels were not normally distributed with a p-value 
< 0.01 and a skewness of 1.51. 
The mean plasma ProGuanylin levels was 15249pg/ml (1230.95pmol/l) and the determined 
mean plasma ProUroguanylin concentration was 2594pg/ml (214.93pmol/l). Although it is 
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recommended to use at least 120 individuals to assess the definitive 95% confidence intervals 
for reference and to partition the volunteers according to age and gender (Institute, 2010), 
the 2.5th and 97.5th percentiles were calculated to give a table with expected values which 
includes 95% of values from the population comprising of 51 individuals (figure 5.2C). 
 
Figure 5.2: A. and B. Assessment of data distribution and normality for ProGuanylin and ProUroguanylin. 
n=51 healthy volunteers in fasting conditions. Assessment of Skewness and kurtosis and Shapiro-Wilk test are 
summarised in table C. which includes the expected values using the lower reference limit (LRL; 2.5th 
percentile), median and upper reference limit (URL; 97.5th percentile). 
 
ProGuanylin and ProUroguanylin levels in response to oral glucose or liquid meal in healthy 
volunteers 
Guanylin and uroguanylin have been postulated as candidate effector molecules within the 
GI-renal natriuretic axis and, consequently, gut transit (Romi, Cohen, Landau, Alkrinawi, 
Yerushalmi, Hershkovitz, Newman-Heiman, Garry R. Cutting, et al., 2012). One proposed 
mechanism for these actions is the regulated secretion of ProGuanylin and ProUroguanylin 
from cells lining the proximal intestine following oral ingestion of a salt load.  
The newly developed assay allowed the measurement of proforms in the circulation in fed 



































under the supervision of Dr Claire Meek. The baseline characteristics of the participants are 
presented in table 5.1. 
Table 5.1: Demographics of study volunteers. Characteristics are shown as mean (SD) for continuous variables 
and n’s for categorical variables. 
 
A pilot MSD experiment was performed on plasma samples taken from 3 subjects to 
determine the effect of 50g oral glucose on the plasma levels of ProGuanylin and 
ProUroguanylin at 15, 30, 45, 60, 90 and 120 minutes (figure 5.3).  
 
Figure 5.3: Effect of glucose intake on ProGuanylin and ProUroguanylin levels in healthy volunteers. 
ProGuanylin and ProUroguanylin were measured immediately before ingestion of 50g glucose and at 15, 30, 
45, 60, 90 or 120 minutes in three healthy fasted volunteers. ProGuanylin (A.) and ProUroguanylin (B.) levels 
were measured in Lith Hep plasma samples using the MSD assay. 
 
The data showed a negligible impact of oral glucose on the plasma concentrations of 
ProGuanylin and ProUroguanylin. However, volunteers following prophylactic total 
gastrectomy presented a noticeable change at 60 minutes following glucose challenge (data 
not shown). Subsequently, proforms were measured in Lith Hep plasma samples from healthy 
volunteers after ingestion of a liquid standardised meal test (11g of fat, 13g of protein as well 
as 50g of carbohydrate and 0.52g of salt), 50g or 75g glucose tolerance test at time 0 and after 
60 minutes (figure 5.4). A small, but statistically significant, decrease in ProGuanylin was 
measured in the two oral glucose tolerance tests after 60 minutes compared with the time 0. 
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Gender 4F 7M 8F 4M 15F 13 M 6F 7M 3F 8M 5F 1M 3 F 7M 22F 13M  21U
Age (years at 
enrolment) 29.6 (6.9) 27.2 (4.6) 32.3 (11.6 ) 29 .7 (5 .9) 36.1 (8.1) 41.7 (1 5.0) adults (18 -6 0)
33.8  (11.5) for 35  
patients
Body Mass index 
kg/m2 25.0 (3.9) 25.2 (4.0) 2 5.2 (4 .1) 25 .0 (3 .2) 22.1 (2.2) 20.3 (2.9) N/A 25.6 (4.7 )
Amount of time post 
operation N/A N/A N/A N/A 2.9 (2) 4 .7 (5 .2) N/A N/A
HbA1c mmol/mol 32.3 (2.6) 34.3 (3.0) 3 4.5 (3 .3) N/A 38.4 (6.2) N/A N/A N/A
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minutes of ingestion of the liquid meal. ProUroguanylin plasma concentration was 
significantly higher (p value = 0.0379) 60 minutes following ingestion of the liquid meal. In 
contrast, 50g of oral glucose resulted in a significant decrease of ProUroguanylin (p value = 
0.0186).  
 
Figure 5.4: Effect of Liquid meal or glucose ingestion on ProGuanylin and ProUroguanylin levels in 
healthy volunteers. ProGuanylin and ProUroguanylin were measured immediately before and 60 
minutes after ingestion of liquid meal, 50g glucose or 75g glucose in healthy fasted volunteers. 
ProGuanylin (A. and B.) and ProUroguanylin (C. and D.) levels were measured in Lith Hep plasma 
samples using the MSD assay on n=28 participants for Liquid meal ingestion, n=11 participants for 
50mg glucose ingestion, and n=12 participants for 75mg glucose ingestion. In B. and D. Data are mean 
± SEM. Statistical significance was assessed by paired t test for ProGuanylin and Wilcoxon test for 
ProUroguanylin. * indicates p<0.05.  
 
The differences between 0 and 60 minutes were measured for both ProGuanylin and 
ProUroguanylin following the OGTT. A significant decrease in ProGuanylin levels were 
measured in both OGTT tests (p values = 0.0376 and 0.0464, for 50g and 75g glucose 
respectively) (figure 5.4A and B). A small but significant decrease in ProUroguanylin was 
measured for a 50mg OGTT only (p value = 0.0186) (figure 5.4C and D). In response to the 
liquid meal, ProUroguanylin levels significantly increased 60 minutes following ingestion, 
however no changes in Proguanylin levels were detected.  
Effect of fasting on ProGuanylin and ProUroguanylin levels in healthy volunteers 
A study coordinated by Prof. Jørgen Jensen (University of Copenhagen) determined gut 
hormone levels of healthy volunteers during a 7-day fast. The baseline characteristics of the 























participants are listed in table 5.1. ProGuanylin and ProUroguanylin levels were measured on 
plasma samples from these subjects to determine the effect of a prolonged fast on 
ProGuanylin and ProUroguanylin plasma levels (figure 5.5).  
 
Figure 5.5: Effect of 7 days of fasting on ProGuanylin and ProUroguanylin levels in healthy volunteers. 13 
healthy volunteers fasted for 7 days and ProGuanylin (A. and B.) and ProUroguanylin (C. and D.) levels were 
measured pre-fast and on day 0, 1, 3, 5 and 7 in Lith Hep plasma samples using the MSD assay. In B. and D. 
Data are mean ± SD. Statistical significance was assessed by Friedman with a post-hoc Dunn’s test against the 
pre-fast condition. *** indicates p<0.001, ** indicates p<0.01, * indicates p<0.05. 
 
ProGuanylin and ProUroguanylin levels were decreased significantly when compared to pre-
fast levels. Furthermore, levels of both hormones continued to decrease during fast with 
hormone levels on day 7 approximately 50% less than levels measured at the start of the fast. 
These findings may be explained by mucosal atrophy with a diminution of epithelial 
proliferation, cells and in consequence proforms. Another hypothesis would be that the gut is 
trying to maximise absorption of salt and water during the fast and therefore does not secrete 
the proforms. To test this effect determining the luminal concentrations in future experiments 
may help to investigate this possibility. 
Professor Jensen’s research team also conducted a 50g OGTT assay on the volunteers before 
and after a 7-day fast and we measured levels of gut hormones, including ProGuanylin and 
ProUroguanylin (figure 5.6). Similar to previous results, the OGTT assay on the volunteers 

















































the levels of both proforms significantly decreased 60 minutes following glucose ingestion. 
However, after a 7-day fast, glucose ingestion did not provoke a decrease in the levels of the 
proforms.  
 
Figure 5.6: Effect of glucose intake after 7 days of fasting on ProGuanylin and ProUroguanylin levels in 
healthy volunteers. 13 healthy volunteers completed a 50g OGTT before and after a 7 day fast. ProGuanylin 
(A. and B.) and ProUroguanylin (C. and D.) levels were measured immediately before ingestion of 50mg 
glucose, and after 30 and 60 minutes in Lith Hep plasma samples using the MSD assay. In B. and D. Data are 
mean ± SD. Statistical significance was assessed by paired t test for ProGuanylin and Wilcoxon test for 
ProUroguanylin. *** indicates p<0.001, * indicates p<0.05. 
 
5.2.3 ProGuanylin and ProUroguanylin levels in volunteers with metastatic midgut 
neuroendocrine tumours and carcinoid syndrome 
In 1995, Kuhn et al. published a study on volunteers with Crohn’s disease, ulcerative colitis 
and neuroendocrine tumours (NETs) (Kuhn et al., 1995). The majority of the NET patients had 
carcinoid tumours and, consequently, chronic diarrhoea.  Interestingly, greater than 60% of 
subjects had elevated plasma guanylin concentrations assessed with their in house 
radioimmunoassay.  
Dr Ben Challis (Institute of Metabolic Science, University of Cambridge) collected samples from 
subjects with neuroendocrine tumours who were treatment naïve or receiving therapy with 





















































































listed in table 5.1. ProGuanylin and ProUroguanylin levels were determined in these subjects 
in an attempt to observe possible differences in proforms concentrations similar to the 
previously described differences in active hormones (figure 5.7). Serum and plasma Lith Hep 
samples were collected and were compared to either serum or plasma Lith Hep samples from 
healthy participants. A previous experiment had shown that serum, plasma Lith Hep and 
plasma EDTA gave different interindividual concentrations of the proforms (data not shown). 
This result was also observed by Biovendor (www.biovendor.com). Therefore, plasma and 
serum samples were compared separately. 
Preliminary data from samples isolated from subjects with neuroendocrine tumours showed 
a statistically significant increase in ProGuanylin levels in both serum and plasma Lith Hep. 
One outlier and one slightly elevated sample, in combination with a sample size of n=4, might 
explain this significance. ProUroguanylin levels in participants with neuroendocrine tumours 
did not present a significant difference with the healthy volunteers. However, the participant 
with extremely high levels of ProGuanylin also expressed extremely high levels of 
ProUroguanylin.  
Subjects with neuroendocrine tumours treated with either octreotide or lanreotide did not 
have significantly increased ProGuanylin levels compared with control subjects. This result 
concurs with Kuhn’s hypothesis that guanylin plasma levels in some patients could be 
normalised by an octreotide treatment but in order to verify this data, more participants 





Figure 5.7: ProGuanylin and ProUroguanylin levels in healthy volunteers and volunteers with 
neuroendocrine tumours with and without treatment. ProGuanylin (A.) and ProUroguanylin (B.) levels were 
measured in fasted volunteers in serum or Lith Hep plasma samples using the MSD assay. Five volunteers with 
neuroendocrine tumours were under 30mg octreotide or 60mg lanreotide treatment. Data are mean ± SD. 
Statistical significance was assessed by Mann-Whitney test. ** indicates p<0.01 and * indicates p<0.05. 
 
5.2.4 ProGuanylin and ProUroguanylin levels in subjects with severe gastrointestinal 
dysfunction  
Recently, guanylin and uroguanylin have been proposed as signalling peptides in the 
regulation of energy balance through their effects on the brain (Valentino et al., 2011; Begg 
et al., 2014; Cintia Folgueira et al., 2016). Work performed on obese  subjects showed a 
decrease in uroguanylin levels in plasma and biopsy tissues of female adolescent volunteers 
compared to healthy participants (Di Guglielmo, Perdue, et al., 2018; Di Guglielmo, Tonb, et 
al., 2018). 
Gut hormone profile is altered following bariatric surgery (Jacobsen et al., 2012). Recently, 
mRNA expression of the guanylin peptides was measured in human subjects pre- and post-
Roux-en-Y gastric bypass-surgery with transcripts levels for both GUCA2A and GUCA2B 
significantly upregulated in enteroendocrine cells (Fernandez-Cachon et al., 2018).  
In similarly themed research studies, the Gribble and Reimann lab have investigated the effect 





access Lith Hep plasma and serum from subjects with severe gastrointestinal dysfunction. The 
baseline characteristics of the subjects are presented in table 5.1. 
In the first study, a 50g OGTT study was completed on otherwise healthy volunteers that 
underwent a prophylactic total gastrectomy (due to the presence of a gastric cancer 
predisposing E-cadherin mutation); and ProGuanylin and ProUroguanylin levels were 
measured in Lith Hep plasma samples before and after 60 minutes of the OGTT (figure 5.8). In 
the fasting state, volunteers with prophylactic total gastrectomy had statistically higher levels 
of both ProGuanylin and ProUroguanylin. The means of the ProGuanylin and ProUroguanylin 
levels are 1.5 and 2-fold higher respectively in the participants with total gastrectomy. After 
60 minutes post-OGTT, ProUroguanylin showed a statistically significant decrease when 
compared to baseline as previously observed in healthy volunteers. ProGuanylin, on the 
contrary, did not show any decrease as seen for healthy volunteers.  
 
Figure 5.8: Effect of glucose ingestion on ProGuanylin and ProUroguanylin levels in healthy volunteers and 
volunteers with prophylactic total gastrectomy. 50g glucose was ingested at time 0, immediately after 
baseline blood samples were taken. ProGuanylin (A.) and ProUroguanylin (B.) levels were measured at time 0 
and time 60 minutes in Lith Hep plasma samples using the MSD assay on n=11 healthy fasted volunteers and 
n=11 volunteers with prophylactic total gastrectomy. Statistical significance was assessed by paired t test 
when compared in between timepoints for ProGuanylin results or Wilcoxon test for ProUroguanylin. *** 
indicates p<0.001 and * indicates p<0.05. Statistical significance was assessed by Mann-Whitney test when 
compared in between volunteers’ groups. ### indicates p<0.001 
 
Other volunteers with extreme gut conditions were studied. ProGuanylin and ProUroguanylin 
levels were measured in serum samples from fasted subjects who had undergone small bowel 
transplants for a number of different clinical indications, and healthy volunteers (figure 5.9). 
The baseline characteristics of the participants are listed in table 5.1. ProGuanylin and 
ProUroguanylin levels were significantly higher in participants with small bowel transplants 
compared to healthy volunteers. However, these results must be interpreted with some 


















caution as participants that had a small bowel transplants did not all undergo the same 
operation.  For example, some participants had both small intestine and colon transplanted, 
another had liver, stomach, pancreas, small bowel to native colon transplanted, whilst a third 
subject underwent a combined liver, pancreas and small bowel transplant  
One subject of particular interest was M053 from whom a blood sample was collected 
following removal of the small and large intestine but prior to bowel transplantation. The 
serum sample did not contain any measurable levels of ProGuanylin or ProUroguanylin 
thereby demonstrating that the gut is the predominant source of these peptides in human 
blood (data not shown). 
 
Figure 5.9: ProGuanylin and ProUroguanylin levels in healthy volunteers and volunteers with small bowel 
transplants. ProGuanylin (A.) and ProUroguanylin (B.) levels were measured in fasted volunteers in serum 
samples using the MSD assay. Data are mean ± SD. Statistical significance was assessed by Mann-Whitney 
test. *** indicates p<0.001 and * indicates p<0.05. 
 
The role of ProGuanylin and ProUroguanylin in sodium homeostasis, and their potential 
effects on kidney function was previously studied by Kinoshita and colleagues. These 
investigators demonstrated that guanylin levels were increased in patients with impaired 
renal function (Kinoshita, Nakazato, et al., 1997), and plasma uroguanylin levels were higher 
in subjects with chronic glomerulonephritis and hypertension (Kinoshita, Nakazato, et al., 
1997) as well as with chronic kidney disease (Kinoshita, Fujimoto, et al., 1997).  
To investigate whether plasma levels of guanylin-related peptides corrected with osmolality, 
samples from unselected volunteers with a range of osmolality levels were obtained from Dr 















Figure 5.10: ProGuanylin and ProUroguanylin levels in unselected volunteers with a range of different 
osmolality levels. ProGuanylin (A.) and ProUroguanylin (B.) levels were measured in fasted volunteers in 
serum samples using the MSD assay. In (C.) levels of ProGuanylin and ProUroguanylin were plotted against 
each other and the linear regression was calculated. 
 
Levels of ProGuanylin and ProUroguanylin did not show a correlation with osmolality levels, 
however a strong correlation was reached between the levels of ProGuanylin and 
ProUroguanylin with a coefficient of determination R2 of 0.77. A caveat of this experiment was 
the use of unselected volunteers who had a range of different chronic or acute conditions with 
abnormal osmolality. The osmolality originating from chronic or acute conditions which might 
have differing results and would have to be divided into different categories to see a potential 
correlation with proforms’ levels. 
  










5.3.1 Validation of the MSD assay on human serum samples 
The MSD assay, previously described in chapter 3, was used to measure ProGuanylin and 
ProUroguanylin in human serum samples. This assay was compared with the commercial kit 
provided by Biovendor. The MSD assay presented a broader dynamic range of prohormone 
detection and was more sensitive at detecting lower levels of proforms compared to the 
competitor assay (Cf. chapter 3). Both proform MSD assays showed a strong correlation with 
the Biovendor kits when measuring proform levels from the same human plasma samples, but 
the values detected by the MSD assay were higher than the one detected by the ELISA. 
However, the MSD assay was able to detect and measure the provided Biovendor standards 
and their assessed concentrations were matching the expected values in the case of the 
ProUroguanylin. ProGuanylin provided by the Biovendor was, however, overestimated by a 
factor of 1.7. The Biovendor assay was able to detect the proforms values but the measured 
concentrations did not match as closely as the expected values from the MSD standards and 
all concentrations were underestimated. Finally, the MSD assays were easier to use in terms 
of incubation time and dilutions inter-assays when measuring both proforms compared with 
the competitor assays.  
The quality of the MSD assay and binding to the correct target was further supported when 
tested on a human serum sample from a participant who underwent a total small and large 
intestine resection prior to transplantation. The sampling of the serum was performed post-
removal of the small and large bowels but pre-transplant. This unique sample did not present 
any detectable levels of proforms and therefore provides two important insights into the MSD 
assay and fundamental aspects of guanylin peptide biology. Firstly, the MSD assay did not 
present false positive/non-specific binding in plasma Lith Hep samples and therefore the MSD 
assay does not overestimate the proforms in plasma Lith Hep. Secondly, the lack of proforms 
in this sample, correlating to a lack of gut in the volunteer, established the digestive system 
as the predominant source of circulation ProGuanylin and ProUroguanylin in humans.  
The assay was performed on human samples and provided baseline values for ProGuanylin 
and ProUroguanylin in participants in a fasting state. These ranges provide the opportunity to 
assess circulating concentrations of the proforms in various diseases states. A limitation of the 
ranges’ assessment was the limited number of patients that were used to establish them. The 
131 
 
International Federation for Clinical Chemistry (IFCC) and the Clinical and Laboratory 
Standards Institute (CLSI) recommends the use of 120 participants to assess the confidence 
intervals for reference limits which would allow the partition of the individuals according to 
gender or age. While the literature did not provide an insight into the expected concentrations 
of ProGuanylin and ProUroguanylin, the company providing both kits, Biovendor, did provide 
some information about the concentrations that should be expected as they tested their assay 
in different human samples. Whereas the Biovendor kits were performed on unselected 
donors and therefore do not represent a fasting or postprandial state nor a healthy or diseased 
state, the data showed a reasonable consistency with what was measured with the MSD assay 
in terms of order of magnitude. For ProGuanylin, the Biovendor kit measured 11400pg/ml 
when the MSD assay established a fasting concentration at 15249pg/ml. For ProUroguanylin, 
the Biovendor kit measured 1381pg/ml when the MSD assay established a fasting 
concentration of 2594pg/ml. This discrepancy could be caused by an underestimation of the 
levels in the ELISA kit.  
Looking at the circulating levels of proforms in the blood has a potential caveat. The circulation 
levels do not reflect the autocrine or paracrine effect of the proforms in the gut lumen and 
therefore will not necessarily reflect the biological activity of these peptides. However, blood 
samples are the most readily available sample collected and is easy to test, thus making the 
establishment of reference ranges in blood samples critical to the usefulness of the developed 
assay.  
5.3.2 Effects of standardised liquid meal and glucose on ProGuanylin and ProUroguanylin 
secretion 
This work demonstrated that standardised liquid meal and glucose tolerance tests did not 
elicit a strong physiological response in plasma ProGuanylin and ProUroguanylin. A first pilot 
study allowed the measurement of those levels over a period of 2 hours and showed that a 
60 minutes time point might measure a difference with baseline. Whereas the standardised 
liquid meal provoked an increase in ProUroguanylin, the oral glucose test had a decreasing 
effect on both ProGuanylin and ProUroguanylin. The standardised liquid meal consisted of a 
230ml bottle of ensure plus, a balanced nutritional supplement containing 11g of fat, 13g of 
protein as well as 50g of carbohydrate and 0.52g of salt which would modify the physiological 
response on plasma ProGuanylin and ProUroguanylin levels when compared to an oral glucose 
132 
 
intake. A caveat of this study is the inability to measure the posited active version of the 
peptides. For instance, the decrease in ProGuanylin and ProUroguanylin levels could be 
caused by the action of proteases that elicit the action of guanylin peptides onto the Guanylate 
Cyclase-C receptor. Therefore, a decrease of proforms levels might be a sign of utilisation of 
the proforms. 
In participants who fasted over 7 days, levels of proforms were decreased over the course of 
the study to half of the original concentration. An interesting finding of this study was the lack 
of physiological response in proforms plasma after a 50g OGTT assay after 7days of fasting, as 
it was originally the case.  
5.3.3 Insight from patients with extreme gut conditions 
Oral glucose tolerance tests were performed on participants that received a total gastrectomy. 
The levels of ProGuanylin and ProUroguanylin in a fasting state were extremely high with 
means 1.5 to 2-fold higher when compared to healthy participants. It was in accordance to a 
study showing that GUCA2A and GUCA2B transcripts were increased in participants that 
undertook a Roux-en-Y gastric bypass (Fernandez-Cachon et al., 2018). Levels of proforms 
were measured again 60 minutes after 50mg OGTT. While ProGuanylin did not present a 
significant decrease as it was previously the case in healthy participants, ProUroguanylin levels 
decreased significantly when compared to time 0. A potential explanation is that the lack of 
stomach might result in a more dramatic and immediate glucose effect on the small intestine’s 
response. ProUroguanylin is thought to be mostly expressed in the small intestine compared 
to the colon and the reverse was shown about ProGuanylin according to the literature (Qian 
et al., 2000; Ikpa et al., 2016) and would explain the apparent decrease in ProUroguanylin in 
total gastrectomy participants after 60 minutes. The reasons why ProGuanylin levels do not 
decrease over time after 50g OGTT are unclear and might have required measurements of 
hormones over a longer time period and might require further studies. 
5.3.4 Use of the calculated expected values of proforms to diagnose diseases 
Guanylin was mentioned as a potential marker for carcinoid tumours (Kuhn et al., 1995). 
Levels of proforms were measured in patients before and after octreotide or lanreotide 
treatment. A significant increase in ProGuanylin only was measured in the small panel of 
samples. When treated with octreotide or lanreotide, no statistical significance was measured 
between the healthy volunteers and the volunteers with adenocarcinoma. Both treatments 
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are long-acting analogue of somatostatin. They inhibit gut hormone release and could explain 
the lower levels of ProGuanylin in blood. 
However only 2 out of 4 samples (from the panel of serum sample) and 2 out of 3 samples 
(from the Lith Hep plasma) did present levels that were considered above the calculated upper 
reference limits. Also, the number of subjects was small, and more measurements needs to 
be performed on a substantial panel of individuals in order to confirm the preliminary data. If 
new results confirmed a reliable and significant difference in ProGuanylin levels when 
compared to healthy volunteers, the measurement of ProGuanylin could serve as a useful 
biomarker in the diagnosis and monitoring of patients with neuroendocrine tumours.   
Another potential application of the measurement of the proforms as a biomarker would be 
on the potential implication of the guanylin peptides in colorectal cancer. Guanylin and 
Uroguanylin were shown to be the most commonly lost gene in colorectal cancer. More than 
85% of 300 tumour samples presented a loss in GUCA2A and GUCA2B when compared to 
adjacent healthy tissues (Wilson et al., 2014). A hypothesis suggested by Shailubai et al. was 
that the silencing of the receptor by the lack of guanylin peptides would result in colorectal 
cancer (Kunwar Shailubhai et al., 2000). One of the arguments supporting this theory is the 
observed obesity-induced colorectal cancer driven by the loss of guanylin in a mouse model 
(Lin et al., 2016).  
5.3.5 Conclusions 
In conclusion, the MSD assays were validated in human samples and managed to find levels 
of proforms that were correlating with the Biovendor kits. The advantages of the MSD assays 
include a broader dynamic range and is more user-friendly as undiluted samples can be used. 
Assays were used to measure baseline levels of proforms and gave interesting preliminary 
results from a variety of human clinical samples.  These assays will be able to provide insights 
to the physiological roles of proforms in human health states as well as a diagnostic tool in 




Chapter 6: The effect of salt and gut stimuli on the secretion of 
ProGuanylin and ProUroguanylin 
6.1 Introduction 
The role of the guanylin peptides in the gastrointestinal tract became of interest when 
intraluminal guanylin and uroguanylin were shown to activate the GC-C receptor localised in 
the brush border membrane of enterocytes. Guanylin peptides are thought to be released into 
the intestinal lumen after the ingestion of high oral salt intake as well as on the basolateral 
side of the epithelium as it was detected in the circulation and in the urine (Kinoshita, 
Fujimoto, et al., 1997; Kinoshita et al., 1999). This theory was supported by a study performed 
in rat showing that sodium chloride oral intake increased mRNA expression of guanylin and 
uroguanylin in the intestine after 4hrs and the mRNA expression plateaued after 8hrs 
(Carrithers et al., 2002). The lack of a high-throughput assay slowed down the understanding 
of the mechanisms of secretion of guanylin and uroguanylin. Such assay being now developed 
(cf. chapter 3), it allowed the investigation of the effect of salt, gut or vagal stimuli in different 
secretion models. 
6.1.1 Models of interest to study the secretion of proforms 
Caco-2/TC7 cell line as a secretion assay model 
The Caco-2 cell line is a human intestinal cell line established from colonic adenocarcinoma in 
1977 (Fogh, Wright and Loveless, 1977). When most of the cell lines required differentiation 
via synthetic or biological factors supplementation, Caco-2 upon confluence can undergo 
polarisation and differentiation to give rise to mature enterocytes upon confluence (Pinto et 
al., 1983). Even though this cell line was originated from colonic adenocarcinoma, specific 
morphological and functional properties of the absorptive small bowel enterocytes as well as 
the colonocytes were displayed such as α1-AT surfactant-like particle, a 55kDa protein only 
found in small intestine (Engle, Goetz and Alpers, 1998; Xie, Shao and Alpers, 1999; Sambuy 
et al., 2005). Caco-2 cell monolayers have been extensively used for metabolism study (Béaslas 
et al., 2008) and drug transport analysis (Artursson, Palm and Luthman, 2001). 
In an attempt to make the Caco-2 cell line more homogenous, several subclones, such as Caco-
2/15 (Beaulieu and Quaroni, 1991), Caco-2/BBE (Peterson and Mooseker, 1992) and Caco-
2/TC7 (Caro et al., 1995), were generated from the parental Caco2/ATCC cell line. The TC7 cell 
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line, originated from a Caco-2 wild type at late passage, demonstrated tighter junctions and 
reproducibility inter-experiments (Zucco et al., 2005). Another advantage of the use of TC7 
cell line is the quicker differentiation period of those cells compared to the standard Caco-2. 
Fourteen days of culture was enough to reach the same permeability characteristics when 21 
days minimum were necessary for the use of the Caco-2 cell line (Zeller et al., 2015). Finally, 
ProGuanylin and ProUroguanylin mRNA expression could be detected and protein and 
proforms production was measurable with the newly developed MSD assay, allowing their use 
as a secretion model. 
Human intestinal organoids as a secretion assay model 
The identification of the small intestine and colon stem cells by Barker et al. at the bottom of 
the crypts allowed the potential of three-dimensional, long-term and self-sufficient cultures, 
called organoids (Barker et al., 2007). The Lgr5 marker was identified as a marker for adult 
stem cells. Stem cells lineage tracing acknowledged their differentiation into all intestinal 
epithelial cells.  
The same group developed crypt villous organoids from either single Lgr5+ stem cells or 
isolated crypts (Sato et al., 2009). They developed a culture media allowing the organoids to 
develop into budding structures, consisting of a central lumen with bourgeoning crypt 
structures and villus domain toward the centre of the 3D structure (figure 6.1). 
 
Figure 6.1: Schematic representation of an intestinal organoid. Figure adapted from Roeselers et al., 2013. 
 
New advances on protocols enabled the culture of human organoids from isolated human 
crypts. They are kept in an undifferentiated state by the addition of Wnt protein and can be 
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differentiated by its removal (Jung et al., 2011; Sato et al., 2011). Gastrointestinal organoids 
were successfully validated as a tool to assess hormone secretion to different stimuli (Petersen 
et al., 2014; Zietek et al., 2015; Goldspink et al., 2018a) and when differentiated, they 
expressed, produced and secreted some guanylin and uroguanylin. 
Air-Liquid Interface monolayer cultures on transwells 
Transwells are permeable supports that provide access to both sides of a cell monolayer and 
allow to study side-specific stimulation and look at the results of secretion on both sides of 
the membrane. Transwells have been extensively used with Caco-2 cell lines in order to look 
at drug absorption across the intestinal epithelium as cells do not polarise and differentiate as 
well on glass/plastic (Artursson and Karlsson, 1991; Miret, Abrahamse and Groene, 2004).  
Emergence of human organoids as a tool provides the opportunity to have readily available 
human intestinal epithelium material. Caco-2 cell lines harbouring cancerous mutations (for 
instance APC mutations) and not accurately representing any intestine part could therefore 
be replaced by organoids. A study compared the development and characterisation of mouse 
intestinal monolayer in transwells from organoids and compared gene expression of the 
differentiated cultures to corresponding tissues as well as trans-epithelial electrical resistance 
(TEER) (Kozuka et al., 2017).  
In an attempt to improve even further morphological and functional properties of the 
organoids monolayer, as well as oxygen supply, air-liquid interface (ALI) cultures were 
developed for gastric cultures (Ootani et al., 2000; Yokoyama et al., 2007). More recently, 
research was performed on the structural and functional differentiation of intestinal porcine 
epithelial cells in ALI cultures that showed an improved columnar shape and cell volume 
(Nossol et al., 2011). Successful ALI cultures were established from human colonic organoids 
(Usui et al., 2018) and intestinal ALI cultures established from stem cells presented 
crypt/villous configuration and typical epithelial cell markers of Paneth, goblet, and 
enteroendocrine cells (Wang et al., 2015; Yamamoto et al., 2016). 
Ussing chamber 
Ussing chamber is a device allowing the measurement of ions, nutrients, and drugs transport 
across various epithelial tissues. The method and apparatus were developed by Hans H. Ussing 
to understand the active transport of ions across frog skin. The technique principle relies on 
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the separation of the apical and basal part of an epithelium in two chambers containing the 
same Ringer solution and measure the short-circuit current as an indicator of net ion transport 
taking place across the epithelium. Since then, the Ussing chamber system evolved little but 
has been applied to the understanding of the mouse intestine (Clarke, 2009).  
Ussing chamber is now a common tool to investigate the apical or basolateral response to 
stimuli (Brighton et al., 2015; Pais et al., 2016). However, Ussing chamber studies were mainly 
performed on animals, but studies by Collins et al., and McDermott et al. also used mounted 
human colonic epithelia obtained during surgery (Collins et al., 2009; McDermott et al., 2015). 
6.1.2 Sodium chloride role on the secretion of the guanylin peptides 
Some previous studies tried to look at the implication of guanylin and uroguanylin on the 
gastrointestinal-renal natriuretic axis and the implication of an oral salt load on their secretion.  
In a study performed in rat, a high salt diet correlated with higher levels of uroguanylin in 
urinary excretion when compared to a lower salt diet (0.08% Vs 4% NaCl). Interestingly plasma 
levels did not increase (Fukae et al., 2002). A study from the same year supported by a study 
showing that sodium chloride oral intake increased mRNA expression of Guca2a and Guca2b 
in the intestine (Carrithers et al., 2002). A similar method showed in rats that levels of Guca2b 
transcripts were increased after 4hrs of feeding with 7% NaCl in chow diet (Carrithers et al., 
2002). Finally, a study by Kinoshita and colleagues highlighted the physiological role of high 
salt diet on uroguanylin levels in a human study. Urinary excretion and blood levels of healthy 
participants were measured over 24hrs and uroguanylin levels were higher in participants on 
a high salt diet (10g/day) compared to volunteers on low salt diet (7g/day) (Kinoshita, 
Fujimoto, et al., 1997). 
The role of sodium on acute guanylin secretion has been investigated as well. A perfused small 
intestines rat model was used to look at the response of different salt and mannitol 
concentrations. Mannitol is used as a control to match the osmolarity levels of the solution 
without interacting with the cell as NaCl would. Kita et al. showed that a 200mM salt loading 
led to a 3-fold increase in guanylin with an effect lasting over 60 minutes. Such increase was 
not detected for uroguanylin in this model. However, a caveat of this study was that increasing 
concentration of mannitol also increased the guanylin release (Kita et al., 1999). Finally, 
another study evaluated the guanylin protein and mRNA expression in colon of rats that 
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received low, normal or high salt diet (0.08%, 0.47%, 1.65% net NaCl concentration) for a 
week. Guanylin production was reduced by 30% in animals on low salt diet (Li et al., 1996). 
6.1.3 Other mediators implicated in the secretion of the guanylin peptides 
Other stimuli of the guanylin and uroguanylin secretion were studied, but only in rat models. 
A study by Martin et al., looked at the regulation of ProGuanylin by neuronal mediators that 
are implicated in intestinal ion regulation and water transport (Martin et al., 1999). Carbachol, 
a cholinergic agonist and potent parasympathetic agent (Shiroma and Costa, 2015), triggered 
a 7-fold increase of ProGuanylin release on both sides of the mucosa in an Ussing chamber 
experiment on rat colonic mucosa. Other neuronal mediators NO and VIP did not affect the 
release of ProGuanylin. The use of cGMP mimetic (8-bromo-cGMP), a downstream signalling 
effector of the guanylin peptides and product of the GC-C receptor, increased the release of 
ProGuanylin as well. In this study however, measurement of ProGuanylin levels was 
performed using an ELISA with an antibody specific to the C-terminal (the active part of 
guanylin) and having a 100-fold lower affinity than for the smaller peptide. This low affinity 
can be an important problem as the proforms could dissociate from the antibody during one 
of the wash step leading to miscalculation of the levels of ProGuanylin (Martin et al., 1999). 
Those results were corroborated with an experiment using isolated perfused rat colon where 
cholinergic regulation was studied with carbachol and bethanecol, both muscarinic agonist. 
Luminal guanylin release displayed a 6-fold increase in presence of carbachol or bethanecol. 
Similarly, in perfused rat colon, forksolin and the neuropeptide bombesin have also been 
identified as potential stimuli of guanylin release (Moro et al., 2000). 
6.1.4 Project aims 
Using Caco-2/TC7 cell line, human organoids, ALI cultures and Ussing chamber in combination 
with the MSD assays, the aims were to: 
a) Investigate the secretion of ProGuanylin and ProUroguanylin in response to standard 
vagal and gut stimuli as well as previously described stimuli. 
b) Study the secretion of ProGuanylin and ProUroguanylin in response to salt. 




To address those aims, the secretion of ProGuanylin and ProUroguanylin in response to salt, 
gut or vagal mediators was investigated performing secretion assays on different culture 
models: TC7 cell line, human organoids, ALI cultures on transwells and Ussing chambers.  
Duodenal and colonic human organoid lines were generated from human tissues using a 
modified protocol from Sato et al.  Organoids were maintained in an undifferentiated state 
with a high concentration of Wnt-3a and differentiated when needed for 7-10 days through 
the removal of growth factors in media as described in section 2.8.2. ProGuanylin and 
ProUroguanylin secretion were performed on organoids differentiated for 7-10 days and on 
9-day old confluent TC7 cells using test agents dissolved in basal media. Secretion assays were 
performed according to methods described in 2.8.3. Total protein levels in cell lysate of 
organoids were measured by BCA assay (See 2.8.4) while transcripts levels of TC7 were 
measured by qPCR after RNA extraction and reverse transcription (See 2.10).  
Ussing chamber studies were performed on human tissue biopsies obtained through 
Addenbrooke’s hospital tissue bank program from patients undergoing partial colectomy. 
Stripped epithelia were mounted in an Ussing chamber and samples were taken from both 
apical and basolateral compartments at 15, 45 and 90 minutes. At 45 minutes forskolin/IBMX 
was added bilaterally as described in section 2.9. 
ProGuanylin and ProUroguanylin levels were measured in the newly developed MSD assay 
with methods described in sections 2.7.2 and toxicity of the test agents was evaluated by LDH 




6.2.1 Proforms are not accumulated in the cells but secreted in the media in TC7 model 
Pilot experiments were performed on TC7 cells to measure the levels of proforms in the 
supernatant as well as in the lysis samples. Early time points (30 minutes, 1hr and 2hrs) were 
tested in standard HEPES-buffered saline solution (138 buffer) but levels were too low to be 
measured in the MSD assays (data not shown). Concentrations of both proforms were in the 
detection range and in the linear part of the standard curves after 4hrs of secretion. In order 
to perform 4hrs, 8hrs or 24hrs secretion experiments and keep cells alive, standard growing 
media were used as basal media and stimuli were added to it. Consequently, the second pilot 
experiment was performed on TC7 cells and levels of proforms were measured after 4, 8 and 
24 hrs for 2 conditions: basal media and media complemented with 10M Forskolin and IBMX 
in cell lysates and supernatants (figure 6.2). 
Figure 6.2: Measurement of ProGuanylin and ProUroguanylin levels in TC7 cells supernatant and cell lysis 
over 24 hours. TC7 cells were incubated with standard growing media with/without 10μM Forskolin/IBMX. 
Supernatant and cell lysis were collected after 4hrs, 8hrs and 24hrs incubation and ProGuanylin (A.) and 
ProUroguanylin (B.) levels were measured using the MSD assay. Data are mean ± SD, n=6 (two wells from each 
of 3 independent experiments). 
 
A control experiment was performed in which proforms were spiked in DMEM media as well 
as in lysis buffer and measured in the MSD assays (data not shown). Percentage recoveries 
were above 95% in both the DMEM and the lysis media and it was concluded that the antibody 
pairs were able to measure proforms in the DMEM media and lysis buffer. Levels of proforms 




















Supernatant sample - Basal
Supernatant sample - 10 M Forskolin IBMX
Lysis sample  - Basal


















Supernatant sample - Basal
Supernatant sample - 10 M Forskolin IBMX
Lysis sample  - Basal




3ng of ProUroguanylin in the supernatant over 24hrs. While proforms levels were 
accumulating in the supernatant, their levels stayed unchanged in cell lysates over the 3 
different time points indicating that cells did not change their proform production during the 
experiment. The low but constant levels of proforms in the cell lysates suggest a minimal 
storage in the TC7 cells.  Therefore, rather than a direct regulation of the secretion of the 
proforms already stored in the cells, it is the rate of production of the prohormone (RNA levels, 
translation machinery or RNA stability) which might be affecting the amount secreted into the 
media.  
From this pilot experiment, it was decided to look at the protein levels of ProGuanylin and 
ProUroguanylin in the supernatant and at the transcript levels in the cell lysates after stimulus 
to correlate different release levels to possible changes in prohormone expression after 4hrs 
and 24hrs application of a potential stimulus.  
6.2.2 Effect of gut stimuli on the secretion of proforms 
We investigated the proforms release using this approach in response to previously described 
stimuli like bombesin and carbachol and other products known to stimuli intestinal cells such 
as peptones, a protein digest product activating pathways sensitive to amino acids and 
peptides (CASR, GPR93 (Choi et al., 2007; Pais, Gribble and Reimann, 2016)), the secondary 
bile acid TDCA (activating TGR5 (Brighton et al., 2015)),  forskolin, in conjunction with IBMX, 
(inducing high levels of cAMP (Simpson et al., 2007; Alasbahi and Melzig, 2012)), or PMA, a 
stimulator of protein kinase C (PKC) (Castagna et al., 1982; Parker et al., 2009).  
6.2.2.1 Use of Caco-2/TC7 cell line  
Using the pilot experiment results TC7 cells were in incubated for 4hrs and 24hrs with the 
aforementioned stimuli. Protein levels of ProGuanylin were measured using the MSD assay 
and concentrations were normalised to the basal condition (figures 6.3A and B). At the 4hrs 
incubation time point, 10M forskolin/IBMX was the only condition that increased the release 
of ProGuanylin. The GUCA2A transcript levels were measured on the extracted RNA by RT-
qPCR (figure 6.3C) and only forskolin/IBMX showed a significant increase in expression of the 
proform ProGuanylin in media. 
After 24hrs peptone along with forskolin/IBMX increased ProGuanylin levels (p<0.001) 
whereas PMA decreased levels. On the other hand ProGuanylin levels were decreased in the 
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presence of PMA when compared to the basal condition (p<0.01). Transcript analysis at 24hrs 
showed changes in GUCA2A expression when stimulated with peptone (figure 6.3D). 
 
Figure 6.3: Effect of gut stimuli on ProGuanylin secretion on TC7 cultures. TC7 cells were incubated with 
standard growing media with 100nM bombesin, 1mM carbachol, 5mg/ml peptone, 10M forskolin/10M 
IBMX, 1μM PMA, or 100μM TDCA. ProGuanylin levels were measured after 4hrs incubation (A.) and after 
24hrs incubation (B.) using the MSD assay. The measured concentrations were normalised to the mean basal 
value. The relative expression of mRNA for GUCA2A (Guanylin) was measured after 4hrs incubation (C.) and 
24hrs incubation (D.) with stimuli. The relative expression to ACTB (beta-actin) is represented as 2(-ΔCT). 
In (A.) and (B.) data are mean ± SD, n=9 (from 3 independent experiments). In (C.) and (D.) data are geometric 
mean ± SD. Statistical significance was assessed by one-way ANOVA with a post-hoc Dunnett’s test. *** 
indicates p<0.001, ** indicates p<0.01, * indicates p<0.05. 
 
ProUroguanylin levels were measured using the same supernatant: after 4hrs and 24hrs with 
stimulus. After 4hrs incubation, only a slight decrease in ProUroguanylin was noticed in 
presence of PMA and none of the transcript levels presented a significant difference when 
compared to the basal level (figures 6.4A and C). A 24hrs incubation displayed similar results 
with only PMA having a detrimental effect on the ProUroguanylin levels (figure 6.4B). Only the 
forskolin/IBMX condition presented a slight but significant decrease in GUCA2B transcript 
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Figure 6.4: Effect of gut stimuli on ProUroguanylin secretion on TC7 cultures. TC7 cells were incubated with 
standard growing media with 100nM Bombesin, 1mM Carbachol, 5mg/ml Peptone, 10μM Forskolin/IBMX, 
1μM PMA, or 100μM TDCA. ProUroguanylin levels were measured after 4hrs incubation (A.) and after 24hrs 
incubation (B.) using the MSD assay. The measured concentrations were normalised to the mean basal value. 
The relative expression of mRNA for GUCA2B (Uroguanylin) was measured after 4hrs incubation (C.) and 24hrs 
incubation (D.) with stimuli. The relative expression to ACTB (beta-actin) is represented as 2(-ΔCT). 
Data are median and interquartile ranges, n=9 (from 3 independent experiments). Statistical significance was 
assessed by Kruskal-Wallis with a post-hoc Dunn’s test. *** indicates p<0.001, ** indicates p<0.01, * indicates 
p<0.05. 
 
PMA toxicity on the TC7 cell line 
When compared to basal secretion, levels of proforms were decreased after 24hrs and this 
result could be explained either by an inhibiting effect of PMA on the cells or a toxic effect 
leading to cell death. Toxicity of the PMA was therefore investigated on the TC7 cells after 
24hrs using a Lactate Dehydrogenase (LDH) cytotoxicity assay. LDH is a marker of osmotic lysis 
or cytotoxicity and the LDH cytotoxicity assay is a colorimetric assay which measures and 
quantify the release of LDH in the media (Korzeniewski and Callewaert, 1983). 
Toxicity effect of PMA on the TC7 cells was measured after 24hrs of exposure (figure 6.5). Cells 
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condition. The toxicity of PMA provoked cell death and could explain the decrease in proforms 
secretion in the media and gene expression observed for both hormones. 
Figure 6.5: Toxicity effect of PMA on TC7 cultures. TC7 cells were incubated with standard growing media 
with 1μM PMA. LDH activity was measured in supernatant and cell lysate after 24hrs incubation using the 
LDH assay. Levels of LDH activity in supernatant were normalised to the total LDH activity per well 
(supernatant and cell lysate). 
Data are mean ± SD, n=9 (from 3 independent experiments). Statistical significance was assessed by unpaired 
t-test. *** indicates p<0.001. 
 
6.2.2.2 Use of human organoid  
Assessment of the differentiation period to use organoids for secretion 
Human organoids are a relatively new tool to study the effect of stimuli on secretion (Zietek 
et al., 2015; Goldspink et al., 2017). Human organoids were maintained in an undifferentiated 
state in WENR media. To differentiate the organoids, Wnt3a is removed from the media. As 
early indication showed that the guanylin peptides are produced in mature enterocytes and 
goblet cells, monitoring the differentiation of the organoids was necessary to perform 
secretion assay while knowing the cells were able to express ProGuanylin and ProUroguanylin. 
To control that organoids were sufficiently differentiated, GUCA2A and GUCA2B expression 
was measured in organoids over a 12 days period (figure 6.6). After 12 days, the organoids 


















Figure 6.6: Effect of differentiation media on mRNA expression and visual aspect of human duodenum 
organoids. Undifferentiated human duodenum organoids were incubated with differentiation media over a 
12 days course. Every other day, mRNA was extracted and the expression levels of GUCA2A (Guanylin) (A.) 
and GUCA2B (Uroguanylin) (B.) were measured by qPCR. Data is represented as relative expression to ACTB 
(beta-actin) using the 2(-ΔCT) method. Data are geometric mean ± SD, n=7 wells (two or three wells from each 
of 3 independent experiments). (C.) Phase contrast images of human duodenum organoid over 13 days of 
differentiation. 
 
GUCA2A and GUCA2B were undetected in the undifferentiated duodenal organoids and 
transcripts levels increased over time during differentiation. After 8 days of differentiation, 
the transcripts levels plateaued, and it was decided to perform the secretion between 8 and 
10 days of differentiation. Similar results were found in human colonic organoids. 
Secretion and transcription levels with previously described stimuli on human organoids 
Human colonic and duodenal organoids were used to study the secretion of ProGuanylin and 
ProUroguanylin in response to bombesin, carbachol, peptone, forskolin/IBMX, PMA, TDCA 
and aldosterone. Aldosterone was tested on organoids due to its role on the mineralocorticoid 
receptor, regulating electrolyte balance in the circulation. The receptor is not expressed by 
TC7 cells and therefore aldosterone as a stimulus was not investigated on the TC7 cells. After 
differentiating the organoids for 8-10 days, cells were used for secretion. A pilot experiment 
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was performed on 2D organoid cultures and 3D organoid cultures on basal media over 24hrs 
and levels of proforms were higher in MSD assays on 3D organoid cultures after 24hrs (data 
not shown). Secretion were started after washing wells three times with differentiation media. 
Stimuli were diluted in differentiation media and supernatant was collected after 24hrs. 
Proforms were measured using the MSD assay developed in chapter 3. The concentrations 
were normalised to the total protein levels (measured by BCA) to correct inconsistencies of 
organoid sizes and organoids density between splitting.  
Normalisations of the measured ProGuanylin and ProUroguanylin levels after 24hrs 
incubation in duodenum and colon are summarised in figure 6.7 and figure 6.8 respectively. 
As expected, undifferentiated organoids did not secrete the proforms and were in accordance 
with the measured mRNA levels (figures 6.6A and B). ProUroguanylin levels were low to 
undetectable in the duodenum organoids but quantifiable in colonic samples.  
Levels secreted of ProGuanylin and ProUroguanylin (in colon) were not altered by any stimuli 
except PMA which had a significant inhibiting effect on the secretion of ProGuanylin in 
duodenum and a trend in colon. ProUroguanylin levels appeared also to be decreased by PMA 
in the colonic organoid. 
Figure 6.7: Effect of different stimuli on ProGuanylin secretion on human differentiated organoids. (A.) 
Duodenal human organoids and (B.) Colonic human organoids were incubated with differentiation media 
supplemented with 100nM bombesin, 1mM carbachol, 5mg/ml peptone, 10μM forskolin/IBMX, 1μM PMA, 
100μM TDCA or 100nM aldosterone. ProGuanylin levels were measured after 24hrs incubation using the MSD 
assay. Data normalised to total protein content and to the mean basal value. 
Duodenal and colonic organoids lines were established from a single human donor each. Data are mean ± SD, 
n=6-18 (from 3 independent experiments). Statistical significance was assessed by one-way ANOVA with a 
post-hoc Dunnett’s test. *** indicates p<0.001, * indicates p<0.05. 
 



























































































































































































Figure 6.8: Effect of stimuli on ProUroguanylin secretion on human differentiated colonic organoids. Colonic 
human organoids were incubated with differentiation media supplemented with 100nM Bombesin, 1mM 
Carbachol, 5mg/ml Peptone, 10μM Forskolin/IBMX, 1μM PMA, 100μM TDCA or 100nM Aldosterone. 
ProUroguanylin levels were measured after 24hrs incubation using the MSD assay. Data normalised to total 
protein content and to the mean basal value.  
The colonic organoid line was established from a single human donor. Data are median and interquartile 
ranges, n=3-9 (from 3 independent experiments). Statistical significance was assessed by Kruskal-Wallis with 
a post-hoc Dunn’s test.  ** indicates p<0.01 and * indicates p<0.05. 
 
6.2.2.3 Summary  
Two models were used to look at the effect of gut stimuli on proforms secretion and results 
are summarised in the table 6.1. Bombesin and carbachol which were described in the 
literature as stimulating secretion of guanylin did not present any effect on the proforms 
secretion in both the TC7 cell line and duodenal and colonic organoid model. 
Standard gut stimuli action on the proform release and transcript levels of the guanylin 
peptides was investigated using the 2 models.  Peptones presented a low but significant effect 
on the protein secretion of ProGuanylin after 24hrs. A similar effect was noticed for 
forskolin/IBMX as a stimulus, displaying higher levels of ProGuanylin proteins after 4hrs and 
24hrs. PMA had a consistent adverse effect on the cells (either organoids or TC7) when used 
for over 24hrs and could be explained by the toxic effect of the drug over such period of time. 
Bile Acid TDCA and mineralocorticoid receptor activator aldosterone did not modify the 
secretion of proforms. 
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Table 6.1: Summary of the effects of stimuli on proforms secretion and mRNA levels using different in vitro 
models. Protein and mRNA levels of ProGuanylin (A.) and ProUroguanylin (B.) were measured at 4hrs and 
24hrs after stimulation with 100nM bombesin, 1mM carbachol, 5mg/ml peptone, 10μM forskolin/IBMX, 1μM 
PMA, 100μM TDCA or 100nM aldosterone in a TC7 cell secretion assay. Proteins levels were only measured 
after 24hrs secretion when using human organoids as a model. NA indicates not applicable. nc indicates no 
change. – or + indicates significant decreased or increased levels compared to the basal condition.  
 
6.2.3 Effect of salt levels on the secretion of proforms 
Studies have shown the importance of the guanylin peptides (Cf. 6.1.2) in response to salt 
intake. Protein expression and transcripts levels of ProGuanylin and ProUroguanylin were 
studied in response to salt stimulus in the secretion models. 
6.2.3.1 Use of TC7 cell line  
Salt toxicity on the TC7 cell line 
To control which salt concentrations could be used on the ProGuanylin and ProUroguanylin 
secretion assay, a LDH cytotoxicity assay study was performed on the TC7 cells with a range 
of different NaCl and Mannitol concentrations. Mannitol was used as a control to match the 
osmolarity levels of the solution without being able to interact with the cell as NaCl would. 
TC7 cultures were incubated with concentrations ranging from 50mM to 150mM of NaCl or 
100mM to 300mM mannitol on top of the salt already contained in DMEM. LDH assay was 
performed after 4hrs and 24hrs incubation time with the salt or mannitol concentrations 
(figure 6.9). 
ProGuanylin mRNA and protein levels
100nM 
Bombesin 1mM Carbachol 5mg/ml Peptone
10μM Forskolin
IBMX 1μM PMA 100μM TDCA
100nM 
Aldosterone
TC7 4H protein levels nc nc nc + nc nc nc
TC7 4H mRNA levels nc nc nc + nc nc nc
TC7 24H prote in levels nc nc + + - nc nc
TC7 24H mRNA levels nc nc + nc nc nc nc
Duodenum Organoids 24H protein levels nc nc nc nc nc nc nc
Colon Organoids 24H protein levels nc nc nc nc nc nc nc
ProUroguanylin mRNA and protein levels
100nM 
Bombesin 1mM Carbachol 5mg/ml Peptone
10μM Forskolin
IBMX 1μM PMA 100μM TDCA
100nM 
Aldosterone
TC7 4H protein levels nc - nc nc - nc nc
TC7 4H mRNA levels nc nc nc nc - nc nc
TC7 24H prote in levels nc nc + nc - nc nc
TC7 24H mRNA levels nc nc nc - - nc nc
Duodenum Organoids 24H protein levels nc nc nc nc nc nc nc






Figure 6.9: Toxicity effect of NaCl and Mannitol on TC7 cultures. TC7 cells were incubated with standard 
growing media complemented with 50mM NaCl, 100mM NaCl, 150mM NaCl, 100mM mannitol, 200mM 
mannitol or 300mM mannitol. LDH activity was measured using a colorimetric assay (Pierce) in supernatants 
and lysed cells after 4hrs incubation (A.) and after 24hrs incubation (B.) as per manufacturer’s instructions 
and expressed as a percentage of total LDH. 
Data are mean ± SD, n=9 (from 3 independent experiments). Statistical significance was assessed by one-way 
ANOVA with a post-hoc Dunnett’s test. *** indicates p<0.001. 
 
A 4hrs incubation with concentrations ranging from 50mM to 150mM of NaCl or 100mM to 
300mM mannitol did not present any effect on the cell death when compared to basal. After 
24hrs, high concentrations of NaCl and mannitol did impact on the cytolysis of the TC7 cells. 
A concentration of 100mM NaCl (200mM mannitol) presented 10% of LDH activity or doubled 
the LDH activity compared to basal levels. A concentration of 150mM NaCl and 300mM 
mannitol had a 25% and 15% LDH activity respectively. In conclusion, concentration of 100mM 
NaCl or 200mM mannitol were decided as the highest concentration to use on secretion assay 
on TC7, with the knowledge that a 24hrs incubation slightly affects cell viability. 
Protein expression and transcription levels with elevated levels of salt on TC7 cell line 
Concentrations of salt ranging from 10mM to 100mM were incubated for 4hrs and 24hrs on 
TC7 cells. Mannitol concentrations of 100mM and 200mM were used as osmolarity control. 
Levels of ProGuanylin were measured using the MSD assay (figures 6.10A and B) as well as 
GUCA2A transcript levels by qPCR (figures 6.10C and D). An identical protocol was applied for 
ProUroguanylin levels (figures 6.11A and B) and GUCA2B transcripts levels (figures 6.11C and 
D).  
A first look at the data showed that after 4hrs and 24hrs incubation, TC7 stimulated with NaCl 




























































































































mannitol. Therefore, osmolarity may affect total protein release and the observed decreasing 
levels of proforms might be due to cytotoxicity. 
A 4hrs incubation on salt decreased both ProGuanylin and ProUroguanylin levels in the 
supernatant for salt and mannitol concentrations above 10mM and 50mM respectively. 
Transcript levels were also decreased for GUCA2A but not significant for GUCA2B after 4 hours 
when compared to the basal.  
After 24hrs incubation, ProGuanylin protein levels were not significantly different anymore 
for the 10mM and 50mM NaCl concentration when compared to basal (figure 6.10). However, 
the protein levels of ProGuanylin under 100mM NaCl stimulus were lower but might be 
attributed to cytotoxicity as previously seen in cytotoxicity assay. GUCA2A transcript levels 
were raised significantly after 24hrs when the 50mM NaCl concentration was used as stimuli. 
The equivalent mannitol concentration did not increase significantly the GUCA2A levels. A 
discrepancy exists between the secreted protein levels of high salt concentrations being 
identical to the ones from basal condition after 24hrs, when they were significantly decreased 
after 4hrs, attesting of 2 effects imposed by the salt. The first effect decreasing the levels of 
protein and transcript would be due to the change in osmolarity. The second effect would be 
salt-dependent increasing the transcript levels and readjusting the levels of ProGuanylin to 
basal levels after 24hrs. In order to produce the same amount of proforms after 24hrs than 
what is present in the basal, cells might have to adapt themselves to the high salt 
concentration after 24hrs either in transcription rate as well as potential translation rate or 
secretion rate. Indeed, a potential explanation would be a mechanism of compensation of the 







Figure 6.10: Effect of salt on ProGuanylin secretion and mRNA expression on TC7 cultures. TC7 cells were 
incubated with standard growing media complemented with 10mM NaCl, 50mM NaCl, 100mM NaCl, 100mM 
mannitol or 200mM mannitol. ProGuanylin levels were measured after 4hrs incubation (A.) and after 24hrs 
incubation (B.) using the MSD assay. The measured concentrations were normalised to the mean basal value. 
The relative expression of mRNA for GUCA2A (Guanylin) was measured after 4hrs incubation (C.) and 24hrs 
incubation (D.) with stimuli. The relative expression to ACTB (beta-actin) is represented as 2(-ΔCT). 
In (A.) and (B.) data are mean ± SD, n=9 (from 3 independent experiments). In (C.) and (D.) data are geometric 
mean ± SD. n=9 (from 3 independent experiments). Statistical significance was assessed by one-way ANOVA 


























































































































Figure 6.11: Effect of salt on ProUroguanylin secretion and mRNA expression on TC7 cultures. TC7 cells were 
incubated with standard growing media complemented with 10mM NaCl, 50mM NaCl, 100mM NaCl, 100mM 
mannitol or 200mM mannitol. ProUroguanylin levels were measured after 4hrs incubation (A.) and after 24hrs 
incubation (B.) using the MSD assay. The measured concentrations were normalised to the mean basal value. 
The relative expression of mRNA for GUCA2B (Uroguanylin) was measured after 4hrs incubation (C.) and 24hrs 
incubation (D.) with stimuli. The relative expression to ACTB (beta-actin) is represented as 2(-ΔCT). 
Data are median and interquartile ranges, n=9 (from 3 independent experiments). Statistical significance 
between conditions was assessed by Kruskal-Wallis test with a post-hoc Dunn’s test against the basal 
condition. *** indicates p<0.001, ** indicates p<0.01. In (D.), Mann-Whitney test was performed between 
NaCl and mannitol conditions. # indicates p<0.05. 
 
Similarly, after 24hrs incubation ProUroguanylin protein levels under 100mM NaCl stimulus 
were significantly lower compared to basal but matched levels in the osmolarity controlled 
samples, indicating a potential effect of cytotoxicity at high osmolarity. Also, ProUroguanylin 
protein release after 24hrs incubation with 10mM and 50mM NaCl stimuli were not 
significantly different compared to basal (figure 6.11). GUCA2B transcript levels did not 
present significant difference after 24hrs for 10mM NaCl salt concentration, however 
transcripts levels were significantly higher in the case of salt concentration above 50mM NaCl. 



























































































































































between salt and the corresponding mannitol concentration. This control showed that the 
effect was due to the NaCl concentration and not the osmolarity levels. However, the mRNA 
levels are difficult to translate to the protein levels as the 50mM NaCl concentration did not 
present a significant difference compared to basal.  
6.2.3.2 Use of human organoid lines  
Human organoids were used to study the secretion of ProGuanylin and ProUroguanylin in 
response to salt stimuli. Human organoids coming from duodenum and colon were 
differentiated for 8-10 days before being used in a secretion assay. Secretion were started 
after washing wells three times with differentiation media containing the stimuli (salt and 
mannitol) after which organoids were incubated for 24hrs. The MSD assays measured 
ProGuanylin and ProUroguanylin in supernatant after 24hrs. Proforms levels were normalised 
to the total protein levels (measured by BCA) to normalise according to organoid sizes and 
organoid densities between splits. Secretion were performed on both human duodenum and 
colon organoids and ProGuanylin levels are summarized on figure 6.12.  
 
Figure 6.12: Effect of Salt stimuli on ProGuanylin secretion on human organoids. (A.) Duodenal human 
organoids and (B.) Colonic human organoids were incubated with differentiation media supplemented with 
50mM NaCl, 150mM NaCl, 100mM mannitol or 300mM mannitol. Duodenal and colonic organoids lines were 
established from a single human donor each. ProGuanylin levels were measured after 24hrs incubation using 
the MSD assay. Data normalised to total protein content and to the mean basal value.   
Data are mean ± SD, n=3-18 (from 3 independent experiments). Statistical significance was assessed by one-
way ANOVA with a post-hoc Dunnett’s test. *** indicates p<0.001, ** indicates p<0.01, * indicates p<0.05. In 













































































































































A. Duodenal organoids B. Colonic organoids
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ProGuanylin levels were also measured on undifferentiated organoids. Those organoids were 
split at the same time as the ones used for the experiment but were kept in an 
undifferentiated state using Wnt3a in the media. A 24hrs secretion was performed on the 
undifferentiated organoids using Wnt3a media instead of differentiation media. Levels were 
significantly decreased compared to the basal level of differentiated organoids and were 
below the linear range of detection in both organoid systems.  
Concentrations of 50mM and 150mM NaCl and equivalent mannitol osmolarity control 
conditions were used on the duodenum organoids (figure 6.12A). The highest salt 
concentration gave a low response in ProGuanylin compared to the basal levels but this might 
be explained by toxic effects of such concentration similar to what was seen with TC7 cells. 
Only a triplicate was performed at such concentration and the experiment was not repeated. 
Using 50mM NaCl concentration as stimuli, did not provoke cell death and the supernatants 
were analysed in the same fashion. A 24hrs time point showed a significant increase in 
ProGuanylin compared to the basal condition. When the 50mM NaCl condition was compared 
to the 100mM mannitol, samples were also significantly different (p<0.05) attesting that the 
increase in ProGuanylin was not due to osmolarity increase. In colon organoids, ProGuanylin 
did not follow the same trend and a 50mM concentration induced a small but significant 
decrease in ProGuanylin release (figure 6.12B). 
On the same experiments, ProUroguanylin levels were measured using the MSD assay (figure 
6.13). A first look at the data demonstrated that ProUroguanylin levels were really low 
compared to the ProGuanylin levels. Therefore all 3 repeated experiments performed in 
duodenum did not display strong enough concentrations to interpolate the detected values 
to the linear range of standard concentration. In conclusion, the secretion experiment on 
duodenum did not provide any information on salt effect on ProUroguanylin secretion.  
Surprisingly, ProUroguanylin levels were detectable in the colon organoid experiment when it 
is thought to be less expressed in comparison to the duodenum (figure 6.13). No significant 
difference was measured between basal and the salt/mannitol conditions. 
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Figure 6.13: Effect of Salt stimuli on ProUroguanylin secretion on human colonic organoids. Colonic human 
organoids were incubated with differentiation media supplemented with 50mM NaCl or 100mM mannitol. 
ProUroguanylin levels were measured after 24hrs incubation using the MSD assay. The measured 
concentrations were normalised to the total protein per well and to the mean basal value. The colonic 
organoid line was established from a single human donor each Data are mean ± SD, n=3-9 (from 3 
independent experiments). Statistical significance was assessed by Kruskal-Wallis test with a post-hoc Dunn’s 
test. ** indicates p<0.01. 
 
6.2.3.3 Use of ALI cultures on transwells as preliminary examination 
The use of human organoids as a monolayer in transwells has been described in the literature 
as a new way to reproduce similar gene expression to normal tissues. These culture models 
showed suitable for studying the paracrine and endocrine secretory functions of different 
segments of mouse as well as human intestinal tract (Kozuka et al., 2017). Air-Liquid Interface 
(ALI) monolayer culture model presented crypt/villous structures and typical epithelial cell 
markers of Paneth, goblet, and enteroendocrine cells (Wang et al., 2015). 
A first pilot experiment was designed using the transwells with human duodenum ALI cultures. 
Fourteen-day old ALI cultures were pre-incubated for 20 minutes with standard secretion 138 
buffer, or buffer with identical osmolarity but free from sodium or chloride. Proforms levels 
were measured using the MSD assays on both apical and basal side. While proforms were not 
detectable in the basolateral side, ProGuanylin levels measured in the apical side. This 
interesting result suggests that proforms are preferentially secreted into the lumen. Proforms 
amounts were normalised to total protein (from the cell lysis) and summarised in figure 6.14. 
From this pilot study, ProGuanylin secretions in buffer without sodium or without chloride did 







































ProUroguanylin levels were too low in all conditions to be detected by the MSD assay. This 
result was not surprising because ProUroguanylin levels were below the detection limit in 
conventionally cultured and differentiated duodenal organoids (figures 6.8A and 6.13A). 
Figure 6.14: Effect of Salt stimuli on ProGuanylin secretion on human duodenal ALI cultures in transwells. 
Duodenal human transwells were incubated with standard buffer 138, Sodium-free buffer 138, Chloride-free 
buffer 138 or a mixture of standard buffer with sodium or chloride free buffer. ProGuanylin levels were 




Three models were used to look at the effect of salt on secretion of proforms and results are 
summarised in the table 6.2.  
The TC7 cell line model was useful to look at protein levels as well as transcript levels in 
response to salt and mannitol stimuli. Levels ranging from 10mM to 100mM NaCl presented 
an inhibitory effect on the secretion of proforms and on the transcription after 4hrs 
incubation. A similar reduction in proforms and transcripts was found using an osmolarity 
control, mannitol, as stimulus. Therefore, the osmolarity instead of the salt might be affecting 
the levels of ProGuanylin and ProUroguanylin. After 24hrs incubation, salt concentration 
above 100mM had a toxic effect on the cells. For 50mM salt concentration, ProGuanylin and 
ProUroguanylin levels were equal to the one found in the basal secretion with an increase in 





Pre-incubation Na+ free buffer Cl- free buffer Na+ free buffer Buffer 138 50% Na
+ free 
50% Buffer 138
50% Cl- free 
50% Buffer 138
Incubation Na+ free buffer Cl- free buffer Buffer 138 Buffer 138 50% Na
+ free 
50% Buffer 138




Table 6.2: Summary of the effects of gut stimuli on proforms secretion and mRNA levels using different in 
vitro models. Protein and mRNA levels of ProGuanylin (A.) and ProUroguanylin (B.) were measured at 4hrs 
and 24hrs after stimulation with NaCl or Mannitol in the TC7 cell line model. Proteins levels were only 
measured after 24hrs secretion when using human organoids as a model. NA indicates not applicable. nc 
indicates no change. – or + indicates significant decreased or increased level compared to the basal condition.  
 
6.2.4 Preliminary data on the secretion using Ussing chambers 
J. Rievaj performed preliminary experiment on human colonic mucosa that were isolated after 
surgery and mounted in Ussing chamber. Colons were mounted on the Ussing chambers and 
equilibrated for 20 minutes in Ringer solution. During pre-treatment, a sample was removed 
from both chambers and 10mM glucose final concentration was added to the media. After 30 
minutes, another aliquot was removed and 10μM forskolin/IBMX was added before the last 
time point at 90 minutes. MSD assays were performed on samples from both apical and basal 
chambers and ProGuanylin and ProUroguanylin concentrations are summarised in figure 6.15. 
ProGuanylin mRNA and protein levels
10mM NaCl 50mM NaCl 100mM Mannitol 100mM NaCl 200mM Mannitol
TC7 4H protein levels - - - - -
TC7 4H mRNA levels nc - - - nc
TC7 24H protein levels nc nc - - -
TC7 24H mRNA levels nc + nc nc nc
Duodenum Organoids 24H protein levels N/A + nc - -
Colon Organoids 24H protein levels N/A - nc nc nc
ProUroguanylin mRNA and protein results
10mM NaCl 50mM NaCl 100mM Mannitol 100mM NaCl 200mM Mannitol
TC7 4H protein levels nc - - - -
TC7 4H mRNA levels nc nc nc nc nc
TC7 24H protein levels nc nc nc - -
TC7 24H mRNA levels nc + nc + nc
Duodenum Organoids 24H protein levels N/A nc nc nc nc






Figure 6.15: Preliminary data on secretion of ProGuanylin and ProUroguanylin by Ussing chamber. Proforms 
were measured on both the apical and basolateral side. Data are mean, from 2 independent experiments. 
 
A first interesting result was the levels of ProGuanylin in comparison to the levels of 
ProUroguanylin. In both tissues, the levels or ProGuanylin are ~10-fold higher than those of 
ProUroguanylin. In addition, the preliminary data showed that both ProGuanylin and 
ProUroguanylin were secreted mainly at the apical side. The apical compartment presented 
an amount 4 to 6-fold higher in ProGuanylin and ProUroguanylin compared to the basolateral 
compartment, confirming also the results found on the ALI model. ProGuanylin, in accordance 
with Martin et al.’s results, presents site-directed secretion (Martin et al., 1999); and this site-





6.3.1 An unconventional secretion of ProGuanylin and ProUroguanylin  
Interestingly, measurement of proforms through time in the TC7 model did not present 
accumulation in the cell lysate and levels found in the supernatant were much higher than in 
the lysates. Consequently, there is no accumulation of the proforms in the lysate and proforms 
are directly secreted by the cells and it was therefore unlikely that acute secretion of the 
peptides could be increased. Gene expression, translation machinery, RNA stability, protein 
turnover would be the parameters affecting the protein secretion in media. To look at some 
of those parameters, proforms were measured only in supernatants and cells were used to 
extract RNA and look at transcript levels.  
An unconventional aspect of the secretion of both proforms was the site-directed secretion in 
the luminal as well as in the basolateral side. However, apical levels were much higher than 
basolateral levels in the ALI and Ussing chambers models. Whilst this is in accordance with the 
only available study performed on the subject by Martin et al., 1999, we cannot exclude the 
simple explanation of selective apical secretion with some leak into the basolateral 
compartment; however, proforms were also detectable in human plasma suggesting that 
either this leak is also present in vivo or some basolateral secretion does take place. 
Basolateral prohormone detection is thus unlikely a result of a compromised barrier function 
in the experimental setups. Future work could address this further, including the identification 
of signals resulting in preferential apical secretion. 
6.3.2 Secretion models in contradiction with the literature on the effect of NaCl on proforms 
secretion 
Several models were used to look at the secretion response to salt and other stimuli: TC7 cell 
line, human organoids, and ALI cultures.  
ProGuanylin and ProUroguanylin transcript levels in TC7 cells were affected by moderately 
elevated salt concentration and the protein levels under stimuli differed between the 4hrs and 
24hrs timepoints when compared to the basal levels. The concentration above 50mM NaCl 
presented a toxic effect and won’t be discussed further. Salt and mannitol decreased proforms 
release as well as transcript levels during the first 4hrs of incubation, but no difference could 
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be found after 24hrs of incubation for the protein levels. Osmolarity might affect either the 
transcription rate, and potentially the translation rate or the secretion of the proforms in the 
supernatant but after 4hrs incubation, cells could adapt to the salt concentration: increasing 
the transcription rate, they would produce proforms to match the basal levels.  
Incubation of duodenum organoids in presence of 50mM salt presented a small but significant 
1.3-fold increase in ProGuanylin secretion. This modification was also significantly different to 
the levels of ProGuanylin secreted in presence of osmolarity-matching mannitol. The salt 
concentration on colon organoids however did have an inhibitory effect on the ProGuanylin 
levels. These results are mainly in contradiction with the literature. Kita et al. and Li et al. both 
showed in perfused rat colons that guanylin in circulation increased in response to salt (Li et 
al., 1996; Kita et al., 1999). However, both studies were measuring guanylin on the basolateral 
side of the cell membrane whereas the secretion models used only allowed a measurement 
of the proforms summing up basolateral and apical secretion. Another caveat of the secretion 
performed in this chapter was the fact that levels of active guanylin peptides could not be 
measured. Potentially, ProGuanylin could be cleaved when secreted from the cells and 
therefore would not have been accounted in the measurement. On the other hand, the 
protein cleavage could happen as well in the basal levels and therefore the normalisation 
should account for the potential loss of protein. 
Similarly, ProUroguanylin secretion in response of salt concentration did not corroborate the 
literature. None of the models used showed a positive effect on the ProUroguanylin levels but 
showed an increase in transcript levels. A similar caveat mentioned previously would be the 
potential processing of ProUroguanylin into the active form or the fact that levels in the 
circulation might not be directly regulated by secretion from epithelial cells. 
It was hypothesised that the lack of response to salt was due to its presence in the media 
which would make the cells already expressing and secreting proforms at the maximum of 
their capacity. When ALI cultures were used, a different experimental set up was considered 
because of concerns on the salt concentration already present in the differentiation or DMEM 
media. The TC7 cells media already contained 110.34mM of NaCl (Gibco High Glucose DMEM) 
and the differentiation media contained 120.61mM of NaCl. Those concentrations of salt 
might already be in excess and affect the secretion of ProGuanylin and ProUroguanylin, to the 
point that cells reached their maximum protein expression and secretion capacity. Therefore, 
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work on ALI duodenal cultures was performed with standard secretion 138 buffer 
with/without sodium and with/without chloride. The result of this work did not show any 
difference on the apical secretion of ProGuanylin when using standard 138 buffer when 
compared to buffer without sodium or without chloride. More work could be performed on 
ALI cultures with matching concentration of salt to what was used previously in the organoids 
and TC7 cell line. 
The discrepancy in results about salt or gut stimuli effect on proforms secretion could be due 
to the difference in models but also the difference in species that were looked at. Most 
experiments were performed on rats, when the study performed in this chapter only focused 
on human models. In a human study, 15 volunteers were controlled for their response to acute 
intravenous versus oral sodium load. They did not find a difference in NaCl excretion nor 
changes in ProGuanylin concentrations in response to either oral versus intravenous (IV) 
sodium administration over 6hrs but observed a decrease in ProUroguanylin concentration in 
response to both oral and IV sodium (Preston et al., 2012). 
6.3.3 2 Secretion models did not find a consensus on stimulus for the secretion of proforms 
ProGuanylin and ProUroguanylin expression in the presence of other stimuli did not present 
a strong correlation with the literature either. Forskolin, previously identified as a stimulus for 
guanylin secretion (Moro et al., 2000), was the only stimulus in which the TC7 cell line model 
reproduced literature reports. Significant increase in secretion over 4hrs and 24hrs were 
measured when compared to basal and difference in transcript levels were detected. Peptone 
was the only other gut stimulus that presented a positive effect on the secretion of 
ProGuanylin in the TC7 cell line model after 24hrs only. Bombesin and carbachol which were 
mentioned as stimuli (Martin et al., 1999; Moro et al., 2000), did not show any positive effect 
on the secretion of both proforms using both TC7 cell line and human organoids. A caveat of 
the experimental design from this chapter is that only one concentration was used to trigger 
a secretion of proforms. A range of higher concentrations of each stimulus could have ensured 
that the tested stimuli did not have an effect. 
From the models used no real consensus for potential stimuli was achieved. A possible 
conclusion from these results is that both proforms are secreted by the intestine in a constant 
rate and that yet to be determined signals might modify this rate.  
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6.3.4 Limitations and advantages of the used secretion assay models 
Several secretion assay models were used in this chapter and all present advantages and 
limitations. While the TC7 cell line model is potentially the most high-throughput and cheapest 
one, it represents an enterocyte-like system. Originally from colonic adenocarcinoma, cells 
contain cancerous mutations, and even though this cell line was isolated from the colon, it 
does not represent an intestine segment in particular as it expresses markers for both small 
intestine and colon (Engle, Goetz and Alpers, 1998; Sun et al., 2008). Studies have mainly used 
Caco-2 cell monolayers grown on transwells (culture inserts). This standard protocol allows 
the polarisation of the cells after 21 days for the standard Caco-2 cell line and 14 days with 
the TC7 cell line. In this chapter, TC7 cells were plated directly at the bottom of 24 well plates. 
The lack of evidence that cells do have apical and basolateral sides in these cultures might 
affect the polarity and differentiation of the monolayer and prevent the display of 
physiological response to stimulus. However, the expression of guanylin peptides was 
investigated with the measurement of GUCA2A and GUCA2B transcript levels in the cell line 
and 7 days post splitting already showed measurable levels of transcripts levels (data not 
shown).  
Duodenal and colonic organoids on the other hand keep polarity between basal and apical 
part. However, a limitation of this system is the apical membrane facing the inside of the 
organoids. Therefore, the organoids will contain dead cells and mucus inside the organoids. 
The presentation of the basal part of the cells on the outside of the organoid is a limitation in 
this chapter as the general idea of the salt or gut stimuli is that it comes from the lumen and 
secretion should be at the apical side. Methods were developed to convert organoids into 
monolayers cultures, but characterisation of these cultures has been limited (VanDussen et 
al., 2015; Kozuka et al., 2017; Goldspink et al., 2018b). The 2D cultures from human organoids 
were investigated as part of this chapter. Secretion on organoids plated in 2D culture on 2% 
Matrigel coated 48-well plates presented lower levels of ProGuanylin and ProUroguanylin 
than 3D cultures that were measured in parallel. As the levels of ProGuanylin and 
ProUroguanylin from 3D organoid cultures were quite low after 24hrs, with ProUroguanylin 




2D cultures were investigated again but this time using ALI cultures with transwells. Even 
though human colonic organoids showed stronger levels of proforms detected by MSD assays, 
the use of duodenal organoid for the ALI cultures was decided based on the duodenal 
organoids growing faster and their differentiation easier than the colonic organoids and the 
fact that the duodenum is more likely to see changes in nutrients whereas the colon is most 
of the time in presence of bacterial products. The use of standard secretion buffer, prevented 
the experiment to run for 24hrs. Therefore, only ProGuanylin was detected in the MSD assays 
and only in the apical side of the transwells. The preliminary experiment highlighted other 
limitations of this experiment in term of costs and low-throughput of the experiment. 
Transwells are expensive and come on top of an already costly organoid model due to 
matrigel/BME and drugs necessary to organoid growth. 
The Ussing chamber technique provides a really relevant short-term representation of a 
human organ that enables measurement of transport and stimulus response of a complete 
polarised intestinal epithelium. However, limitations of this technique are important in terms 
of low-throughput as well as need of fresh human tissues. The dissection should be performed 
as soon as possible but sometimes the reception of the colectomy can be delayed and is 
consequently detrimental to the tissue integrity. Moreover, not all tissues survive that long. 
6.3.5 Future work  
The main work performed in this chapter was performed using TC7 cell lines and 2 different 
human organoid lines, one originating from duodenum and one originating from colon. Both 
organoids and TC7 cell line are relatively high-throughput methods but results showed that 
nothing really stimulate strongly the secretion of ProGuanylin and ProUroguanylin on the 
apical side of the epithelium. 
Preliminary results on Ussing chambers exhibiting detectable levels of both ProGuanylin and 
ProUroguanylin in 2 human colon tissues are encouraging. ALI cultures from human 
duodenual organoids showed secretion of ProGuanylin to detectable levels on the apical side. 
The Gribble/Reimann lab has now created and banked several lines of human organoids 
covering the different sections of the small and large intestine. Using these other organoid 
lines in ALI cultures that potentially express more ProGuanylin and ProUroguanylin is of 
interest for more secretion assays with specific stimuli. The use of differentiation media 
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instead of secretion 138 buffer, would allow longer secretion that might be necessary to 
detect the proforms in ALI cultures.  
Both ALI cultures and Ussing chambers are low-throughput therefore selecting carefully which 
experiments will be performed on them is necessary. From this results chapter, the rare 
stimulus that showed a possible impact on the secretion of the proforms were a 50mM NaCl 
concentration, forskolin/IBMX and peptone and would have the priority on the future 
experiments. Effect of neuronal mediators carbachol, bethanecol, bombesin, NO and VIP were 
looked at in previous rats’ studies (Martin et al., 1999; Moro et al., 2000). While carbachol, 
bethanecol and bombesin showed an effect on the secretion of ProGuanylin, NO and VIP did 
not. The discrepancy with the lack of response to stimulus in this chapter might be species 
dependent as well as concentration dependent (as only one concentration was tested in this 
chapter). More research on the role of the vagal system in human is necessary with the use of 
human models.  
Finally, the Gribble/Reimann lab developed techniques to study gut hormones secretion from 
primary cultures of either murine or human primary cultures (Habib et al., 2013; Psichas et al., 




Chapter 7: Identification and characterisation of guanylin-expressing 
cells  
7.1 Introduction 
7.1.1 Tissue distribution and cellular localisation of guanylin-related peptides 
The specific cell types that express guanylin and uroguanylin, both within and outside the 
gastrointestinal tract, remains uncertain. Data from early research studies suggested that the 
guanylin-related peptides play a critical role in the gut’s response to an oral salt load through 
communication with the kidneys in the so-called gut-renal axis.  Therefore, it was speculated 
that gastrointestinal tract and kidneys were the main organs expressing guanylin peptides 
(Potthast et al., 2001). Following identification of the receptor for guanylin and uroguanylin, 
many researchers, using a number of different methodologies, reported peptide expression 
across a number of different tissues. Miyazato and colleagues found in rats uroguanylin 
transcripts in the lung, pancreas and stomach by Northern-blot and qRT-PCR (Miyazato et al., 
1996). Kulaksiz confirmed the presence of guanylin peptides in pancreas and salivary glands 
of rats with ambiguous immunohistochemistry (Kulaksiz, Rausch, et al., 2001; Kulaksiz, 
Schmid, et al., 2001; Kulaksiz et al., 2004). Miyazato’s group subsequently identified 
uroguanylin in the pancreatic islet β cells in rats (Nakazato et al., 1998). In the opossum, 
Guca2a transcripts were found in the brain (Fan et al., 1997), and reproductive organs, (Fan 
et al., 1997; Jaleel et al., 2002). Finally, Schwabe revealed that in both the rat and opossum 
guanylin related peptides were expressed within the liver (epithelial cells of the bile duct), and 
gallbladder (Schwabe and Cetin, 2012). All the mentioned papers presented data obtained 
through a number of different experimental methods, all of which have their limitations. For 
example, northern blot analysis presents risk of mRNA degradation as well as low sensitivity. 
Therefore, validating and reproducing the current data that exists for the tissue distribution 
of guanylin-related peptides are required with alternative and more advanced techniques. In 
the human protein atlas database (www.proteinatlas.org), protein expression for guanylin is 
reported to occur within the gastrointestinal tract as well as low levels in glandular cells of the 
appendix. Low mRNA expression for GUCA2A was found in the stomach, cerebral cortex, 
smooth muscle, and gallbladder. No protein expression was reported for uroguanylin, but 
mRNA expression was detected in stomach and GI tract, as well as low level expression within 
gallbladder, liver and smooth muscle. 
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Early studies suggested that based on the hormonal function proposed for guanylin peptides, 
enteroendocrine cells were the likely source of these peptides. Indeed, a few studies have 
demonstrated enteroendocrine cells as a possible source of uroguanylin in the duodenum, 
and Kokrashvili and colleagues presented immunohistochemical data that demonstrated co-
staining of uroguanylin with GFP specific antibodies in Trpm5 gene reporter mice. However, 
Trpm5 is considered a marker for both enteroendocrine cells and tuft cells (Kokrashvili et al., 
2009). Enterochromaffin cells were also shown to express guanylin in guinea pigs, and, in rats, 
this cell type was also shown to express uroguanylin, based on studies reported by Cetin and 
Perkins, respectively (Cetin et al., 1994; Perkins, Goy and Li, 1997). Other cells from the 
secretory lineage have been convincingly found as a source of guanylin peptides. Goblet cells 
were identified as a source of peptides, and these findings were more recently confirmed by 
Rubio and Ikpa (Li et al., 1995; Rubio, 2012; Ikpa et al., 2016). Paneth cells have been shown 
to secrete guanylin in rat (de Sauvage et al., 1992; Whitaker, Witte, et al., 1997) and Paneth-
like cells in colon express Guca2a and Guca2b transcripts as detected by a sensitive in situ 
hybridization method called RNAscope (Ikpa et al., 2016). This method also detected tuft cells 
as a potential source of Guca2a and Guca2b transcripts in accordance with Kokrashvili’s 
finding in duodenum. Finally, this sensitive method found guanylin peptide present in most of 
the enterocytes in mice (Ikpa et al., 2016).  
7.1.2 Use of mass spectrometry as a translational model between species 
Considerable work has been performed on rodents to understand and characterise the 
expression of guanylin and uroguanylin expressing cells using different approaches, including 
immunohistochemistry and techniques that assess gene expression (in situ hybridization, 
Northern blot). However, when referring to the currently available human data, a lack of data 
exists regarding the characterisation of guanylin peptides expressing cells. So far only 
clinically-based assumptions exist regarding the cellular basis for guanylin secretion; and few 
published about their localisation in the GI tract (Kuhn et al., 1994, 1995; Kinoshita, Fujimoto, 
et al., 1997; Kulaksiz, Rausch, et al., 2001).  
Recently, members of our research group have used transcriptomic and peptidomic profiling 
to draw a comparison between human and murine enteroendocrine cells (Roberts et al., 2018) 
and precisely analyse gut hormone distribution along the GI tract. Their work aimed at 
translating the knowledge from mouse to human at RNA and peptides levels. 
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While the distribution of the guanylin and uroguanylin along the rostro-caudal axis of the GI 
tract has been studied through gene expression in mice (Ikpa et al., 2016) and in rat (Qian et 
al., 2000), with uroguanylin being more expressed proximally and guanylin distally, no 
comparison has been performed with human tissue. Moreover, gene expression does not 
necessarily reflect protein levels and a phenotype cannot be based only on transcript levels. 
On the other hand, mass spectrometry is an approach that detects and identifies 
unambiguously peptides in a biosample. For example, Drs Geoff Roberts and Pierre Larraufie 
from the Gribble/Reimann lab have looked at mouse and human intestinal homogenates 
allowing them to identify and quantify gut hormones along the GI tract in human and mouse 
(Roberts et al., 2018). Through collaboration with them, it was possible to assess and compare 
the distribution of guanylin and uroguanylin peptides along the GI tract in mouse and humans.  
7.1.3 Generation of a guanylin-reporter transgenic mouse 
In order to establish the cellular source of guanylin and uroguanylin and due to a lack of 
reliable antibodies, an alternative approach had to be used. To this end, a transgenic reporter 
mouse model expressing a fluorescent protein in cells expressing guanylin or uroguanylin is a 
methodology that does not require specific antibodies or probes for guanylin and uroguanylin. 
Two new mouse models were designed by cloning the reporter Venus sequence into the 
coding sequence of Guca2a or Guca2b in a bacterial artificial chromosome (BAC) and 
integrating this sequence in the mouse genome. The Venus sequence codes for an enhanced 
yellow fluorescent protein (EYFP) which was developed by Nagai et al. who introduced 5 
mutations into the already-characterised EYFP (Nagai et al., 2002). These new mutations 
improved the protein maturation and folding of the Venus variant, increased its brightness 
and reduced its environmental sensitivity (Rekas et al., 2002). 
The recombination using BAC vectors was first described by Yang et al. as an alternative to 
manipulation of large genomic DNA by yeast artificial chromosome (YAC) (Yang, Model and 
Heintz, 1997). By replacing the Guca2a (or Guca2b) sequence with the Venus sequence from 
its starting codon to its stop codon, the promoter sequence as well as most transcription unit 
is conserved in the BAC vector. As the location of regulatory elements of transcriptions are 
usually unknown, continuous experience by Gong substantiated that 50kb of genomic region 
flanking both 5’ and 3’ ends of the reporter gene in the BAC would lead to 85% of successful 
transgene expression in different transgenic lines (Gong et al., 2003). Therefore, the choice of 
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BAC vector among those containing the gene of interest is essential to achieve proper 
regulation of the reporter genes and thus its cell specific expression.  
Founder mice for the Guanylin-Venus construct were backcrossed with C57Bl6 and positive 
Guanylin-Venus offspring were found to have fluorescence in Guca2a-expressing cells. The 
fluorescence allowed immunohistochemistry using validated antibody against the Venus 
protein as well as detection and sorting of live cells to identify the guanylin-expressing cell 
type. 
7.1.4 Project Aims 
The overall objective of this chapter is to identify and characterise the guanylin and 
uroguanylin cells population. Using Mass Spectrometry on human and mouse samples, FACS 
analysis and transcriptomic on new mouse models guanylin-Venus and uroguanylin-Venus 
mouse model, the specific aims were to: 
d) Characterise guanylin peptides along the GI tract in human and mice  
e) Generate guanylin-Venus and uroguanylin-Venus mouse models  
f) Characterise the mouse models and looking for guanylin expression along the rostro-
caudal axis of the GI tract and the crypt-villus axis 
g) Identify the guanylin and uroguanylin expressing intestinal cell types 
 
In order to establish the tissue distribution and cellular localisation of guanylin peptides, 
reporter gene mice models were generated (see section 2.13). The reporter Venus sequence 
was cloned into the coding sequence of the guanylin or uroguanylin gene of a BAC vector. The 
codons of the guanylin peptides genes were replaced by a fluorescent gene -Venus- into the 
BAC vectors using Red/Et recombination. After confirmation of the correct positioning of the 
Venus gene sequence, DNA was purified and microinjected in mice ova according to the 
methods described in section 2.13.  
To assess the expression of the guanylin peptides and the Venus fluorescent marker along the 
gut axis and the crypt-villi axis, tissues were immunostained for specific cell markers and/or 
GFP as described in section 2.14 and 2.15 for whole mounted tissues. Using the new Guca2a-
Venus mouse model, primary murine intestinal single cell suspensions from different regions 
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along the GI tract were generated and then sorted using FACS into Venus-positive and Venus-
negative populations (See section 2.16). RNA was then extracted from these samples and used 
for both quantitative RT-PCR and bulk RNA sequencing (see methods described on section 
2.10 and 2.17).  
Finally, in order to measure guanylin peptides levels along the gastrointestinal tract, peptides 
were extracted from human and murine tissue by homogenisation in 80% ACN. The peptides 
were analysed using a Thermo Fisher Ultimate 3000 nano-LC system coupled to a Q exactive 
Plus Orbitrap mass spectrometer and the analysis was performed using nano-flow-based 




7.2.1 Generation of the transgenic mice 
Two transgenic mice models were designed to study, separately, the guanylin-expressing cells 
and the uroguanylin-expressing cells. The murine models were generated by recombination 
to express the Venus fluorescent protein under the control of the guanylin or uroguanylin 
promoter. 
Guanylin and uroguanylin are both present on the murine chromosome 4 but for the purposes 
of construct generation, two different BAC vectors were used for each gene: RP23-104G3 and 
RP23-440N21 respectively. Both sequences were removed starting from the start codon in 
exon 1 and finishing at the stop codon of exon 3 (figure 7.1). The guanylin gene was initially 
deleted and replaced by the counter-selection cassette rpsL-neo before exchanging it for the 
Venus sequence using, each time, the Red/ET recombination technology. This method was 
successful in the generation of the Guanylin-Venus construct; however, it was unsuccessful in 
the generation of the Uroguanylin-Venus construct when removing the counter-selection 
cassette. While the 3 codons encoding for uroguanylin were quickly replaced by the counter-
selection cassette rpsL-neo, the removal of the cassette proved challenging. When the 
removal of the rpsL-neo cassette should have made the BAC vector kanamycin sensitive, 
numerous colonies were growing on kanamycin plates. Another method was applied to create 




Figure 7.1: Schematics represent the insert of the BAC RP23-104G3 and replacement of the Guca2a coding 
region (1-3) with Venus in (A.) and the insert of the BAC RP23-440N21 and replacement of the Guca2b coding 
region (1-3) with Venus in (B.). 
 
In the first instance the uroguanylin sequence was replaced by a PCR construct containing 
both a counter-selection cassette rpsL-Tet fused to the Venus sequence using the Red/ET 
recombination technology. Once the rpsL-Tet-Venus construct was recombined in the BAC 
vector, the counter-selection cassette was removed using a single stranded oligonucleotide of 
119bp consisting only of homology arms for the Venus sequence and the uroguanylin 
promoter.  
Positive recombinants of Guanylin-Venus and Uroguanylin-Venus constructs were screened 
by PCR. The location of the Venus sequence in the different BAC vectors was controlled by 
sequencing using the oligonucleotides FSD045-FSD076 for the Guanylin-Venus construct and 
FSD110-127 (cf. appendix 2) for the Uroguanylin-Venus construct (data not shown).  Finally, 
the final constructs and intermediates were controlled by enzyme restriction DNA fingerprint 
(figures 7.2 and 7.3). The DNA finger print experiments presented the expected pattern of 
enzyme-restricted DNA bands for both the Guanylin-Venus construct and Uroguanylin-Venus 
construct. Differences between the starting, intermediate and final constructs were 





























Figure 7.2: Quality control of the BAC vector recombination for the construct Uroguanylin-Venus by DNA 
fingerprint. Four BAC vectors were subjected to enzyme restriction to control the recombination: 1/ Modified 
RP23-440N21 Uroguanylin-Venus purified DNA for microinjection, 2/ Unmodified RP23-440N21 miniprep, 3/ 
Modified RP23-440N21 Uroguanylin-RpsL/Tet-Venus, 4/ Modified RP23-440N21 Uroguanylin-Venus 
miniprep.  A. Table summarising the different cleavage products using XhoI as restriction enzyme. The 
expected changes are bolded and italicised. B. DNA gel picture of the 4 different DNA constructs following 
enzyme restriction. In blue are the expected changes in cleavage products between the unmodified and 
modified BAC vectors.  
 
Figure 7.3: Quality control of the BAC vector recombination for the construct Guanylin-Venus by DNA 
fingerprint. Four BAC vectors were subjected to enzyme restriction to control the recombination: 1/ Modified 
RP23-104G3 Guanylin-Venus purified DNA for microinjection, 2/ Unmodified RP23-104G3 miniprep, 3/ 
Modified RP23-104G3 Guanylin-RpsL/Neo, 4/ Modified RP23-104G3 Guanylin-Venus miniprep.  (A.) Table 
summarising the different cleavage products using ZraI as restriction enzyme. The expected changes are 
bolded and italicised. In (B.) and (C.) DNA gel pictures of the 4 different DNA constructs following enzyme 
restriction after 4hrs and 16hrs running on a gel. In blue are the expected changes in cleavage products 
between the unmodified and modified BAC vectors. 
 
The BAC DNA constructs were purified using a commercial kit (Qiagen) and the purified DNA 
was microinjected into ova derived from C57Bl6/CBA F1 parents and resulting embryos were 
implanted in pseudopregnant females. Isolated DNA from the pups was screened for the 
Cleavage products using ZraI
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transgene using a pair of oligonucleotides specific to the Venus transgene (GFPF1 and GFPF2, 
cf. appendix 2). The first injection failed and none of the mice pups harboured the transgene. 
In a second attempt, two Guanylin-Venus pups (#26 and #28) were positive (figure 7.4) and 
presented a band of the 442bp expected size. A fainter band was also present in the 
Uroguanylin-Venus mouse pup #2. Several PCR attempts using different set of primers did not 
corroborate the integration of the entire transgene in the pup #2 (data not shown). 
Confirmation PCRs were performed alongside the mouse pup #2 for the Guanylin-Venus 
founders #26 and #28 and presented strong bands at the expected size (data not shown). A 
third attempt to microinject the Uroguanylin-Venus BAC vector was unsuccessful and it was 
decided to focus only on the guanylin-Venus line. 
 
Figure 7.4: PCR screening of the mice ear biopsies. 40 mice pups where screened in order to assess the 
potential presence of the Venus transgene. Mice pups 1-22 were screened for the integration of the 
Uroguanylin-Venus transgene and mice pups 23-40 were screened for the integration of the Guanylin-Venus 
transgene. The expected size of the PCR product is 442bp and is specific to the Venus gene. The modified and 
unmodified BAC vectors were used as PCR controls. 
 
Once the founders reached sexual maturity they were backcrossed against a C57Bl6 
background. Whereas the female founder #26 passed the transgene to its offspring, the male 
founder #28 did not. Every effort made to transfer the transgene to the next generation failed 
from this founder. The positive offspring of the founder #26 have been so far backcrossed for 
6 generations and most mice used for characterisation of the mouse model thus still harbour 
some CBA-background; this was considered of little relevance as it seems reasonable to 
assume similar expression profiles in C57Bl6 and CBA. 
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7.2.2 Mapping out the Guanylin-expressing cells along the murine gut axis using the mouse 
model 
Cells expressing Guca2a should also express Venus in this model. To identify cells that express 
Venus, duodenal, jejunal, ileal and colonic sections of the Guanylin-Venus mice were immune-
stained for GFP. Frequency and distribution of GFP-positive cells varied along the intestinal 
axis (figure 7.5). Jejunum and ileum presented a similar staining pattern where positive cells 
were mainly present at the top of the villi (white arrow). Some fainter staining was also 
present in the crypt (yellow arrow). The colon presented high levels of marker expression at 
the surface epithelium at the top of the crypt. These first observations brought some light on 
the potential nature of the guanylin-expressing cells, indicating that guanylin-expressing cells 
might be mature enterocytes. Unexpectedly the duodenum presented a different 
immunostaining pattern with scarce cells that were not positioned toward the tip of the villi. 
 
Figure 7.5: Presence of guanylin cells in the gut. Gut tissues from Guanylin-Venus mice (n=2) were assessed 
by immunohistochemistry. All sections were stained for GFP (green), β-catenin (red) and DNA (Hoechst; blue) 
(A.) Representative villi sections from duodenum. (B.) Representative villi (top and bottom) and crypt 
(bottom) section from the jejunum. (C.) Representative villi (top) and crypt (bottom) section from the ileum. 




Coexpression of the reporter with guanylin in this mouse model was investigated by 
quantifying the RNA expression of Venus and Guca2a in the Venus-positive and -negative cells 
of the GI tract. Epithelial cells were dissociated to single cells with EDTA and were FACS sorted 
(figure 7.6). Epithelial cells from each tissue were separated and collected in two 
subpopulations: highly fluorescent and non-fluorescent population.  
 
Figure 7.6: Gating procedures for FACS isolation of gut Guanylin-Venus positive epithelial cells. 
Representative plots illustrating the similar gating strategy for sorting positive Guanylin-Venus cells from mice 
duodenum, jejunum, ileum and colon. (A.) Cells were initially gated by size using forward and side scatter to 
exclude cell debris. (B.) Doublets and larger aggregates were excluded using pulse width. (C.) Dead cells were 
excluded using DAPI staining. (D.) Live cell-shape remains were removed by DRAQ5 staining. Cells were sorted 
and collected into a positive (YFP+) population with high green fluorescence and non-fluorescent negative 
cells (Neg) population in the duodenum (E.), jejunum (F.), ileum (G.) and colon (H.). Immune cells (CD45 
positive) were excluded from the sort 
 
RNAs of all subpopulation were purified and reverse transcribed before controlling the 
expression of guanylin, uroguanylin and Venus by qPCR (figure 7.7). The subpopulations with 
high fluorescence expressed higher levels of Guca2a, Guca2b and Venus in all tissues, and 
statistical significance was reached in the jejunum and in the colon. The statistical significance 
for the duodenum and ileum components was not reached due to important standard 
deviation between mice samples and the low sample numbers. It was still possible to conclude 
that a clear difference was demonstrated between positive and negative subpopulations. 
Finally, the strong correlation between Venus positive cells and Guca2a positive cells 
concluded that the sorting strategy worked and is validating the gene reporter mouse model. 
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Guanylin positive subpopulations presented statistically significant higher expression of 
Guca2b compared to the subpopulation. This result is valid across the 4 tissues but levels of 
expression of Guca2b are particularly high in the duodenum and in the jejunum (figure 7.7). 
Figure 7.7: Analysis by qPCR of separated populations for each tissue for Guca2a, Guca2b or Venus 
expression. Data are mean, n=3 mice. Statistical significance was assessed by t test. * indicates p<0.05, ** 
indicates p<0.01. 
 
Levels of Guca2a are particularly high in the positive cells of the duodenum when normalised 
to Actb and are contrasting with the levels of Venus. This discrepancy is not uniform across 
the 4 different tissues for reasons which remain uncertain.  
The number of cells expressing the Venus marker was measured when performing the cell 
sorts and it presented a great disparity in the number of positive cells (figure 7.8). In the 
duodenum, the percentage of positive cells represented 2.5%. It drastically increased to 49.8% 
in the jejunum, 30.5% and 21.1% in the ileum and colon respectively. In the regions where 
positive cells are rare, positive cells had higher Guca2a expression levels. We can hypothesise 
that the different levels of Guca2a expression detected in the different tissues (figure 7.7) and 
the difference in percentage of positive cells are due to different populations of cells.  
 
Figure 7.8: Percentage of positive Guanylin-Venus cells present in each intestinal tissue. Mouse duodenum, 
jejunum, ileum and colon tissues were sorted by FACS and the percentage of positive Guanylin-Venus cells 





























































To explore further the disparity of cell localisation throughout the gut, an immunostaining of 
the complete GI tract was performed using an adapted method that was developed by Winton 
and Ponder, 1990. Whole mounted duodenum, jejunum, ileum and colon were stained for 
GFP and tissues were scanned using Zeiss Axioscan Z1 slidescanner. Most of the villi and crypts 
were stained in the tissue, making impossible to analyse the staining with a quantitative 
approach due to the villi hiding one another on the slide (figure 7.9). However, nuances in the 
brightness per tissue were apparent. Most of the duodenum parts that were scanned present 
a dimmed fluorescence compared to the jejunum and ileum parts. On the contrary of the 
rectum, the colonic invaginations in the proximal and mid distal colon parts presented bright 
fluorescence. 
 
Figure 7.9: Immunohistochemistry on the whole mounted gut tissue.  Whole mounted gut tissues from 
Guanylin-Venus mice were stained for GFP (green).  All sections were stained for GFP (green) and a tile-scan 
of the duodenum (A.), jejunum (B.), ileum (C.) and colon-rectum (D.) was performed. The tissues had to be 




7.2.3 Measuring guanylin peptides in the murine gut axis using mass spectrometry 
mRNA levels do not necessarily reflect protein levels and transcriptome analysis cannot be 
used as a strict correlation to a phenotype (Vogel and Marcotte, 2012; Edfors et al., 2016; Silva 
and Vogel, 2016). Post-transcriptional regulations -such as translation, protein stability and 
protein modification- all play a role in the discrepancy between RNA levels and protein levels. 
To investigate the protein phenotype, transcriptomic data must be correlated to 
proteomic/peptidomic data analysis. 
It was possible to tackle the peptidomic challenge thanks to the work of Pierre Larraufie and 
Geoff Roberts from the Gribble and Reimann’s lab who looked at peptide levels along the GI 
tract by mass spectrometry in mouse and human samples (Roberts et al., 2018). Briefly, 
samples were homogenised, and protein extracted. Peptides were separated from proteins 
by precipitating proteins with 80% Acetonitrile in water. Samples were extracted using a solid-
phase extraction plate. After resuspending the peptides in 0.1% v/v Formic acid, samples were 
reduced/alkylated to perform a peptidomic analysis. Extracted peptides were analysed using a 
high flow rate based LC/MS-MS which was previously described (Kay et al., 2017).  
ProGuanylin derived peptides were detected in the 10 different regions analysed by LC-
MS/MS by Peaks 8.0 against the mouse Swissprot databases. Peptides were later searched in 
the 10 different regions –from the duodenum to the rectum- using the Quantitation tool of 
Excalibur software (figure 7.10B). ProGuanylin derived peptides 22-49 and 60-116 were the 
peptides described previously in chapter 4. Including peptide 60-90, these peptides were 
detected at the highest quantity. Quantification for each peptide draw an interesting 
representation of the localisation of the peptides production through the GI tract. ProGuanylin 
derived peptides are barely detectable in homogenates from the proximal duodenum. Their 
expression is linearly increasing through the small intestine where the MS response peaks in 
the ileum and distal ileum. The proximal colon presents high levels of ProGuanylin derived 
peptides 22-49 and 60-116 which decline drastically to low or no detectable levels in the 
rectum. These results correlate with the immunohistochemistry data (figures 7.5 and 7.9) and 
show an increasing staining from proximal to distal small intestine and low-level staining in 
the rectum. 
The mass spectrometry data for the ProGuanylin derived peptide 60-90 presented a different 
pattern of expression compared to the peptide 60-116 in the colon. The peptide expression 
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was really low in the colon and a hypothesis explaining this discrepancy could be a difference 
of peptide processing in the colon and in the small intestine. 
Only one ProUroguanylin derived peptide was found by LC-MS/MS in all mice homogenates 
using Peaks 8.0 against the mouse Swissprot databases. This peptide 93-106 was searched 
using the Quantitation tool of Excalibur software in the 10 different regions. The peak areas 
measured for this peptide were low in all samples and the peptide was not detectable in the 
colon and rectum (figure 7.10C).  
 
Figure 7.10: Guanylin and uroguanylin peptides presence in homogenates of mouse gut tissues. Ten 
different mice section were homogenized (A.). Peptides fragments of GUC2A (guanylin) were detected in 
several regions of the mouse guts (B.) Only one peptide fragment of GUC2B (uroguanylin) was found in the 
mouse (C.). The average quantification (peak area) from 4 mice is represented for each region. Data are mean 






















































7.2.4 Similitude of guanylin-expressing cells in human tissue 
A similar experiment was performed in human samples to confirm the pattern of peptides 
localisation by mass spectrometry. Human samples were biopsies from the stomach (n=7) the 
duodenum (n=9), jejunum (n=2), ileum (n=5), caecum (n=1), ascending colon (n=3), sigmoid 
colon (n=6) and rectum (n=3). Human mucosas were treated in a similar method but were 
analysed using nano-flow based separation and electrospray approaches on a Thermo Fisher 
Ultimate 3000 19 nano LC system coupled to a Q Exactive Plus Orbitrap mass spectrometer 
(ThermoScientific). Downstream analysis was performed using Peaks 8.0 software against the 
human Swissprot database as described in Roberts’ paper (Roberts et al., 2018).  
In a peptidomic analysis, only 2 ProGuanylin derived peptides could be detected and 
recognised on Peaks 8.0 in human samples: peptides 22-49 and 100-115 (as described in 
chapter 4). These peptides were later searched in the 8 different regions using the 
Quantitation tool of Excalibur software (figure 7.11). The result in human samples presented 
a higher disparity in MS response implicating high standard deviation. The highest expression 
levels of ProGuanylin derived peptides were found in the jejunum and in the sigmoid colon. 
An interesting difference to note, when comparing with the mouse result, was the presence 
of ProGuanylin derived peptides in the rectum and in the duodenum. Ileum, caecum and 
ascending colon presented overall the lowest levels of peptides. Finally, barely any peptides 
were measured in the stomach. 
 
Figure 7.11: Guanylin peptides presence in human homogenates of gut tissues. Peptides fragments of 
ProGuanylin were detected in several regions of the human guts and the average quantification (peak area) 














































































7.2.5 Guanylin-producing cell types in the GI tract 
Transcriptomic profiling of Guca2a-expressing cells 
To determine the identity of the fluorescent cells in the small and large intestine, Venus-
positive and non-fluorescent control cell population were isolated from Guanylin-Venus mice. 
RNAs were extracted using Qiagen RNEasy micro plus kit. Their quality was measured by 
calculation of the RIN (RNA integrity number), a user-independent algorithm calculating RNA 
quality (Schroeder et al., 2006). The 24 samples (2 subpopulations of 4 tissues for 3 replicate 
mice) RIN were of high quality, averaging 9.6. Libraries were generated from these samples 
using the Takara's SMARTer Pico V2 kit protocol, starting from 10ng of RNA. Libraries were 
sequenced at CRUK Cambridge on the Illumina HiSeq SE50 platform. The average total number 
of reads in each sample was 32.3 million with an average of 21.4 million mapping the mouse 
genome GRCm38 using STAR (Dobin et al., 2013). The average mapping efficiency was 66.4 % 
(lowest 46.6 %), showing a very good sequencing depth. 
 The Principal-component analysis (PCA) of the 4 tissues subpopulation transcriptomes 
showed a clear separation of the positive and negative subpopulation as well as a distinct 
clustering per tissue and group, which was a comforting result on the quality of the RNA-
sequencing (figure 7.12).  
 
Figure 7.12: Principal-Component analysis (PCA) of the transcriptomes of the 4 tissues (duodenum, 
jejunum, ileum and colon) subpopulations. Non-coding and mitochondrial genes were excluded. In blue are 




In these results the PC1 would explain the variance in the tissue whereas the PC2 would 
explain the variance in the positive and negative subpopulation. A heatmap of the absolute 
expression of the top 100 most differentially expressed coding genes is shown on figure 7.13 
as determined by using a negative binomial model (DESeq2). The heatmap highlighted Guca2a 
as one of the top differently expressed genes between negative and positive cells, as expected. 
The presence of Guca2b in the top 100 most differentially expressed coding genes was 
consistent with the positive vs. negative cells qPCR results (figure 7.7). Cell specific markers 
are highly represented in the top 100 DE genes, giving indications about the Guca2a-producing 
cell identity. Goblet cell markers (Fcgbp, Muc2, Tff3) were significantly enriched in the Venus-
positive cells across the 4 tissues. Paneth cell markers (Spdef, and some defensin genes 
Defa24, Defa22, Defa21, Defa29, Defa27) appear significantly enriched in all tissues but the 
colon, consistently with the fact that Paneth cells are not present in the colon. Finally, 






Figure 7.13: Heatmap showing the top 100 most differentially expressed genes between positive and 
negative cells found during RNA-sequencing of FACS-isolated cell populations from three Guanylin-Venus 
mice GI tract. Non-coding and mitochondrial genes were excluded. Values are log10 (normalised read counts 
using DEseq2). Genes are grouped via hierarchical clustering based on Euclidean distance and complete 





















































































































To confirm what cell types are the Guca2a-expressing cells, single genes were singled out of 
the RNA sequencing analysis. Figure 7.14 presents the gene of interest Guca2a, Guca2b and 
the guanylate-cyclase C receptor gene: Gucy2c. These results agreed with the previous qPCR 
results (figure 7.7) that found higher levels of Guca2a in the duodenum and in the colon and 
higher levels of Guca2b in the duodenum and jejunum compared with the negative 
population. The low levels of Guca2b in the negative population would suggest that both 
guanylin and uroguanylin could be expressed by common cell-populations. 
 
Figure 7.14: Gene expression levels of Guca2a, Guca2b and Gucy2c assessed by RNA-sequencing on cell 
sorted positive and negative subpopulations of Guanylin-Venus mice. 
  
The RNA-sequencing results of specific secretory cell markers of enteroendocrine cells, goblet 
cells, Paneth cells and tuft cells were looked at and qPCR were performed on some of the 
markers (figures 7.15 and 7.16). As mentioned, markers of enteroendocrine cells were 
depleted in the Guca2a-positive subpopulations (Cck, and ChgA) as well as enterochromaffin 
cells (Tph1). The qPCR presented a similar trend with depletion of Gcg and Pyy in the Guca2a- 
enriched population. Cck and Gip were also depleted in the duodenum and jejunum of 
Guca2a-enriched subpopulations but their levels too low for detection in the ileum and colon 
even in the negative population. This result is not surprising as GIP-expressing cells are the 
enteroendocrine K-cells predominantly found in the proximal small intestine (Buchan et al., 
1978).  
Paneth cell marker Lyz1 is highly expressed in the guanylin-expressing cell subpopulation 
suggesting a potential guanylin-producing cell type. Sox9, however, seems depleted in all 
tissues (except duodenum for which non enriched). Sox9 is expressed specifically in stem cells, 
progenitor cells, tuft cells and in early-differentiated Paneth cells (Bastide et al., 2007). On the 
other hand, the expression of Defa22, regarded as a differentiated Paneth cell marker (Wang 
et al., 2011), is dramatically increased in the guanylin-producing cells. Those results support 
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the differentiated Paneth cell as a subgroup of guanylin-expressing cells in duodenum, 
jejunum and ileum. 
Figure 7.15: Gene expression levels of secretory cell markers assessed by RNA-sequencing on cell-sorted 
Venus-positive and negative control subpopulations of Guanylin-Venus mice. Markers for enteroendocrine 
cells (Gcg, Gip, Pyy, Cck, Chga, Tph1), Paneth cells (Lyz1, Sox9, Defa22), goblet cells (Muc2, Tff3, Spdef), and 
tuft cells (Dclk1, Trpm5) were checked for both negative (red) and positive (blue) subpopulation. Data are 
mean, n=3 mice. 
 
Goblet cell markers (Muc2, Tff3, Spdef) are highly expressed in the guanylin-enriched 
subpopulations of the duodenum and colon, and Muc2 is still significantly increased in the 
jejunum (p<0.01) when looking at the qPCR results. (Figures 7.15 and 7.16). Goblet cells are 
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therefore a second main population of guanylin-expressing cells in duodenum and colon and 
probably an additional source of guanylin in the jejunum and ileum. 
Figure 7.16: Gene expression levels of secretory cell markers measured by qPCR on cell-sorted Venus-
positive and negative control subpopulations of Guanylin-Venus mice. Markers for enteroendocrine cells 
(Gcg, Gip, Pyy), Paneth cells (Lyz1, Sox9), goblet cells (Muc2, Spdef), and tuft cells (Dclk1, Trpm5) were checked 
for both negative (red) and positive (blue) subpopulation. Data are mean, n=3 mice. Statistical significance 
was assessed by paired t test in between subpopulations. *** indicates p<0.001, ** indicates p<0.01 and * 
indicates p<0.05. 
 
Finally, the tuft cell markers presented depleted transcript levels compared to the negative 
control subpopulation. This last result is contradictory to previous reports that used in situ 
hybridization by RNAscope and suggested that tuft cells were a potential cell type expressing 
guanylin and uroguanylin (Ikpa et al., 2016). 
Previously shown immunohistochemistry (figure 7.5), highlighted the fact that jejunum and 
ileum had a huge number of Venus positive cells along the villi, leading to the assumption that 






































































































Pmepa1) presented a strong enrichment in guanylin-expressing cells in the jejunum and ileum 
but not in the duodenum (figure 7.17). Statistically significant qPCR results showed 
corroborating results (figure 7.18) identifying enterocyte cells as the main source of guanylin 
in jejunum and ileum. 
 
Figure 7.17: Gene expression levels of non-secretory cell markers assessed by RNA-sequencing on cell-
sorted Venus-positive and negative control subpopulations of Guanylin-Venus mice. Markers for 
enterocytes cells (Vil1, Elf3, Pmepa1), M cells (Ccl9, Marcksl1, SpiB) and stem cells (Lgr5) as well as a marker 
for proliferative cells (Mki67) were checked for both negative (red) and positive (blue) subpopulation. Data 
are mean, n=3 mice. 
 
Lgr5 stem cell’s marker showed a reduction in transcripts in the Guca2a-enriched 
subpopulations compared to the negative control subpopulations. Mki67 marker for 
proliferative cells presented a reduction as well in transcripts in guanylin-positive cells. 
M cells are a poorly defined lineage of intestinal epithelial cells that initiate mucosal immune 
responses by uptake of luminal antigens (Neutra, Frey and Kraehenbuhl, 1996). Several M cells 
markers were described in the literature (Kanaya et al., 2012) and looked at in the RNA-
sequencing data: Ccl9, Marcksl1, SpiB, Gp2 and Anxa5. While SpiB, and Anxa presented low 
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cpm values (0-30cpm) in both negative and positive subpopulations (data not shown for 
Anxa5), Ccl9 presented a significant increase in the guanylin-positive subpopulation in the 
duodenum whereas Marcksl1 was significantly increased in the ileum. Finally, the fully 
differentiated M cells marker Gp2 was not detected in our subpopulations. The disparity in 
results might be due to markers appearing at different stages in the differentiation of M cells. 
Marcksl1 appears at the early stage of the differentiation whereas Ccl9 appears only in the 
last differentiation stage (Ohno, 2016). The discrepancy of Gp2 not being detected by RNAseq 
while being a marker of late differentiation is so far unexplained. M cells are also present in 
follicle-associated epithelium (FAE) which could have been removed during the preparation 
of the cell sort. 
 
Figure 7.18: Gene expression levels of non-secretory cell markers measured by qPCR on cell-sorted Venus-
positive and negative control subpopulations of Guanylin-Venus mice. Markers for enterocytes cells (Vil1), 
stem cells (Lgr5), and M cells (Ccl9, Marcksl1) were checked for both negative (red) and positive (blue) 
subpopulation. Data are mean, n=3 mice. Statistical significance was assessed by paired t test in between 
subpopulations. * indicates p<0.05. 
 
Validation of guanylin-expressing cells by Immunohistochemistry 
RNA-sequencing data suggested there may be some overlap between Paneth cells and the 
fluorescent cells in Guanylin-Venus mice. Sections of small intestine and colon were stained 
using antibodies raised against GFP and lysozyme. Double-positive staining of GFP and 
lysozyme was present at the bottom of the crypt when staining duodenum, jejunum and ileum 
sections (figure 7.19). 69.7% of Paneth cells were also positive for GFP in the duodenum. No 

























































Figure 7.19: Triple staining of guanylin cells with Paneth cells marker. 
Immunohistochemistry sections of jejunum (A.) and duodenum (B.) were stained for GFP (green), lysozyme 
(red), β-catenin (white) and Hoechst (blue). The white arrow highlights a double-stained cell. The yellow arrow 
highlights a cell that is not a double positive cell. 
 
RNA-sequencing data also suggested that goblet cell markers were expressed in the 
fluorescent cells of the Guanylin-Venus mice. Sections of duodenum, jejunum, ileum and colon 
were stained using antibodies raised against GFP and Muc2 (figure 7.20). Double-positive 
staining was identified for all tissues with some difference in between them. In jejunum and 
ileum, double positive staining was less common, and figure 7.20B presents staining of a 
goblet cell that does not co-stain for Venus but is surrounded by Venus-positive cells. In the 
duodenum (figures 7.20B, C and D) however, double-positive staining represented 51% of 
goblet cells and 53% of the GFP staining was co-stained with muc2.  
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Figure 7.20:  Triple staining of guanylin cells with goblet cells marker. Immunohistochemistry sections of 
colon (A.), jejunum (B.), and duodenum (C. and D.) were stained for GFP (green), muc2 (red), β-catenin (white) 
and Hoechst (blue). (E.) Muc2 and GFP double positive cells were counted and compared to single positive 
cells in duodenum, jejunum, ileum an colon sections. White arrows highlight a double-stained cell. Yellow 
arrows highlight cells that are not double positive. 
 
These results support the previous RNA-sequencing data highlighting gene expression markers 
for Paneth cells and goblet cells in the duodenum. Jejunum and ileum showed GFP positive 
cells co-staining with Paneth cells in the crypt. In jejunum and ileum’s villi, the GFP was 
essentially present in enterocytes (figure 7.5), with the odd goblet cells. Goblet-rich colon 
displayed a co-staining of GFP-cells with goblet cells marker muc2. Potential other GFP-
positive cells could be mature colonocytes. 
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7.2.6 Guanylin-producing cells in stomach and kidneys 
Uroguanylin was shown in the past to be present in the collecting ducts and distal tubules of 
the kidneys (Nakazato et al., 1998; Fujimoto et al., 2000). Another group looked at the 
uroguanylin and guanylin mRNA distribution along the mouse nephron and claimed that qPCR 
analysis showed guanylin expression in the collecting ducts (Potthast et al., 2001). In a similar 
fashion, qPCRs were used in the past to detect mRNA for guanylin and uroguanylin mRNA in 
stomach (London et al., 1997). The Guanylin-Venus mouse is a good tool to study the potential 
expression of guanylin in different tissues, however a pilot data showed no evidence of 
Guanylin-Venus staining in kidneys nor in stomach. (Figure 7.21). 
 
Figure 7.21: Absence of guanylin in kidney and stomach sections. Kidney (A.) and stomach (B.) sections from 
Guanylin-Venus mouse were assessed by immunohistochemistry. All sections were stained for GFP (green), β-
catenin (red) and Hoechst (blue). 
 
7.2.7 Insight from the RNA-sequencing on the guanylin-expressing cells per tissue 
Guanylin expressing cells were previously analysed without distinction between tissues. 
However, a look at the different cell marker genes showed a great disparity between tissues. 
To look at the difference of genes enrichment per tissue, 4 heatmaps were generated to 
compare enriched population per tissues (figure 7.22). Tissues showed all distinct maps and 
each top 50 enriched genes presented few of the cell markers that were already described. 
The duodenum heatmap highlights the gene enrichment of goblet and Paneth cell markers 
Fcgbp, Tff3, Muc2, Spdef in the Guca2a-positive subpopulation. Both jejunum and ileum 
heatmaps displayed the enterocyte cell marker Vil1 in the top 50 enriched genes, and the 




Figure 7.22: Heatmaps showing the top 50 most differentially expressed genes found for the duodenum (A), 
jejunum (B), ileum (C) and colon (D) from RNA-sequencing of FACS-isolated cell populations from three 
Guanylin-Venus mice. Non-coding and mitochondrial genes were excluded. Values are log10 (normalised read 
counts using DEseq2). Genes are grouped via hierarchical clustering based on Euclidean distance and complete 


























































































































End of figure 7.22. 
 
Several ribosomal family genes and histone family genes were highly depleted in the guanylin-
positive subpopulation (figure 7.22B). Jejunum’s guanylin-positive subpopulation being 
mainly mature enterocytes, a decrease in division or secretion from this subpopulation would 
explain this trend. 
Finally, the uroguanylin gene Guca2b is in the top 50 differentially expressed genes across the 
4 heatmaps providing further evidence that guanylin-producing cells are producing 
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To represent how many positively-enriched genes overlapped between tissues, Venn 
diagrams were used (figure 7.23). The duodenum had 1575 positively-enriched genes in total, 
the jejunum 3077 genes, the ileum 2811 and the colon 1419 positively-enriched genes. 515 
positively-enriched genes were common to all 4 tissues. When looking specifically to the small 
intestine overlap, jejunum and ileum had a high number of shared enriched genes with 2339 
(888+1451) genes overlapping. On the contrary the duodenum only shared 1006 (888+118) 
positively-enriched genes in common with either the jejunum or the ileum; result which 
agrees with the jejunum and ileum having similar guanylin-expressing cell types. 
 
Figure 7.23: Venn diagrams summarising the overlap of positively-enriched genes in the guanylin-positive 
cell subpopulation. In A. duodenum, jejunum and ileum were compared in a 3 sets Venn diagram. Colon 
positively-enriched genes were added in the 4 sets Venn diagram B. Positively enriched genes were selected 
for a p-adjusted value <0.05.  
 
A gene ontology (GO) analysis was performed using GOseq on the positively enriched genes. 
It is used to highlight biological processes and was used on the positively enriched genes of 
the 4 tissues. The summary of the 4 tissues Gene Ontology (GO) is shown in appendix 5. Sixty 
gene categories came out of the analysis with 1/6 of them related to the defence against 
bacteria, linking the enriched genes to the defensive role of Paneth cells that secrete 
antimicrobial peptides and proteins in the mucus layer. Few of the gene ontology functions 
emphasised on the glycosylation of protein which was connecting the enriched genes to the 





7.3.1 Generation of the Guanylin-Venus and Uroguanylin-Venus transgenic mice 
While this chapter focused on the generation and characterisation of a Guanylin-Venus mouse 
model, a Uroguanylin-Venus mouse model was attempted to be developed in parallel. The 
generation of both mouse models was performed by cloning Venus into the Guca2a or Guca2b 
coding sequence in a BAC vector. Vectors were microinjected into mice ova which were 
reimplanted into pseudo-pregnant mice. Random integration of the modified BAC vector into 
the DNA from the mice ova is supposed to express the gene reporter when the native Guca2a 
or Guca2b was also expressed. The generation of both the Guanylin-Venus and the 
Uroguanylin-Venus BAC vectors was performed using Red/ET recombination technology 
between linear double stranded DNA and the BAC vector. The pRed/ET system encodes for 
the phage λ homologous recombination system. It includes 3 components: 5' to 3' 
exonuclease, annealing protein Beta, and inhibitor of E. coli exonuclease and recombination 
complex, Gamma. After breaking the double-stranded DNA, the exonuclease degrades the 5’ 
end of the broken sites and the Beta component protects the remaining 3’ single strand before 
recombination (Shizuya et al., 1992; Murphy, 1998; Wang et al., 2006). 
This system was a success in facilitating Guanylin-Venus BAC vector recombination, but it was 
not successful for the Uroguanylin-Venus BAC vector recombination. Therefore, a new 
recombination method was designed by replacing the uroguanylin gene with an rspL-Tet 
counter-selection cassette fused to the Venus sequence in the BAC vector. The removal of the 
counter-selection cassette was done with a second round of recombination using a single-
stranded DNA oligonucleotide. The use of single-stranded DNA oligonucleotides was identified 
as a more efficient method to perform recombination in E. coli chromosomal targets (Ellis et 
al., 2001; Costantino and Court, 2003) or BAC vectors (Swaminathan et al., 2000) compared 
to the standard recombination on double-stranded DNA. This recombination method requires 
only the Beta compound of the λ homologous recombination system due to the complex 
formed by dsDNA and the Beta compound being resistant to single-stranded DNase. It also 
promotes the annealing to complementary single-stranded DNA (Costantino and Court, 2003). 
When the constructs were completed and quality controlled, they were microinjected into 
one-day old ova and reimplanted in pseudopregnant females. Two Guanylin-Venus founders 
were identified following the second microinjection but a third attempt to make uroguanylin 
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founders was unsuccessful. Due to the cost of each microinjection campaign, and time 
constraint for the project, the decision was made not to proceed with the generation of a 
Uroguanylin-Venus mouse model. However, one potential way to overcome the failed 
microinjection would have been by linearizing the BAC vector, which can make the 
recombination more efficient. However, to microinject linearised BAC vectors, larger needle 
openings and lower injection pressures will have to be applied to minimize the easy shearing 
of the BAC vector (Liu et al., 2013).  
Fortunately, one of the two Guanylin-Venus founders managed to pass the transgene to its 
offspring. According to the Mendelian ratio, 50% of the progenies should contain the 
transgene if the transgene is integrated in one chromosome in a cell from the germline. An 
explanation to the second founder not transmitting the transgene would be that it was a 
mosaic mouse with the transgene not present in the germ cells (Haruyama, Cho and Kulkarni, 
2009). This is not an uncommon problem; microinjection is performed on a day old fertilized 
eggs which should still be at a 1 cell stage, but the recombination can happen at a later stage 
and integrate the DNA into a non-germline cell. 
7.3.2 Guanylin tissue and cellular localisation in the GI tract 
The development of a new transgenic mouse model expressing Venus under the guanylin 
promoter is the strongest surrogate for the lack of specific antibodies to guanylin and the 
limitation of in situ hybridization.  
Guanylin and uroguanylin have long been described as two hormones having a differential 
expression along the GI tract with Guca2b mainly expressed in the proximal small intestine 
and Guca2a mainly expressed in the distal small intestine and the colon (Qian et al., 2000; Ikpa 
et al., 2016). The pattern of Guca2a expression in the mouse model is overall agreeing with 
the published data, it is important to emphasize that the highest percentage of Venus-positive 
cells compared to the total epithelial cells was found in the jejunum, followed by the ileum 
and the colon. While jejunum and ileum guanylin-expressing cells were the most abundant 
ones, the guanylin-expressing cells from these tissues displayed the lowest gene expression in 
average compared to positive cells coming from the duodenum or the colon. This is potentially 
caused by higher Guca2a expression in the goblet cells and Paneth cells compared to the 
expression in enterocytes. Therefore, a bulk RNA-sequencing would reduce the apparent 
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expression of Guca2a, as the expression counts would be diluted by the heterogeneity of the 
cell population.  
Despite previous studies suggesting that guanylin is barely expressed in the duodenum and 
highly expressed in the colon, both peptidomic analysis and immunohistochemistry showed 
that guanylin was expressed to detectable levels in the duodenum and guanylin levels were 
low to absent in the rectum. Finally, the human data presented an overall high expression in 
jejunum for guanylin. Uroguanylin peptides were not detected in human homogenates. 
Conflicting literature describes guanylin and uroguanylin expression pattern along the crypt-
villus axis. Early in situ hybridization indicated uroguanylin primarily localised to the intestinal 
villi whereas guanylin was reported in both crypts and villi in the small intestine as well as in 
the colonic surface epithelium (Whitaker, Witte, et al., 1997). However, an improved in situ 
hybridization method, RNAscope, also detected guanylin and uroguanylin at the base of the 
colonic crypt in Paneth-like cells (Ikpa et al., 2016). This last result is in contradiction with the 
immunohistochemistry performed on the mouse model which agrees with guanylin being 
present on the superficial epithelium only. Despite not having a Uroguanylin-Venus mouse 
model, data from the RNA-sequencing on the Guanylin-Venus mouse model informed us 
about the localisation of uroguanylin. Guca2b gene expression was statistically significantly 
higher in positive cells compared to negative cells in the colon concluding that guanylin-
expressing cells do express Guca2b. By deduction, uroguanylin-expressing cells should be 
present in the surface epithelium of the colon and not at the bottom of the crypt where 
Paneth-like cells were described. 
Guanylin-expressing cell types vary between tissues as revealed by the analysis of cell type 
markers by RNA-sequencing and qPCR. Markers for stem cells, enteroendocrine cells and tuft 
cells were depleted in the Guanylin-Venus subpopulation across the 4 tissues. This is in 
contradiction with early literature showing guanylin expression in enterochromaffin cells in 
guinea pig (Cetin et al., 1994) and human (Fernandez-Cachon et al., 2018) and uroguanylin in 
enterochromaffin cells in rat (Perkins, Goy and Li, 1997). The data reported here is supported 
by results from other researchers who found other cell types from the secretory and 
absorptive lineages as the main source for guanylin peptide expression. While groups only 
distinguished Paneth cells in mouse (de Sauvage et al., 1992; Whitaker, Witte, et al., 1997), 
several groups localised guanylin in goblet cells (Cohen et al., 1995; Li et al., 1995; Rubio, 
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2012). More recent work on the localisation of guanylin peptides showed that goblet cells and 
Paneth cells in small intestine express them as well as tuft cells and enterocytes (Ikpa et al., 
2016). The RNAscope technique used for this study highlighted similar regional differences 
existing along the small and large intestine that was found with the transgenic mouse model 
described in this chapter. RNA-sequencing data in the duodenum, identified goblet cells and 
mature (only) Paneth cells as the main sources of guanylin. Enterocyte markers presented a 
low but significant increase in the guanylin-enriched cells. Their RNAscope experiment agreed 
with goblet and Paneth cells but found tuft cells as well expressing guanylin and uroguanylin 
in the duodenum. In another study, cells were found in mouse duodenum that co-stained with 
uroguanylin (but not guanylin) with Trpm5 concluding that tuft cells (or enteroendocrine cells) 
in the duodenum do express uroguanylin (Kokrashvili et al., 2009). Tuft cells being a relatively 
rare cell population, the RNA-sequencing method would not be able to detect Guca2b 
transcripts in the negative population. In conclusion, it is not possible to corroborate or 
disprove the presence of uroguanylin in tuft cells with our data. In the jejunum and ileum, 
RNA-sequencing and immunohistochemistry data concurred with their study agreeing that 
enterocytes are the main cell-type expressing guanylin peptides in the villi, though crypts are 
still expressing guanylin through Paneth cells and goblet cells. In the colon, goblet cells and 
enterocytes expressed guanylin according to the RNA-sequencing and immunohistochemistry 
data, however Ikpa’s data indicated Paneth-like cells as the main source. While the lack of 
gene markers for Paneth-like cells cannot disprove such theory, the Guanylin-Venus 
immunostaining only stained the top of the crypt in the surface epithelium.  
7.3.3 Guanylin peptides support the defence mechanisms of secretory lineage cells  
Across the GI tract and more specifically in the duodenum and colon, one of guanylin’s 
predominant sites of cellular expression occurs within Paneth cells. Paneth cells release 
secretory granules when exposed to bacterial antigens. Those granules contain antimicrobial 
peptides and compounds (α-defensins, CRS peptides, Lysozyme C, sPLA2, REG3 α, ANG4) that 
have either Gram-positive or Gram-negative antibacterial activities (Bevins and Salzman, 
2011) and these molecules are thought to shape the microbiota composition (Salzman et al., 
2010). Guanylin and uroguanylin’s receptor GC-C when activated results in cGMP conversion. 
cGMP will activate a variety of effector proteins such as phosphodiesterases, protein kinases 
(PKGII and PKA) and ion channels thereby stimulating CFTR channels resulting in an osmotic 
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imbalance leading to water release in the GI tract (Guba et al., 1996). Secretion of fluid into 
the duodenum contributes to the nutrient transit through the small intestine and water 
secretion in the colon shapes the stool formation and consistency and therefore intestinal 
transit (Jarmuz et al., 2015). An interesting theory proposed by de Sauvage hypothesized that 
antimicrobial defence mechanism of Paneth cells could be supported by the action on the 
liquid content by the guanylin peptides (de Sauvage et al., 1992). This theory is supported by 
the Gene Ontology analysis performed on the RNA-sequencing. Genes enriched in guanylin 
expressing cells showed implications in the defence response to bacterium with 1/6 of the GO 
functions related to this area.  
A similar theory could also be applied to the function of goblet cells. Goblet cells are 
responsible for the production and maintenance of the protective mucus on the epithelium 
by synthesizing and secreting glycoproteins called mucins (Specian and Oliver, 1991). From 
the RNA-sequencing data, out of the 60 gene functions that were enriched in the gene 
ontology analysis of the differently expressed genes enriched in the positively-enriched 
guanylin-expressing cells, 4 functions were related to protein glycosylation. In conclusion, in 
addition to finding markers of goblet cells, these cells express a higher proportion of genes 
corresponding to the cell type function of goblet cells. Finally, two independent groups show 
that mucin and guanylin secretion are driven by cholinergic stimulation (Phillips, 1992; Martin 
et al., 1999).  
7.3.4 Summary  
In conclusion, here I describe the successful generation of a new transgenic mouse model that 
enables accurate localisation of the cells that express guanylin. The recombination of the 
fluorescent marker was performed by modifying a BAC vector that contained Guca2a. The 
Guanylin-Venus mice possessed a transgene that directly transcribed the yellow fluorescent 
protein Venus under the control of the Guca2a promoter. An advantage of the use of BAC 
vectors for recombination is their cargo carrying capacity. Furthermore, BACs are more likely 
to contain all the regulatory elements required to replicate the endogenous gene expression 
pattern of the gene of interest. 
This new transgenic mouse model helped defined the localisation of guanylin-expressing cells 
on the rostro-caudal axis of the small and large intestine and along the crypt-villous axis of 
each intestinal section (or crypt-surface axes in the case of the colon). RNA-sequencing data 
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analysis allowed the identification of guanylin-expressing cell types. Major cell types found to 
express guanylin and include goblet cells, Paneth cells and enterocytes with different patterns 
of expression depending on the intestinal tissue analysed. Expression in M cells will have to 
be confirmed through specific immunostaining around the FAE. 
This work allowed to address similar conclusions on uroguanylin-expressing cells to some 
extent. It is indeed possible to assume that the negative control cells from the cell sort were 
not producing uroguanylin through careful interrogation of the RNA-sequencing data; later 
confirmed by the qPCR data performed on negative control and guanylin-expressing cells. 
However, at this stage it is not possible to conclude on the cellular subpopulations among the 
guanylin-expressing cells that also express Guca2b. Alternative methods will be required to 
obtain these data. 
Pilot studies did not show any evidence of Guca2a-fluorescence in stomach nor in kidneys. 
Investigations of adrenal glands and reproductive systems should be performed to 
corroborate (or not) already published literature.  
7.3.5 Future work 
The objective of the work described in this chapter was to identify the guanylin-expressing cell 
types in a transgenic mouse model. However, one caveat of a mouse model is its translatability 
to human physiology. For instance, published data on other rodents such as rats and guinea 
pigs did not show guanylin expression in the villus (Cetin et al., 1994; Perkins, Goy and Li, 1997) 
suggesting species differences in peptide expression might exist. Raising monoclonal 
antibodies against human guanylin and uroguanylin was the way I employed to perform 
immunohistochemistry on human samples. Unfortunately, the pilot study performed on 
human tissues, were not successful. Due to time constraint, an optimised version of the 
immunohistochemistry protocol on human samples was not executed. 
The transgenic mouse model described in this chapter provides new opportunities to 
understand and characterise the cellular expression of guanylin. In future studies, the use of 
Guanylin-Venus mouse organoids combined to time-lapse microscopy could be used to 
control in a new and elegant way the gene expression modification under stimuli. 
Fluorescence could be measured overtime in Guanylin-Venus organoids in presence or 
absence of stimuli.  
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A field of research that received much excitement recently, pertains to the role of guanylin 
and uroguanylin on satiety and energy expenditure (Valentino et al., 2011; Cintia Folgueira et 
al., 2016). Some clinical data converging with my own results showed that obese volunteers 
were reported to have lower levels of guanylin and uroguanylin, and volunteers that 
underwent Roux-en-Y gastric by-pass surgery had increased plasma levels of prohormones (A 
Rodríguez et al., 2016). An interesting use of the Guanylin-Venus mouse would be to look at 
the effect of high fat, restricted food intake or standard chow diet on the expression of 
guanylin and uroguanylin in mouse and their circulating levels. The mouse model would 
provide an insight of the effect of different food intake on the guanylin transcript levels.  
Guanylin and uroguanylin role in the crypt-villous proliferation and their role in colon 
carcinoma cells have received some interest from different groups. Guca2a gene expression 
was markedly down-regulated in adenocarcinomas of the colon (Cohen, Hawkins and Witte, 
1998) and guanylin and uroguanylin mRNA levels are reduced in polyps and adenocarcinomas 
of human colon relative to levels from normal colon mucosa from the same patients (Kunwar 
Shailubhai et al., 2000). Alongside the research on guanylin peptides, new cancer related 
mouse models were generated. Tetteh generated for instance an inducible colon-specific Cre 
enzyme mouse model for colon cancer research that initiates the colon cancer and represent 
its progression (Tetteh et al., 2016). A potential mouse line could be generated by crossing 
Tetteh’s mouse line with the Guanylin-Venus mouse. Such line would be useful to directly look 




Chapter 8: Discussion 
8.1 Summary 
The overall aim of this thesis was to characterise the localisation and secretion of the guanylin 
peptides and their proforms, ProGuanylin and ProUroguanylin, in mouse and humans. To 
achieve this goal, several research tools were developed. Firstly, novel high-throughput 
monoclonal antibody-based immunoassays were developed to characterise the levels of the 
proforms in serum and plasma collected from healthy volunteers and across a number of 
physiological and pathophysiological states. These immunoassays were also utilised to 
measure the level of protein expression on samples originating from different secretion assay 
models. In parallel to the attempted development of antibodies against the historically known 
active peptides, mass spectrometry analysis was used on both human and mouse tissues and 
biological samples in order to measure the levels of endogenous active peptides. This 
technique shed light on the endogenous sequence of the guanylin peptides present in those 
samples. Finally, a novel guanylin transgenic reporter mouse model was generated and used 
to identify and characterise guanylin-expressing cells in the gastrointestinal tract. 
8.2 Antibodies against human ProGuanylin and ProUroguanylin, a new tool for 
investigation  
In chapter 3, new monoclonal antibodies for ProGuanylin and ProUroguanylin were identified 
through a hybridoma process. State of the art technologies allowed the characterisation of 
newly isolated monoclonal antibody pairs that were used subsequently to develop extremely 
sensitive immunoassays with high dynamic range. The ability of these immunoassays to detect 
ProGuanylin and ProUroguanylin was confirmed using different human blood samples (serum, 
plasma Lith Hep, and plasma EDTA). The assay was compared with the commercially available 
ELISA and presented higher range of detection as well as an improved user-friendly property.  
The assay proved useful to measure proforms levels in healthy volunteers that underwent oral 
glucose tolerance tests as well as a standardised liquid meal test. As it was demonstrated in 
the past that salt intake elicits a physiological response in the expression of guanylin peptides 
in rat (Carrithers et al., 2002) as well as in humans (Kinoshita, Nakazato, et al., 1997), release 
of the proforms in response to the standardised liquid meal was expected. However, these 
expectations were not fulfilled as no strong physiological release of ProGuanylin and 
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ProUroguanylin was detected in human plasma following food and glucose intake in healthy 
participants. However, levels of ProGuanylin and ProUroguanylin did differ between fasted 
and fed participants in healthy and diseased states (subjects with neuroendocrine tumours, 
participants that had a prophylactic total gastrectomy, or a small bowel transplants). Proforms 
were also increased in subject who previously underwent Roux-en-Y gastric bypass compared 
to standard participants. This was corroborated in a recent publication highlighting an increase 
in GUCA2A and GUCA2B transcripts after gastric bypass surgery (Fernandez-Cachon et al., 
2018).  However, the significance of these findings requires further investigation.  
Immunoassays were able to accurately measure ProGuanylin and ProUroguanylin levels in 
various pre-clinical gastrointestinal human models including the TC7 cell line, organoids and 
Ussing chamber’s supplemented with Ringer buffer. Therefore, the expression of the proforms 
was measured in these different secretion assay models. Salt concentration, gut hormones 
and vagal stimuli were all screened to assess their effect, if any, on the secretion of the 
proforms. Previously reported studies proposed NaCl to be a potent regulator of the secretion 
of guanylin peptides in rats (Li et al., 1996; Kinoshita, Nakazato, et al., 1997; Kita et al., 1999; 
Carrithers et al., 2002; Fukae et al., 2002). The results generated in the human studies 
described herein, however, did not support a critical role for NaCl concentration on the 
secretion of ProGuanylin or ProUroguanylin. Similarly, vagal and other enteroendocrine 
secretory stimuli did not present any noticeable effects in the different models studied.  
Other secretion models would need to be used to better understand the regulatory effects of 
vagal and gut hormones as well as gut lumen nutrient content on ProGuanylin and 
ProUroguanylin secretion and the range of buffer used over the course of the thesis (Ringer 
solution, plasma and serum sample, PBS and DMEM-based cell media) testify about the 
versatility of the use of the immunoassays. Additional experiments could be performed on 
more complex model systems that may better represent human physiology. However, in the 
interests of time and resource available these were not pursued further. Secretion on Ussing 
chambers, air-liquid interface or primary cultures of small/large intestine in association with 
the immunoassays are established and validated research tools routinely used in the 
Gribble/Reimann laboratory to assess the role of potential stimuli (Pais et al., 2016; Larraufie 
et al., 2018). However, these experiments are not high-throughput and depend critically on 
the availability and healthiness of tissues. 
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The use of the newly developed monoclonal antibodies is not restricted to immunoassays. The 
high affinity antibodies could be utilised for immunohistochemistry of human tissues or 
Western blots. Whilst the utility of the antibodies as immunohistochemical reagents for the 
study of human tissues, was briefly explored, due to the inability to develop a robust 
methodology this was not explored further during my PhD.  
The physiological role of ProGuanylin and ProUroguanylin could be investigated in different 
tissues by using the antibodies to block the proforms from activating the GC-C receptor. 
However, this study would require the antibody panel to be cross-reactive for a rodent species 
and involve further characterisation of the panel of antibodies to show that the antibody is 
functional (blocking the access of the peptide to the receptor). 
8.3 Redefining the active guanylin peptides  
Currently, mass spectrometry and peptidomic analysis are increasingly being employed in 
attempt to improve our understanding of the bioactive peptide products that are processed 
from larger prohormone peptides (Kay et al., 2017), as well as the tissue distribution of these 
hormones (Roberts et al., 2018). The development of such methods in the Gribble/Reimann 
laboratory has allowed me to make an unexpected but significant discovery in the guanylin 
peptides field. Previous studies have postulated that the bioactive guanylin peptide is defined 
by the last 15 amino acids of the C-terminal sequence of the GUCA2A protein sequence (Mark 
G Currie et al., 1992). While Currie et al. questions the possibility of a different N-terminal end 
of the sequence, the scientific community accepted the sequence. The method using 
acetonitrile to extract all peptides from different biological sources such as tissue 
homogenates, blood, ileal secretion or intestinal content, highlighted the absence in all 
samples of the 15 amino acid guanylin peptide. The highly sensitive LC-MS/MS method 
identified peptides that were present in abundance across the different biological specimens. 
In mouse, one identified peptide of interest is guanylin 60-116, a peptide that encompasses 
the C-terminal sequence considered as essential for activating the GC-C receptor. In human 
serum samples this peptide was not identified via peptidomic analysis, but a proteomic 
approach supported the potential existence of a similarly sized peptide, however it was too 




Going forward, further studies are required to clearly ascertain the amino acid sequence of 
the human peptide and confirm that both murine and human versions of this larger peptide 
are functional and able to activate the GC-C receptor. It is so far believed that the 15 amino 
acid version of the guanylin peptide is more potent in basic conditions (Hamra et al., 1997) 
and is highly susceptible to degradation via endoproteases (Hamra et al., 1996). The longer 
version of the guanylin peptide might present different physicochemical properties that will 
need to be assessed to understand their physiology along the gastrointestinal tract. 
Uroguanylin peptide was in most samples undetectable.  
8.4 Identifying sites of guanylin peptides expression 
During the course of my PhD, I successfully developed a transgenic reporter mouse in which 
the Venus fluorescent protein was expressed under the guanylin promoter, thereby allowing 
me to identify and characterise guanylin-expressing cells. To date, assessment of the sites of 
guanylin expression has been debated with much discordance in the literature. Therefore, to 
improve our understanding of the physiological, and potentially pathological roles of the 
guanylin peptides detailed knowledge regarding their sites of expression and action is 
required.  The transgenic reporter mouse clearly demonstrated that goblet cells and Paneth 
cells were the main cell-type expressing guanylin in the duodenum. In the jejunum and ileum, 
the main cell-type expressing guanylin are enterocytes as well as goblet and Paneth cells. 
Finally, colonocytes and goblet cells were the only cell types expressing Guca2a transcripts in 
the large intestine. The development of the reporter mouse model for guanylin-expressing 
cells gave some clues about the potential site of expression of uroguanylin as well. RNAseq 
and qPCR showed that uroguanylin transcripts were significantly expressed in guanylin 
expressing cells, suggesting that guanylin-expressing cells express uroguanylin as well. 
However smaller cellular populations (such as tuft cells or Paneth-like cells) would not be 
picked up in the guanylin-expressing cells and therefore further work is required to completely 
delineate the anatomical location(s) of uroguanylin expressing cells.  
At the beginning of my thesis, understanding how guanylin expression and cellular secretion 
is regulated under different physiological states was an unanswered question. The transgenic 
reporter Guanylin-Venus mouse line has been used to address some aspects of this question. 
However, a number of questions regarding the physiological regulation of ProGuanylin 
derived peptides remains to be answered.  
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8.5 Potential future uses for the Guanylin-Venus mouse model 
TC7 cell lines and human organoids provided limited results to understand which stimuli 
regulate the secretion of guanylin and uroguanylin. The Gribble/Reimann laboratory recently 
acquired new technology that will enable time-lapse microscopy of organoids or 2D cultures 
to be undertaken. This powerful instrument, in association with organoids or 2D cultures 
made of the Venus-reporter mouse small or large intestine, may be used to examine guanylin 
expression over time. For example, organoids could be cultured with salt, vagal or gut stimuli 
to determine whether such treatments increase the number of Venus expressing cells or 
increase the fluorescence in differentiated cells. This method would only rely on the 
endogenous reporter and not on antibodies thereby allowing real time expression to be 
determined.  
One study showed that Guca2a expression was reduced in mice fed on HF or HC diets (Lin et 
al.). Similarly, in the human colon, guanylin mRNA levels were inversely proportional to BMI 
in morbidly obese patients (Lin et al.). Finally, other studies have shown that uroguanylin 
levels are lower in obese adolescent and adult participants when compared to healthy 
participants (A. Rodríguez et al., 2016; Di Guglielmo, Perdue, et al., 2018; Di Guglielmo, Tonb, 
et al., 2018). The reporter mouse model is a perfect tool to look at the modification of 
transcript levels in mouse that would be fed on HF or HC diets and compare it to a standard 
diet.  
The long-term effect of salt on guanylin and uroguanylin expression can also be studied using 
the transgenic model. Previous investigators have shown that a low salt diet reduced guanylin 
mRNA and peptide expression in the rat distal colon (Li et al., 1996), while high salt intake over 
4 days significantly increased the expression of guanylin mRNA in the duodenum and jejunum 
(Carrithers et al., 2002). Similar dietary intervention studies could be undertaken with the 
Guanylin-Venus transgenic mice.   
The intersectional role of guanylin and uroguanylin on obesity and colorectal cancer has been 
the recent focus of attention within the field (Lin et al., 2010b). Guanylin gene expression was 
lost in human colonic adenocarcinoma (Cohen, Hawkins and Witte, 1998), and uroguanylin 
transcript levels were found to be decreased in human colonic polyps (Kunwar Shailubhai et 
al., 2000). Mouse models are widely used to study cancer progression and disease 
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mechanisms. To study topical colon cancer, an inducible colon-specific Cre enzyme mouse 
model that initiates colon cancer and replicate its progression has been generated (Tetteh et 
al., 2016). Additionally, a mouse model displaying hyperproliferation induced by nutritional 
stress diet was conceived and could be of interest in the case of the potential intersectional 
role of guanylin and uroguanylin (Newmark, Lipkin and Maheshwari, 1990). Generation of a 
mouse line crossing the guanylin reporter mouse with those colorectal cancer specific mouse 
models would shed light on the potential role of the guanylin peptides on colorectal cancer. 
8.5 Conclusion 
George Box (1919-2013), statistician, once mentioned that “all models are wrong, but some 
are useful”. This could not relate more to the work provided to contribute to the basic 
knowledge of the localisation and secretion of the guanylin peptides. It is hoped that the 
finding presented in this thesis will spur on further characterisation of the mouse cell types 
and understanding of the signals delivered to secrete either guanylin or uroguanylin. Further 
work is required on some of these findings in humans, which is already underway with the 
development of antibodies against both targets. It will be exciting to see whether these 
findings can be applied to the discovery of new treatments for conditions including colorectal 
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Appendix 2: Table of primers. 
Primer Purpose Sequence (5'-3')
Oligo (dC) Forward primer for VH and VL CCCCCCCCCCCCCCCCCCCCCCCCC
IgG77R Reverse primer for mouse VH TARCCYTTGACMAGGCATCC
KconsR Reverse primer for mouse VL CGTTCACTGCCATCAATC
pUC19 reverse Amplify the scfv for Phage sequencing AGCGGATAACAATTTCACACAGG
fdtetseq Amplify the scfv for Phage sequencing GTCGTCTTTCCAGACGTTAGT
PCR L-link Sequencing the phage GGCGGAGGTGGCTCTGGCGGT
mycseq10 Sequencing the phage CTCTTCTGAGATGAGTTTTTG




geneIIIfor2 Ribosome display CCGTCACCGACTTGAGCC
MycgeneIIIshortadapt Ribosome display ATCTCAGAAGAGGATCTGAATGGTGGCGGCTCCGGTTCCGGTGAT
T7te Ribosome display GTAGCACCATTACCATTAGCAAG










T8te Ribosome display CACCAGTAGCACCATTACCATTAGCAAGG
Pecseq1 Forward primer for VH and VL GCAGGCTTGAGGTCTGGAC
P266 VH reverse GCCCTTGACCAGGCATCCCAG
P156_CC VL reverse GGGACAGACAGAAAACAGCATGC
FSD001 Replacement GN by rspL/neoR cassette forward
GCCCCACTGTTTACCCCAGGCACTAGTACTGGCCTGTTCTCTGCATTGCATAC
TGCTACCGGCCTGGTGATGATGGCGGGATCGT
FSD002 Replacement GN by rspL/neoR cassette reverse
CTTCTAGAAGATAGAGGGGCTTCCACATGGGCTGAGAGAAAGGCAAGCGAT
GTCACTCTAGAAGAACTCGTCAAGAAGGCGATAG
FSD003 Replacement GN by Venus cassette forward
GCCCCACTGTTTACCCCAGGCACTAGTACTGGCCTGTTCTCTGCATTGCATAC
TGCTACCATGGTGAGCAAGGGCGAGGAGCTGT
FSD004 Replacement GN by Venus cassette reverse
CTTCTAGAAGATAGAGGGGCTTCCACATGGGCTGAGAGAAAGGCAAGCGAT
GTCACTCTACTTGTACAGCTCGTCCATGCCGAGA
FSD045 To sequence GN-Venus +-5000bp f1 CTCCAGGAGGAGGAAAAAGAG
FSD046 To sequence GN-Venus +-5000bp f2 CAGTGAGCTCCAGCTCACTG
FSD047 To sequence GN-Venus +-5000bp f3 CAAACCGTGCCACTTTATTTC
FSD048 To sequence GN-Venus +-5000bp f4 CTGGCTTGCCAGAAGATGATG
FSD049 To sequence GN-Venus +-5000bp f5 CAGCAGCCTCCACACTCGAG
FSD050 To sequence GN-Venus +-5000bp f6 CTTTGCACACATGCCTTTCAG
FSD051 To sequence GN-Venus +-5000bp f7 CTTCTTCATCGAGGGCTTCC
FSD052 To sequence GN-Venus +-5000bp f8 CAGCAGATGAGGCTGACAAG
FSD053 To sequence GN-Venus +-5000bp f9 CTCCTGGGGTCACTAACTTGC
FSD054 To sequence GN-Venus +-5000bp f10 CCTGATCTTCCACATCCTGTG
FSD055 To sequence GN-Venus +-5000bp f11 GGTACACAGCTTCCTCCCAG
FSD056 To sequence GN-Venus +-5000bp f12 CTGAAAGCTGTCTCAGCATGG
FSD057 To sequence GN-Venus +-5000bp f13 GACAACCCAGGAAGCATCAAG
FSD058 To sequence GN-Venus +-5000bp f14 GAACACTTGGTCCCAGTAGGTG
FSD059 To sequence GN-Venus +-5000bp f15 GGCAGAGAGTAGCTGGGTGTAG
FSD060 To sequence GN-Venus +-5000bp f16 GGACGTGTCACTCCCTGATTG
FSD061 To sequence GN-Venus +-5000bp r1 GTGTTGCTTCTTTGATTGGTCTG
FSD062 To sequence GN-Venus +-5000bp r2 CAATCAGGGAGTGACACGTCC
FSD063 To sequence GN-Venus +-5000bp r3 CTACACCCAGCTACTCTCTGCC
FSD064 To sequence GN-Venus +-5000bp r4 CACCTACTGGGACCAAGTGTTC
FSD065 To sequence GN-Venus +-5000bp r5 CTTGATGCTTCCTGGGTTGTC
FSD066 To sequence GN-Venus +-5000bp r6 CCATGCTGAGACAGCTTTCAG
FSD067 To sequence GN-Venus +-5000bp r7 CTGGGAGGAAGCTGTGTACC
FSD068 To sequence GN-Venus +-5000bp r8 CACAGGATGTGGAAGATCAGG
FSD069 To sequence GN-Venus +-5000bp r9 GCAAGTTAGTGACCCCAGGAG
FSD070 To sequence GN-Venus +-5000bp r10 CTTGTCAGCCTCATCTGCTG
FSD071 To sequence GN-Venus +-5000bp r11 GGAAGCCCTCGATGAAGAAG
FSD072 To sequence GN-Venus +-5000bp r12 CTGAAAGGCATGTGTGCAAAG
FSD073 To sequence GN-Venus +-5000bp r13 CTCGAGTGTGGAGGCTGCTG
FSD074 To sequence GN-Venus +-5000bp r14 CATCATCTTCTGGCAAGCCAG
FSD075 To sequence GN-Venus +-5000bp r15 GAAATAAAGTGGCACGGTTTG




Appendix 2: Table of primers (end). 
  
Primer Purpose Sequence (5'-3')
FSD033 PCR Venus 5' for CATATTTCCATAGAGACGTGCTCGACTACTTGTACAGCTCGTCCATGCCG
FSD034 PCR Venus 3' rev
GCAGGCAGGTGGACAGCAGAGGAAGCAGGAACCCAGAGGTGTGAGCTTGG
AAGCGAGGCCATGGTGAGCAAGGGCGAGGAGC
FSD035 PCR RspLtet 5' for
ACAGGTTGGGCTGTGGGGAAAGTGTCCGGAGTGGTCTTAAGACCCAGAGTC
ATTTCATCATCGAGATGGCGGACGCGATGGATAT
FSD036 PCR RspLtet 3' rev CGGCATGGACGAGCTGTACAAGTAGTCGAGCACGTCTCTATGGAAATATG
FSD037 PCR RspLtet-Venus 5' for ACAGGTTGGGCTGTGGGGAAAG
FSD038 PCR RspLtet-Venus 3' rev GCAGGCAGGTGGACAGCAGAG




FSD110 To sequence UGN-Venus +-3000bp f1 GAGCCTAATACCAAACTAGAGAGAG
FSD111 To sequence UGN-Venus +-3000bp f2 GATACACAAAGAGCACACATGC
FSD112 To sequence UGN-Venus +-3000bp f3 GGAGAGGAGAGATGAGGAGAAG
FSD113 To sequence UGN-Venus +-3000bp f4 GATTCCAGCAGTGGCATG
FSD114 To sequence UGN-Venus +-3000bp f5 GTAGCGACGACAACACAGTG
FSD115 To sequence UGN-Venus +-3000bp f6 CTTGTAACCAGCCTTTGCCTG
FSD116 To sequence UGN-Venus +-3000bp f7 GTCTCCGGTGAACTTTGGAG
FSD117 To sequence UGN-Venus +-3000bp f8 CTCTCCATGACATCTTCCCAG
FSD118 To sequence UGN-Venus +-3000bp f9 GTAGGTTTAGCTGCTCCTCTCC
FSD119 To sequence UGN-Venus +-3000bp r1 GCATTGAATTTGGCAAGTG
FSD120 To sequence UGN-Venus +-3000bp r2 CAGTGGCTGGAGAAAGGAGG
FSD121 to seq UGN-Venus +-3000bp r3 GACAGAATACCAGCCTGTTG
FSD122 To sequence UGN-Venus +-3000bp r4 GACTTGATGTGACACCCCAG
FSD123 To sequence UGN-Venus +-3000bp r5 GTCCAGTGACAGTCAGGAGAC
FSD124 To sequence UGN-Venus +-3000bp r6 GTACACAGACAGCCGAAAGACC
FSD125 To sequence UGN-Venus +-3000bp r7 CTTCTCCTCATCTCTCCTCTCC
FSD126 To sequence UGN-Venus +-3000bp r8 GCATGTGTGCTCTTTGTGTATC
FSD127 To sequence UGN-Venus +-3000bp f10 CTTCTCATCCAGCTCCTCGAG
GFPF1  mouse screening GACGTAAACGGCCACAAGTT





Appendix 3: Table of Taqman assays probes. 
  
Gene Species TaqMan™Gene Expression Assay Id
Guanylin (Guca2a) mouse Mm00433863_m1 
Uroguanylin (Guca2b) mouse Mm01192051_m1
Beta actin (Actb) mouse Mm02619580_g1
Mucin 2 (Muc2) mouse Mm01276696_m1 
Lysozyme (Lyz1) mouse Mm00657323_m1
SAM Pointed Domain Containing ETS Transcription Factor (Spdef gene) mouse Mm00600221_m1
SRY-Box 9 (Sox9) mouse Mm00448840_m1
Villin 1 (Vil1) mouse Mm00494146_m1 
Glucagon (Gcg) mouse Mm01269055_m1
Gastric Inhibitory Polypeptide (Gip) mouse Mm00433601_m1
Peptide YY (Pyy) mouse  Mm00520716_g1
Cholecystokinin (Cck) mouse Mm00446170_m1
Somatostatin (Sst) mouse Mm00436671_m1
Doublecortin Like Kinase 1 (Dclk1) mouse  Mm00444950_m1
Transient Receptor Potential Cation Channel Subfamily M Member 5 (Trpm5) mouse Mm01129032_m1
Chemokine (C-C motif) ligand 9 (Ccl9) mouse Mm00441260_m1
Macrophage Myristoylated Alanine-Rich C Kinase Substrate (Marcksl1) mouse Mm00456784_m11
Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 (Lgr5) mouse Mm00438890_m1
Guanylin (GUCA2A) human Hs00157859_m1
Uroguanylin (GUCA2B) human Hs00951189_m1
Beta actin (ACTB) human Hs01060665_g1





Appendix 4: Table of antibodies and antisera used. 
  
Use Antibody target Company and catalog number Dilution
ELISA to control the proforms Rabbit Polyclonal antibody against ProGuanylin Abcam (Ab14427-50) 1/10
ELISA to control the proforms Mouse Polyclonal antibody against ProUroguanylin Abcam (Ab171982) 5μg/ml
ELISA to control the proforms HRP labelled goat anti-rabbit IgG Sigma (A2074) 1/5000
ELISA to control the proforms HRP labelled goat anti-mouse HRP IgG Jackson ImmunoResearch (115-035-164) 1/5000
For hybridoma FITC labelled monoclonal antibody anti-mouse IgG Jackson ImmunoResearch (115-095-1649) 10μg/ml
HTRF assay AlexaFluor 647 labelled goat anti mouse Fc IgG Jackson ImmunoResearch (115-605-164) 7.5nM 
Phage ELISA anti-M13-HRP Amersham (27-9421-01) 1/5000 
Cell sorting anti-CD45-PE Thermo Fisher (MA110233) 1/500
Immunohistochemistry Donkey anti-mouse 647 Life technologies (A31571) 1/3000
Immunohistochemistry Donkey anti-goat 488 Life technologies (A11055) 1/3000
Immunohistochemistry Donkey anti-rabbit 555 Life technologies (A31572) 1/3000
Immunohistochemistry Goat anti-GFP Abcam (Ab5450) 1/1000
Immunohistochemistry Rabbit anti-Lysozyme Dako (A0099) 1/200
Immunohistochemistry Rabbit anti-Muc2 Santa Cruz (sc15334) 1/200
Immunohistochemistry Rabbit anti-ChgA Santa Cruz (sc13090) 1/200
Immunohistochemistry Mouse anti-E-cadherine BD (BD610181) 1/200
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Appendix 5: Gene Ontology of the functions enriched in Guca2a-expressing cells using 








Number of differentially 
expressed genes in category
Number of genes 
in category
term
GO:0044421 8.95199E-12 1 144 3692 extracellular region part
GO:0005576 1.81137E-11 1 156 4218 extracellular region
GO:0031982 7.60489E-11 1 138 3500 vesicle
GO:0050830 1.41143E-10 1 15 83 defense response to Gram-positive bacterium
GO:0012505 4.21423E-10 1 138 3432 endomembrane system
GO:0042742 2.49716E-09 1 22 233 defense response to bacterium
GO:0031988 4.85984E-09 1 122 3183 membrane-bounded vesicle
GO:0098542 1.15643E-08 1 34 511 defense response to other organism
GO:0006952 2.01695E-08 1 63 1323 defense response
GO:0005509 3.7352E-08 1 39 586 calcium ion binding
GO:0043230 5.07504E-08 1 101 2613 extracellular organelle
GO:0043207 8.24897E-08 1 42 751 response to external biotic stimulus
GO:0051707 8.24897E-08 1 42 751 response to other organism
GO:0005794 1.10259E-07 1 63 1268 Golgi apparatus
GO:0009607 1.2408E-07 1 43 790 response to biotic stimulus
GO:0070062 2.16682E-07 1 98 2593 extracellular exosome
GO:1903561 2.88954E-07 1 98 2607 extracellular vesicle
GO:0009605 3.18102E-07 1 78 1849 response to external stimulus
GO:0006810 5.23917E-07 1 146 4133 transport
GO:0051234 9.86372E-07 0.9999996 150 4283 establishment of localization
GO:0031410 1.04803E-06 0.9999996 54 1105 cytoplasmic vesicle
GO:0097708 1.10872E-06 0.9999996 54 1107 intracellular vesicle
GO:0009617 1.26766E-06 0.9999996 28 452 response to bacterium
GO:0005615 3.69838E-06 0.9999983 57 1385 extracellular space
GO:0004653 4.46346E-06 0.9999998 6 17 polypeptide N-acetylgalactosaminyltransferase activity
GO:0032879 6.69064E-06 0.9999965 95 2432 regulation of localization
GO:0034341 6.74174E-06 0.9999991 10 78 response to interferon-gamma
GO:0008378 7.37446E-06 0.9999989 11 81 galactosyltransferase activity
GO:0050829 1.10079E-05 0.9999989 8 54 defense response to Gram-negative bacterium
GO:0006486 1.39591E-05 0.9999965 17 202 protein glycosylation
GO:0043413 1.39591E-05 0.9999965 17 202 macromolecule glycosylation
GO:0006950 1.80691E-05 0.9999894 109 3103 response to stress
GO:0051049 1.81094E-05 0.9999904 72 1754 regulation of transport
GO:0044444 1.91395E-05 0.9999877 201 6629 cytoplasmic part
GO:0016020 2.08217E-05 0.9999864 261 9136 membrane
GO:0099503 2.3421E-05 0.9999917 26 449 secretory vesicle
GO:1902578 2.40634E-05 0.9999861 97 2609 single-organism localization
GO:0070085 2.4284E-05 0.9999936 17 212 glycosylation
GO:0005795 3.8246E-05 0.9999946 9 64 Golgi stack
GO:0009100 4.15687E-05 0.9999866 21 308 glycoprotein metabolic process
GO:0071346 4.32005E-05 0.9999946 8 60 cellular response to interferon-gamma
GO:0044425 4.35207E-05 0.9999711 198 6727 membrane part
GO:0030141 4.42483E-05 0.9999861 20 318 secretory granule
GO:0008375 4.69602E-05 0.9999913 11 97 acetylglucosaminyltransferase activity
GO:0017137 4.75753E-05 0.9999895 13 126 Rab GTPase binding
GO:0020005 5.43291E-05 0.9999986 4 9 symbiont-containing vacuole membrane
GO:0016758 5.47412E-05 0.9999852 16 199 transferase activity, transferring hexosyl groups
GO:0044765 5.62671E-05 0.9999668 89 2395 single-organism transport
GO:0009101 5.66059E-05 0.9999826 19 269 glycoprotein biosynthetic process
GO:0051179 5.90572E-05 0.9999609 173 5398 localization
GO:0042470 6.35815E-05 0.9999949 6 29 melanosome
GO:0048770 6.35815E-05 0.9999949 6 29 pigment granule
GO:0016757 7.14531E-05 0.9999768 20 295 transferase activity, transferring glycosyl groups
GO:0045087 7.51368E-05 0.9999696 29 566 innate immune response
GO:0048471 7.5477E-05 0.9999685 31 574 perinuclear region of cytoplasm
GO:0020003 7.60942E-05 0.9999977 4 10 symbiont-containing vacuole
GO:0006811 8.33266E-05 0.9999562 55 1279 ion transport
GO:0031224 9.34658E-05 0.9999375 170 5728 intrinsic component of membrane
GO:0008047 0.000100654 0.9999617 25 422 enzyme activator activity
GO:0030968 0.000128321 0.9999813 8 63 endoplasmic reticulum unfolded protein response
